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General introduction 
13 
Anorectal malformations (ARM) are congenital malformations of the digestive system 
resulting from disturbed development of the hindgut during embryogenesis. ARM comprise 
a wide spectrum of phenotypes ranging from narrowing of the anorectal channel to anal 
atresia with or without fistulas to surrounding organs and even complex cloacal 
malformations. Table 1 shows the ARM phenotypes in both males and females, which are 
classified according to the international Krickenbeck criteria for ARM, developed in 2005.1 
Some of the common phenotypes are illustrated in Figure 1. 
 
Table 1. Anorectal malformation phenotypes in male and female patients. 
Males Females 
Perineal fistula Perineal fistula 
Rectourethral bulbar fistula Vestibular fistula 
Rectourethral prostatic fistula Cloaca with common channel < 3 cm 
Rectovesical (bladder neck) fistula Cloaca with common channel > 3 cm 
Atresia without fistula Atresia without fistula 
Anal stenosis Anal stenosis 
Rare complex malformationsa Rare complex malformationsa 
aRare complex malformations include pouch colon, rectal atresia/stenosis, rectovaginal fistula, and H 
fistula. 
 
Before 2005, several international classification systems for ARM were proposed. The 
classification has large impact on the choice for surgical approaches. The Wingspread 
classification, elaborated in 1984, distinguished between low, intermediate, and high 
atresias according to the level of termination of the rectum in relation to the levator ani 
muscle.2 The Peña classification from 2000 was based on the presence and position of the 
fistula.3 In 2005, the Krickenbeck classification was developed by consensus among a large 
group of medical professionals experienced in the management of patients with ARM. 
Nowadays, it is the most commonly used classification system for ARM worldwide. The 
Krickenbeck classification includes the above-mentioned diagnostic classification, but is also 
designed to enable adequate comparison of postoperative results.1  
ARM occur in approximately 1 in 3,000 live born children worldwide.5 In total, 40-70% 
of the ARM patients have one or more other major congenital malformations, mostly 
malformations that are part of the VACTERL (Vertebral, Anal, Cardiac, Tracheo-Esophageal, 
Renal, and Limb defects) association.6-8 Therefore, ARM can be classified into subgroups 
based on the presence or absence of additional congenital malformations, including isolated 
ARM, ARM with one or more other congenital malformations, or VACTERL.  
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Figure 1. Common anorectal malformation phenotypes in male (A-D) and female patients (E-H)4 (with 
permission) 
A: perineal fistula, B: rectourethral bulbar fistula, C: rectourethral prostatic fistula, D: rectovesical fistula 
E: perineal fistula, F: vestibular fistula, G: cloaca with common channel < 3 cm, H: cloaca with common 
channel > 3 cm 
 
Treatment of ARM is considered an enormous challenge in reconstructive pediatric surgery. 
As the majority of patients need a colostomy prior to the definitive repair of the anomaly, 
multiple surgical procedures are often required in the first two years of a patient’s life in 
order to restore bowel function.9 Nowadays, the posterior sagittal approach, which was 
introduced in 1980, is the most commonly used and ideal method to repair ARM.9 
Postoperatively, intensive treatment with anal dilatations need to be performed by the 
parents, which can be painful for the child and have long-term impact on both the child and 
the parents as well.10 The posterior sagittal approach clearly improved the anatomical 
restoration, but complete functional restoration is hardly ever achieved. As a result, ARM is 
often associated with lifelong psychosocial problems and physical impairments, such as 
constipation, fecal incontinence, and urological, sexual and gynecological problems.11,12 
Because of these problems, etiologic research is essential to obtain more insight in the 
development of ARM, with the ultimate aim to provide preventive strategies and improved 
genetic counseling. 
 In approximately 10% of all patients, a genetic cause is known as ARM develop as 
part of a chromosomal disorder or a syndrome,7 such as 13q deletion syndrome, cat eye 
syndrome, Townes-Brocks syndrome, or Currarino syndrome.13-15 In the remaining non-
15 
syndromic ARM patients, however, the etiology is still unclear. Since various modes of 
inheritance have been shown in pedigrees with familial ARM and the majority of cases occur 
sporadically, a multifactorial etiology with involvement of both genetic and non-genetic 
factors seems most likely.16-18 
 
Objectives and outline of this thesis 
The main objective of this thesis is to increase knowledge on the involvement of genetic and 
non-genetic risk factors in the etiology of congenital anorectal malformations. To accomplish 
this objective, studies are performed on:  
 
- definitions and prevalence of ARM phenotypes and associated congenital malformations 
(Part 1) 
- a wide range of potential non-genetic risk factors for ARM (Part 2) 
- the contribution of rare genetic variants and a potential gene-environment interaction to 
the development of ARM (Part 3) 
 
Several databases and biobanks with ARM cases and control children were used for the 
studies performed, with the AGORA (Aetiologic research into Genetic and Occupational/ 
environmental Risk factors for Anomalies in children) data- and biobank as the main source. 
AGORA is a network organization of the departments for Health Evidence and Human 
Genetics and many clinical departments participating in the Amalia Children’s Hospital of the 
Radboud university medical center (Radboudumc), which started with routine data 
collection to facilitate future research into childhood cancer and different congenital 
malformations, including ARM, in December 2004.19 AGORA includes clinical data and DNA 
from the child and DNA and questionnaire data from their parents. As etiologic hetero-
geneity may exist among different phenotypic subgroups of ARM, these subgroups were 
taken into account in the studies if case numbers were sufficient. 
 
Part 1: Introduction, prevalence, and definitions 
An extensive systematic review of the literature on the genetic and non-genetic etiology of 
ARM is presented in Chapter 2. Chapter 3 describes the ARM-Net Consortium that was 
initiated by clinicians, epidemiologists, geneticists, and patient organizations involved in 
ARM from the Netherlands, Germany, Italy, and France at the end of 2009 with the aim to 
exchange data and knowledge and to collaborate in research and clinical topics.20 The first 
results on the prevalence of ARM phenotypes and associated congenital malformations and 
treatment of ARM within the ARM-Net Consortium are presented in Chapter 4. Chapter 5 
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16 
describes a discussion of the definition of the VACTERL association using clinical data from 
AGORA and the German Network for Congenital Uro-REctal malformations (CURE-Net).21 
 
Part 2: Non-genetic factors 
In Chapter 6, associations between ARM and several pregnancy-related disorders are 
presented as assessed using the European Surveillance of Congenital Anomalies (EUROCAT) 
database,22 a large European registry of congenital malformations. Several potential risk 
factors for ARM were also studied using parental questionnaires from 85 ARM cases 
collected within AGORA (Chapter 7). Thereafter, major efforts were done to enlarge the 
ARM case population with patients from the Radboudumc, Sophia Children’s Hospital – 
Erasmus Medical Centre Rotterdam, and University Medical Center Groningen and to collect 
data from a population-based AGORA control group via municipalities throughout the 
Netherlands. These data are used to focus on associations between parental subfertility and 
a range of fertility treatments and the risk of ARM (Chapter 8). 
 
Part 3: Genetic factors and gene-environment interaction 
Chapter 9 concentrates on the assumed role of a gene-environment interaction between 
maternal periconceptional folic acid supplement use and the MTHFR C677T polymorphism in 
the occurrence of ARM. A genome-wide association study to identify rare genetic variants is 
described in Chapter 10. ARM cases were derived from AGORA and CURE-Net and controls 
from the Nijmegen Biomedical Study, a population-based survey of randomly selected 
inhabitants of the municipality of Nijmegen,23 while ARM cases and controls from Hong-Kong 
in China were used for replication analyses. 
 
Part 4: General discussion and summaries 
A general discussion of the studies within this thesis and summaries in English and Dutch are 
included in Chapters 11 and 12. 
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Abstract 
 
Congenital anorectal malformations (ARM) are the most frequently observed birth defects of 
the digestive system, but their etiology remains elusive. Therefore, we aim to summarize 
and critically appraise all existing literature on the genetic and non-genetic etiology of 
nonsyndromic ARM and to conclude with unifying hypotheses and directions for future 
research. A structured literature search on English language human studies was conducted in 
PubMed and Embase up to October 1, 2013, resulting in 112 included articles. Research on 
the identification of genes underlying nonsyndromic ARM is remarkably scarce. Most studies 
were focused on screening of candidate genes for mutations or single nucleotide 
polymorphisms, which did not yield any substantial evidence. Non-genetic factors fairly 
consistently found to be associated with ARM are assisted reproductive techniques, multiple 
pregnancy, preterm delivery, low birth weight, maternal overweight or obesity, and pre-
existing diabetes. This review provides indications for the involvement of both genes and 
non-genetic risk factors in the etiology of ARM. In future studies, large cohorts of ARM 
patients from national and international collaborations are needed to acquire new 
hypotheses and knowledge through hypothesis-generating approaches. Challenges for 
future studies may also lie in the investigation of gene-gene and gene-environment 
interactions. 
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Introduction 
Phenotypic characterization 
Anorectal malformations (ARM) are the most commonly observed congenital malformations 
of the digestive system, characterized by disturbed embryonic development of the hindgut 
4-8 weeks after conception. The embryology of abnormal anorectal development is still 
partly unclear as discussed in a recent review.1 The severity of ARM is variable, ranging from 
mild phenotypes with narrowing of the anorectal channel to anal atresia with or without 
fistulas and even more severe phenotypes, such as cloaca, as described in the international 
Krickenbeck classification for ARM developed in 2005.2 Fistulas can be perineal, 
rectourethral (bulbar or prostatic urethra), or rectovesical in males and perineal or 
rectovestibular in females. In cloacas, the urethra, vagina, and rectum form one single 
common channel to the perineum. ARM is accompanied by one or more other congenital 
malformations in 40-70% of patients, mostly malformations involved in the VACTERL 
(Vertebral, Anal, Cardiac, Tracheo-Esophageal, Renal, and Limb defects) association.3-5 Of all 
patients with ARM, 10-15% are diagnosed with the VACTERL association and in 
approximately 10%, a syndrome or chromosomal anomaly is recognized.  
 
Prevalence and prognosis 
The prevalence of ARM ranges from 2 to 6 per 10,000 births worldwide.6 Although no 
changes in prevalence rates have been observed over time, these rates vary considerably 
across countries. This may reflect true geographical and population variation or differences 
among registration systems, such as dissimilarities in identification, coding, or inclusion 
criteria.7,8 Moreover, mild phenotypes of ARM without clinical symptoms may easily be 
missed, especially among female patients, which may partly explain male/female ratios 
being 1.2–1.6.3,5,9-12 ARM is rarely diagnosed prenatally, but is usually detected during the 
early postnatal period.13 Mortality rates vary between 3 and 16%, with the highest rates 
among children with ARM and other congenital malformations.3,10,14,15 Surgical procedures 
are generally required during the first 2 years of life. Although surgical techniques have 
improved significantly in the last decades, complete anatomical and functional restoration 
cannot be achieved. This accounts for long-lasting problems in the majority of patients,15 
ranging from constipation to fecal soiling or even complete fecal incontinence, urological, 
gynecological and sexual difficulties, and psychosocial problems, which may decrease quality 
of life among patients and their families.16 
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Aim of the review 
Primary prevention of ARM is needed, but this requires extensive knowledge about the 
etiology. In approximately 10% of patients, ARM develops as part of a chromosomal disorder 
or a syndrome caused by a single-gene mutation. Several chromosomal abnormalities 
described in patients with ARM, such as 13q deletion, cat eye syndrome, and trisomy 13, 18, 
and 21, were evaluated in a review by Marcelis et al.17. These loci predispose for ARM, but it 
remains unclear whether candidate genes in these regions cause nonsyndromic or 
syndromic ARM. Syndromes most frequently associated with ARM include Currarino 
syndrome, Townes-Brocks syndrome, and Pallister-Hall syndrome, which are caused by 
mutations in the HLBX9, SALL1, and GLI3 genes, respectively.18-20 The etiology of 
nonsyndromic ARM, however, remains unsolved but is suggested to be mainly multifactorial, 
involving both genetic and non-genetic risk factors. In this systematic review, we will 
summarize and critically appraise the existing literature about the genetic and non-genetic 
etiology of nonsyndromic ARM, involving many studies with small patient series and 
divergent results. Furthermore, we aim to conclude with unifying hypotheses regarding the 
etiology and to provide applicable directions for future research.  
 
Methods 
Literature search 
We conducted a comprehensive systematic literature search on the etiology of 
nonsyndromic ARM in PubMed and Embase up to October 1, 2013. Relevant studies were 
identified using combinations of terms for ARM and etiology. As several researchers 
evaluated non-genetic risk factors for a range of congenital malformations and did not 
always mention a keyword for ARM in their titles or abstracts, these studies were not 
identified using the initial search. Therefore, we performed an additional search on all 
potential non-genetic risk factors for ARM that were evaluated in the studies included from 
the initial search, combined with terms for congenital malformations. Other relevant studies 
were identified by reviewing the reference lists of the selected articles. The complete search 
strategy is available from the authors. 
 
Study selection 
The full screening process and search results are shown in Figure 1. The initial search was 
restricted to English language human studies on ARM and provided 2,335 articles in PubMed 
and 1,175 in Embase, leaving a total of 2,688 unique potentially relevant articles of which 
titles and abstracts were screened. Forty articles turned out to be animal or in vitro studies 
and were excluded. As we focused our review on the etiology of nonsyndromic ARM, we 
23 
excluded all articles that were not about ARM or described ARM phenotypes, syndromic 
forms of ARM, surgery, management, long-term follow-up, or quality of life of patients with, 
and embryology or prevalence of ARM. Because we included peer-reviewed studies 
containing original data only, reviews, meta-analyses, commentaries, and conference 
abstracts were also excluded. In addition, case reports on non-genetic risk factors were 
excluded, whereas we included informative case reports on the involvement of genes in 
nonsyndromic isolated ARM. Full texts of the remaining 63 articles and those from the 
additional search and cross-reviewing were reviewed in detail. Studies that evaluated case 
populations consisting of patients with and without ARM, such as VACTERL cases or a 
heterogeneous group of all intestinal atresias, were excluded when we were not able to 
extract the results for patients with ARM separately. We included gene expression studies 
only if gene expression was investigated in tissues from patients with ARM. Epidemiological 
studies were included when a risk estimate was presented or sufficient information was 
provided to estimate the risk of ARM. This selection process resulted in 112 included articles, 
19 on genetic and 93 on non-genetic risk factors for ARM. 
 
Data extraction 
 A uniform data extraction sheet was used to extract the necessary information and to assess 
the quality of the research hypothesis, study design, study setting, study population (number 
and type of cases and controls), statistical analyses, and risk estimates (with 95% confidence 
interval [CI]), as well as potential biases. If a risk estimate was not presented, we calculated 
one based on numbers given. From the epidemiological studies, we extracted extra 
information about exposure assessment, such as method used and time window of 
exposure, response rates, and confounders and/or effect modifiers. 
 
Results 
Genetic factors 
Although only 2–8% of patients with ARM have an affected first- or second degree 
relative,10,12,21-24 ARM co-occurs more often among family members than would be expected 
by chance.12,24-26 Familial occurrence seems to be most frequent when a perineal or 
vestibular fistula is present.23 Nevertheless, research focused on the identification of genes 
involved in the etiology of nonsyndromic ARM has been limited, and therefore, only 19 
genetic studies are included in this review (Table 1).  
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Most of these studies were focused on screening of specific genes in groups of ARM cases 
aiming to find causal mutations or genetic polymorphisms. The sonic hedgehog (SHH), 
wingless-type integration site (WNT), fibroblast growth factor (FGF), and bone morpho-
genetic protein (BMP) signaling pathways are essential in embryogenesis and are expected 
to be involved in hindgut development based on animal studies. Therefore, several genes 
(and downstream target) genes in these pathways were the subject of genetic studies on 
ARM. Significantly lower SHH, GLI2, and BMP4 expression was noted in the posterior wall of 
the terminal rectum in patients with ARM when compared with controls.27 Mutation 
screening, however, did not reveal relevant functional mutations in SHH or GLI3 in two 
studies with 15 and 88 patients, respectively.28,29 Single nucleotide polymorphisms (SNPs) at 
predicted regulatory sites in (downstream) targets of the SHH pathway, including GLI family 
zinc finger 2 (GLI2), homeobox D12 (HOXD12), BMP4, and proprotein convertase 
subtilisin/kexin type 5 (PCSK5), were suggested to be associated with isolated ARM in a study 
with patients of several ethnic populations. However, none of these associations remained 
after adjusting for multiple testing.30 Other candidate SNPs did not reach statistical 
significance after Bonferroni adjustment in this study either.30 The absence of any replicated 
findings may be explained by small sample sizes, inclusion of different phenotypes of ARM, 
or possible mutations in surrounding regulatory DNA elements or in upstream components 
of the same pathway. A few studies investigated the involvement of the WNT and FGF 
signaling pathways in the occurrence of ARM.30-34 No causal mutations were observed by 
screening the T Brachyury, FGF10, WNT3a, WNT5a, WNT11, DACT1, and FGFR2 genes,31-33 
except for one variant in the T Brachyury gene (C1013T),31 but it remains unclear whether 
this variant has functional consequences. However, a de novo duplication of the dickkopf 
WNT signaling pathway inhibitor 4 (DKK4) gene was identified in one patient with ARM and a 
deletion in the inturned planar cell polarity effector homolog (INTU) gene in two patients 
with ARM, using a candidate gene approach after gene-based analyses of genome-wide copy 
number variation (CNV) data.34 It is unclear whether the deletion in the INTU gene in the 
latter two patients was de novo or inherited from unaffected parents.  
Candidate genes were also selected based on the knowledge from animal studies, 
syndromic forms of ARM or other congenital malformations of the colon. After screening the 
caudal type homeobox 1 (CDX1) gene, four heterozygous mutations (c.213-214InsGAA, 
c.6G>C, c.27G>T, c.18A>C) were identified and lower CDX1 expression levels were found in 
cases when compared with controls.35 Although the ret protooncogene (RET) is a major gene 
involved in Hirschsprung’s disease, it was not associated with ARM.36 In a family consisting of 
a son with ARM and Hirschsprung’s disease and a mother and daughter having ARM, no 
causal mutations were identified in four major Hirschsprung’s disease genes (RET, EDNRB, 
EDN3, and GDNF) either.37 However, three SNPs in endothelin receptor type B (EDNRB) 
2  
 
Fi
gu
re
 1
. F
lo
w
 c
ha
rt
 o
f t
he
 sc
re
en
in
g 
pr
oc
es
s a
nd
 se
ar
ch
 re
su
lts
 fo
r t
he
 sy
st
em
at
ic
 re
vi
ew
 o
n 
th
e 
et
io
lo
gy
 o
f A
RM
.  
25 
Most of these studies were focused on screening of specific genes in groups of ARM cases 
aiming to find causal mutations or genetic polymorphisms. The sonic hedgehog (SHH), 
wingless-type integration site (WNT), fibroblast growth factor (FGF), and bone morpho-
genetic protein (BMP) signaling pathways are essential in embryogenesis and are expected 
to be involved in hindgut development based on animal studies. Therefore, several genes 
(and downstream target) genes in these pathways were the subject of genetic studies on 
ARM. Significantly lower SHH, GLI2, and BMP4 expression was noted in the posterior wall of 
the terminal rectum in patients with ARM when compared with controls.27 Mutation 
screening, however, did not reveal relevant functional mutations in SHH or GLI3 in two 
studies with 15 and 88 patients, respectively.28,29 Single nucleotide polymorphisms (SNPs) at 
predicted regulatory sites in (downstream) targets of the SHH pathway, including GLI family 
zinc finger 2 (GLI2), homeobox D12 (HOXD12), BMP4, and proprotein convertase 
subtilisin/kexin type 5 (PCSK5), were suggested to be associated with isolated ARM in a study 
with patients of several ethnic populations. However, none of these associations remained 
after adjusting for multiple testing.30 Other candidate SNPs did not reach statistical 
significance after Bonferroni adjustment in this study either.30 The absence of any replicated 
findings may be explained by small sample sizes, inclusion of different phenotypes of ARM, 
or possible mutations in surrounding regulatory DNA elements or in upstream components 
of the same pathway. A few studies investigated the involvement of the WNT and FGF 
signaling pathways in the occurrence of ARM.30-34 No causal mutations were observed by 
screening the T Brachyury, FGF10, WNT3a, WNT5a, WNT11, DACT1, and FGFR2 genes,31-33 
except for one variant in the T Brachyury gene (C1013T),31 but it remains unclear whether 
this variant has functional consequences. However, a de novo duplication of the dickkopf 
WNT signaling pathway inhibitor 4 (DKK4) gene was identified in one patient with ARM and a 
deletion in the inturned planar cell polarity effector homolog (INTU) gene in two patients 
with ARM, using a candidate gene approach after gene-based analyses of genome-wide copy 
number variation (CNV) data.34 It is unclear whether the deletion in the INTU gene in the 
latter two patients was de novo or inherited from unaffected parents.  
Candidate genes were also selected based on the knowledge from animal studies, 
syndromic forms of ARM or other congenital malformations of the colon. After screening the 
caudal type homeobox 1 (CDX1) gene, four heterozygous mutations (c.213-214InsGAA, 
c.6G>C, c.27G>T, c.18A>C) were identified and lower CDX1 expression levels were found in 
cases when compared with controls.35 Although the ret protooncogene (RET) is a major gene 
involved in Hirschsprung’s disease, it was not associated with ARM.36 In a family consisting of 
a son with ARM and Hirschsprung’s disease and a mother and daughter having ARM, no 
causal mutations were identified in four major Hirschsprung’s disease genes (RET, EDNRB, 
EDN3, and GDNF) either.37 However, three SNPs in endothelin receptor type B (EDNRB) 
26 
seemed to be associated with specific ARM phenotypes in 14 sporadic South African patients 
with ARM.38 The SNP 178G/A was more prevalent among female cases with a vestibular 
fistula when compared with controls, the 702C/T polymorphism among patients with a 
vesicorectal fistula or cloaca, and the SNP 831G/A among patients with bulbar or prostatic 
fistulas.38 As these findings were based on a small study sample, replication is essential.  
Few studies have been conducted using hypothesis-generating methods to identify 
disease-causing variants for ARM, such as genome-wide association studies (GWAS). To date, 
only one small GWAS was performed in 175 patients with ARM, which did not reveal any 
common SNPs associated with ARM.34 However, a few recent genome-wide CNV analyses 
provided potential candidate regions. Wong et al. found an increase in rare deletions and 
duplications, which applied both to CNVs smaller and larger than 100 kb in size.34 How many 
of these rare CNVs were de novo or were inherited from unaffected parents is unclear. 
Nevertheless, these findings provide strong support for a role of genetic factors in the etiolo-
gy of ARM. The data seem to implicate a large number of different genes and loci, each with 
only limited support from other sources. Wong et al. also found 12 CNVs larger than 1 Mb in 
ostensibly isolated ARM patients, including patients who were diagnosed with autism or who 
had CNVs that had previously been reported in patients with clear syndromic features. These 
CNVs had not been associated with ARM previously. The data suggest that the distinction 
between syndromic and nonsyndromic ARM in this study was likely based on limited clinical 
information and follow-up. Genome-wide CNV screening also revealed a de novo duplication 
of 18p11.21-18q12.1 in a female nonsyndromic patient with,39 and de novo micro-
duplications at 1q41, 2q37.3, and 8q24.3 (involving the SPATA17, GPR35, CAPN10, EPPK1, 
PLEC, PARP10 genes),40 a de novo microduplication at 22q11.21,41 and de novo 13q deletions 
including the EFNB2 gene42 in ARM cases with VACTERL or a VACTERL-like phenotype. 
Previously, 13q deletions have been described in seemingly syndromic patients with ARM 
and penoscrotal transposition, which were reviewed by Marcelis et al.17. Mutation screening 
of the GPR35 and EFNB2 genes among 192 and 331 patients with ARM, respectively, did not 
yield any causal mutations.40,42 No causative CNVs were found among three monozygotic 
twins discordant for ARM and one or more other congenital malformations.43  
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seemed to be associated with specific ARM phenotypes in 14 sporadic South African patients 
with ARM.38 The SNP 178G/A was more prevalent among female cases with a vestibular 
fistula when compared with controls, the 702C/T polymorphism among patients with a 
vesicorectal fistula or cloaca, and the SNP 831G/A among patients with bulbar or prostatic 
fistulas.38 As these findings were based on a small study sample, replication is essential.  
Few studies have been conducted using hypothesis-generating methods to identify 
disease-causing variants for ARM, such as genome-wide association studies (GWAS). To date, 
only one small GWAS was performed in 175 patients with ARM, which did not reveal any 
common SNPs associated with ARM.34 However, a few recent genome-wide CNV analyses 
provided potential candidate regions. Wong et al. found an increase in rare deletions and 
duplications, which applied both to CNVs smaller and larger than 100 kb in size.34 How many 
of these rare CNVs were de novo or were inherited from unaffected parents is unclear. 
Nevertheless, these findings provide strong support for a role of genetic factors in the etiolo-
gy of ARM. The data seem to implicate a large number of different genes and loci, each with 
only limited support from other sources. Wong et al. also found 12 CNVs larger than 1 Mb in 
ostensibly isolated ARM patients, including patients who were diagnosed with autism or who 
had CNVs that had previously been reported in patients with clear syndromic features. These 
CNVs had not been associated with ARM previously. The data suggest that the distinction 
between syndromic and nonsyndromic ARM in this study was likely based on limited clinical 
information and follow-up. Genome-wide CNV screening also revealed a de novo duplication 
of 18p11.21-18q12.1 in a female nonsyndromic patient with,39 and de novo micro-
duplications at 1q41, 2q37.3, and 8q24.3 (involving the SPATA17, GPR35, CAPN10, EPPK1, 
PLEC, PARP10 genes),40 a de novo microduplication at 22q11.21,41 and de novo 13q deletions 
including the EFNB2 gene42 in ARM cases with VACTERL or a VACTERL-like phenotype. 
Previously, 13q deletions have been described in seemingly syndromic patients with ARM 
and penoscrotal transposition, which were reviewed by Marcelis et al.17. Mutation screening 
of the GPR35 and EFNB2 genes among 192 and 331 patients with ARM, respectively, did not 
yield any causal mutations.40,42 No causative CNVs were found among three monozygotic 
twins discordant for ARM and one or more other congenital malformations.43  
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32 
Non-genetic factors 
More scientific attention has been paid to involvement of non-genetic factors in the etiology 
of ARM. These findings are summarized in Table 2. Table 3 and Supplemental Tables 1-3 in 
Online Resource show all existing literature on associations between non-genetic factors and 
ARM in more detail.   
 
Table 2. Summary of the existing literature on the involvement of non-genetic factors in the etiology 
of anorectal malformations.  
Factors (fairly) consistently associated with 
ARM 
Factors (fairly) consistently not associated with 
ARM 
Assisted reproductive techniques (IVF and ICSI) Maternal age at time of conception 
Multiple birth Paternal age at time of conception 
Preterm delivery Maternal alcohol use 
Low birth weight  
Maternal overweight or obesity  
Maternal pre-existing diabetes mellitus  
Factors that seem to be associated with ARM Factors that do not seem to be associated with 
ARM 
Benzodiazepines Contraceptives 
Maternal job exposure to industrial cleaning 
agents and solvents 
Maternal underweight 
Gestational diabetes 
 Chronic hypertension 
 Antimicrobial and antibiotic medication use 
 Antidepressant medication use 
 Maternal smoking 
Factors showing inconsistent results  
Hormonal treatment for ovulation induction Anti-asthmatics and anti-inflammatory 
medication use 
Nulliparity Paternal job exposure to exhaust fumes 
Fever during early pregnancy Paternal smoking 
Antifungal medication use Folic acid or multivitamin use 
Factors investigated in one study only  
Maternal subfertility Pandemic H1N1 influenza vaccination  
Paternal subfertility Maternal use of most other medications 
Prolonged time to pregnancy Most maternal and paternal job exposures 
Preeclampsia Paternal alcohol use 
Influenza Maternal illicit drug use 
Common cold Maternal caffeine intake 
Acute respiratory infections Living in urban or rural areas 
33 
Any chronic thyroid disorder High altitude 
Severe chronic dyspepsia X-rays during pregnancy 
Primary peptic ulcer disease Paternal overweight or obesity 
Epilepsy Use of hot tubs 
Bronchial asthma Use of swimming pool 
Glomerulonephritis during early pregnancy Maternal injury 
 
Fertility issues 
In three studies, associations were investigated between ARM and common methods of 
contraception, including oral contraceptives, spermicides, male condoms and intrauterine 
devices, but no associations were found (Table 3).22,44,45 However, assisted reproduction 
seems to attribute to the occurrence of ARM in several studies showing highly increased risk 
estimates ranging from 2.4 to 13.3.46-50 The highest risks were observed in studies comparing 
personal interviews among case parents with register-based control data.48,50 The size of the 
effect was lower in multiple births than in singletons,49,50 but seemed to be similar for 
different manifestations of ARM, including isolated ARM, ARM with other defects and ARM-
VACTERL.50 In other studies no or only small size associations between ARM and assisted 
reproduction seemed to exist.12,51-53 The study by Källén et al. published in 201051 was a 
repetition of their previous positive study,47 using datasets from different time periods. The 
authors hypothesized that the risk may have been randomly low or declined over time. The 
second negative study suffered from aspecific exposure assessment,12 whereas the third one 
focused specifically on the effect of clomiphene citrate, the most commonly used hormonal 
treatment for ovulation induction.52 Two other studies, however, did find an association 
between ovulation stimulation and ARM.46,53 Only one study looked at parental subfertility 
and reported an association between ARM and paternal but not maternal subfertility.12 This 
association was mainly found among fathers of ARM-VACTERL cases, for whom a five-fold 
increased risk of ARM was shown.12 This study also showed a prolonged time-to-pregnancy 
for parents of patients with ARM when compared with controls.12 
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Parental, pregnancy and infant characteristics 
Parental characteristics, including maternal and paternal age, may attribute to the 
occurrence of congenital malformations due to biological factors, such as ovarian age or 
mutations in sperm, or non-biological factors related to parental age, such as changing 
lifestyle patterns. However, neither maternal nor paternal age at time of conception seemed 
to increase the risk of ARM in most studies,9,10,12,22,30,54-57 although two studies showed 
associations between ARM and higher maternal age (Supplemental Table 1).58,59 In contrast, 
five studies showed an increased risk of having a child with ARM in the first 
pregnancy,9,12,30,53,60 whereas other studies did not show associations between ARM and 
parity,10,22,58,61 or showed the opposite effect.59 The majority of these studies did not adjust 
for confounding, except three studies showing elevated risks of ARM in the first 
pregnancy.9,53,60 ARM was almost consistently found to occur more frequently in multiple 
births than in singletons,10,50,53,61-63 but these results were not adjusted for confounders, 
such as assisted reproduction, in any of the studies. Two studies showed a higher rate of 
isolated ARM, ARM with other congenital malformations, and ARM-VACTERL among multiple 
births.50,53 Associations between ARM and preterm delivery and low birth weight were also 
fairly consistently reported,10,12,22,61,64,65 although these factors are unlikely to be causal. 
They may, however, share a common pathogenic pathway with ARM.  
 
Pregnancy complications and medical drug use 
Only a few maternal health issues complicating pregnancy have been investigated 
extensively in relation to the risk of ARM. For mothers being overweight (25 ≤ body mass 
index [BMI] < 30 kg/m2) or obese (BMI ≥ 30 kg/m2) before pregnancy, increased risks of ARM 
were observed in most studies,12,61,66,67 one of which also showed an elevated risk of isolated 
ARM separately among obese mothers (Supplemental Table 2).66 Carter et al. hypothesized 
that interaction between maternal obesity and variants in the McKusick-Kaufman syndrome 
(MKKS) gene may be involved in ARM, but did not find evidence in their study, probably due 
to unreliable data on obesity.30 No associations were observed between ARM and maternal 
underweight either. Several researchers found increased risks of ARM for pre-existing 
diabetes mellitus.22,68-71 Others did not confirm these results,53,72-74 probably due to lack of 
power or to using children with other congenital malformations as controls. The latter may 
have led to underestimation of the effect, because pre-existing diabetes is a strong risk 
factor for many congenital malformations. Most studies did not show clear associations 
between ARM and gestational diabetes,30,69,73,75 except for the study by Correa et al. when 
looking at isolated ARM only.70 Because gestational diabetes usually develops after the 
critical developmental period for ARM, a positive association may refer to undiagnosed pre-
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existing diabetes. It has been argued that overweight or obesity and diabetes mellitus may 
be factors in the same causal pathway, whereby alternations between glycemic control and 
hyperglycemia may increase the risk of having a child with ARM.66 Associations found 
between ARM and high dietary glycemic intake among non-diabetic mothers strengthen this 
hypothesis.76,77 Some studies on pre-pregnancy BMI excluded mothers with pre-existing 
diabetes and still showed associations between ARM and overweight and/or obesity.66,67 
This may be explained by inclusion of mothers with undetected or subclinical diabetes 
mellitus in early pregnancy. Correa et al. found that the risk of ARM increased enormously 
(odds ratio [OR] 28.7; 95% CI: 5.5-151.0) when mothers with diabetes mellitus did not use 
multivitamins containing folic acid during the critical time period.71  
The role of other pregnancy complications in the occurrence of ARM was less often 
investigated. Chronic hypertension did not seem to be associated with ARM in three 
studies.22,61,78 In two other studies, preeclampsia was not associated with isolated ARM 
either,53,79 but it was associated with ARM with other congenital malformations.53 In 
addition, preeclampsia superimposed on chronic hypertension was associated with isolated 
ARM.79 Maternal influenza, common colds, and acute respiratory infections during the 
second or third month of pregnancy did not increase the risk of ARM, but these results were 
mostly derived from single studies.22,80-82 One rather small study did not find an association 
between ARM and maternal fever during pregnancy either,22 whereas three other studies 
showed increased risks of ARM for mothers who had a fever during the first trimester of 
pregnancy,12,24,53 mainly in ARM with other congenital malformations.53 Chronic thyroid 
disorders and two gastro-intestinal disorders (severe chronic dyspepsia and primary peptic 
ulcer disease) seemed to be associated with ARM as well, especially with isolated ARM.83-85 
Strong associations were found between phenotypic subgroups of ARM and maternal 
epilepsy in a large European study,53 but not in another small study.22 Associations with ARM 
were not found for bronchial asthma, glomerulonephritis, mental disorders, and pandemic 
H1N1 influenza vaccination in single studies that were probably underpowered for these 
maternal disorders.53,86-88 
Maternal use of therapeutic drugs, such as analgesics and antipyretics,89-92 
antimicrobials or antibiotics,93-95 antidepressants,96-98 antihistamines,99 hypotensive medica-
tion,100 barbiturates,101 and decongestants102 did not seem to be associated with increased 
risks of ARM, although separate medical drugs were mostly evaluated in one study only. 
Maternal use of opioid analgesics during early pregnancy seemed to increase the risk, mainly 
for isolated ARM.91 Inconsistent results were found for the use of antifungal medication, 
with metronidazole and miconazole being associated with ARM,103,104 whereas other 
antifungal drugs were not.105,106 Benzodiazepines and other psychotropic drugs were 
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existing diabetes. It has been argued that overweight or obesity and diabetes mellitus may 
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hyperglycemia may increase the risk of having a child with ARM.66 Associations found 
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(odds ratio [OR] 28.7; 95% CI: 5.5-151.0) when mothers with diabetes mellitus did not use 
multivitamins containing folic acid during the critical time period.71  
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investigated. Chronic hypertension did not seem to be associated with ARM in three 
studies.22,61,78 In two other studies, preeclampsia was not associated with isolated ARM 
either,53,79 but it was associated with ARM with other congenital malformations.53 In 
addition, preeclampsia superimposed on chronic hypertension was associated with isolated 
ARM.79 Maternal influenza, common colds, and acute respiratory infections during the 
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between ARM and maternal fever during pregnancy either,22 whereas three other studies 
showed increased risks of ARM for mothers who had a fever during the first trimester of 
pregnancy,12,24,53 mainly in ARM with other congenital malformations.53 Chronic thyroid 
disorders and two gastro-intestinal disorders (severe chronic dyspepsia and primary peptic 
ulcer disease) seemed to be associated with ARM as well, especially with isolated ARM.83-85 
Strong associations were found between phenotypic subgroups of ARM and maternal 
epilepsy in a large European study,53 but not in another small study.22 Associations with ARM 
were not found for bronchial asthma, glomerulonephritis, mental disorders, and pandemic 
H1N1 influenza vaccination in single studies that were probably underpowered for these 
maternal disorders.53,86-88 
Maternal use of therapeutic drugs, such as analgesics and antipyretics,89-92 
antimicrobials or antibiotics,93-95 antidepressants,96-98 antihistamines,99 hypotensive medica-
tion,100 barbiturates,101 and decongestants102 did not seem to be associated with increased 
risks of ARM, although separate medical drugs were mostly evaluated in one study only. 
Maternal use of opioid analgesics during early pregnancy seemed to increase the risk, mainly 
for isolated ARM.91 Inconsistent results were found for the use of antifungal medication, 
with metronidazole and miconazole being associated with ARM,103,104 whereas other 
antifungal drugs were not.105,106 Benzodiazepines and other psychotropic drugs were 
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investigated the most, especially using data from the Hungarian Case-Control Surveillance of 
Congenital Anomalies. Increased risks were observed after maternal use of different kinds or 
combinations of benzodiazepines during the critical period of embryogenesis in three 
studies,107-109 but not in two others.110,111 However, one of the latter studies combined 
benzodiazepines and other psychotropic drugs in one exposure group.111 One study showed 
anti-asthmatic drug use to be associated with ARM,112 whereas another did not.113 The 
above-mentioned study on thyroid disorders also showed an increased risk of ARM for 
thyreostatic medication, but not for thyroxine use.83 An association between ARM and drugs 
for preterm labor (2-amino-1-phenylethanol) was observed in a study from the International 
Clearinghouse for Birth Defects.114 Finally, for anti-inflammatory drugs, no associations with 
ARM were reported except for isolated ARM only.113 However, we doubt the reliability of 
several of these findings as information was mostly based on hospital records or was 
retrospectively collected through interviews or questionnaires that were prone to 
underreporting and recall problems.115 In general, it is difficult to evaluate whether the 
medication used or the underlying disease is involved in the etiology of ARM. 
 
Occupational and lifestyle factors 
Parental occupational exposures were not extensively studied in relation to ARM. However, 
mothers prenatally exposed to industrial cleaning agents and solvents while working as 
cleaners or janitors seemed to have an increased risk of giving birth to a child with ARM 
(Supplemental Table 3).12,24,116,117 In one study, the risk was also elevated for mothers 
employed as scientists during pregnancy.116 Other maternal occupational exposures did not 
seem to be associated with ARM, except for cytostatics with ARM-VACTERL only.12 
Indications for an elevated risk of ARM among fathers occupationally exposed to exhaust 
fumes were found in two studies,12,118 but these results were not confirmed in a replication 
study.24 Increased ORs observed for fathers working as printers, policemen, guards, vehicle 
manufacturers, and artists were mostly not statistically significant and found in single studies 
only.118,119 For scientists and shippers, decreased risks were observed,119 whereas for many 
other jobs and exposures among fathers no clear associations were seen.12,118,119  
Maternal smoking was not associated with ARM in most studies12,22,120-123 and only 
slightly in three.30,61,124 However, one of the latter studies showed that this association was 
not present for isolated ARM only.61 Paternal smoking or exposure to environmental tobacco 
smoke during embryogenesis was associated with ARM in two studies,12,61 but not in two 
other studies.24,122 Neither parental alcohol use nor maternal illicit drug use, including 
cannabis, cocaine or stimulant use during pregnancy, was found to be involved in the 
etiology of ARM.12,22,61,122,125 Maternal caffeine intake, on the other hand, was associated 
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with an increased risk of ARM with the highest OR among mothers who consumed more 
than 300 mg of caffeine per day.61 Although three of the five studies that investigated the 
effect of folic acid use on the etiology of ARM showed reduced ORs, these were not or only 
marginally statistically significant.12,59,71,126,127 The results for maternal multivitamin use 
showed either no effect68 or an adverse effect.12 Living in urban or rural areas did not seem 
to be associated with ARM,22 but a study in South America found an increased birth 
prevalence of infants with ARM at high altitudes.128 Some other parental factors evaluated in 
single studies, such as undergoing X-rays during pregnancy, paternal overweight or obesity, 
use of hot tubs, and swimming pool use were not associated with ARM,12,22,129,130 whereas 
mothers who reported being injured during early pregnancy seemed to have an increased 
risk of having a child with ARM.131 
 
Conclusions 
The etiology of ARM remains elusive for the majority of nonsyndromic ARM cases, but this 
review provides indications that both genetic and non-genetic factors are involved. ARM 
may include monogenic as well as multifactorial forms, but we can only speculate about the 
proportion of each as genetic research on ARM is remarkably scarce.  
Most genetic studies on ARM were based on a candidate gene approach, which did 
not yield any substantial evidence. Candidate genes were mainly genes that are involved in 
the SHH, WNT and FGF signaling pathways, which control multiple processes, including 
embryonic patterning, proliferation, migration, and differentiation. Preliminary evidence for 
a contribution of genes and (downstream) targets in these pathways (Shh, Gli2, Gli3, BMP4, 
Fgf10, and Wnt5a) was derived from animal studies not reviewed in this article.132-137 SHH, 
GLI2, and BMP4 were also identified as candidate genes in a human expression study.27 Only 
one candidate gene study identified functional mutations in the CDX1 gene, as well as lower 
CDX1 expression levels in patients with ARM.35 CDX1 is a transcription factor, which is 
involved in the regulation of proliferation and differentiation of embryonic intestinal tissue 
and is regulated by the WNT/β-catenin signaling pathway.138 These studies may suggest that 
abnormal functioning of the SHH and WNT signaling pathways plays a role in the occurrence 
of nonsyndromic ARM. However, other candidate gene studies did not reveal any functional 
mutations or polymorphisms in genes involved in these pathways. This may be due to small 
sample sizes, which emphasizes that larger patient series are essential. On the other hand, it 
probably implies that other genetic regions contribute to the development of ARM. 
Candidate gene studies are driven by researchers’ a priori presumptions and hypotheses, but 
do not necessarily generate new knowledge. Therefore, it seems highly valuable to acquire 
new hypotheses through hypothesis-generating approaches, such as GWAS to elucidate the 
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than 300 mg of caffeine per day.61 Although three of the five studies that investigated the 
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role of common variants, and exome or whole-genome sequencing to study rare variants. 
Application of the latter techniques in large cohorts of patients with ARM is currently still 
unfeasible, but may be useful to identify genes in large families with multiple affected 
individuals or de novo mutations in sporadic patients with severe phenotypes of ARM who 
frequently encounter reproductive problems.  
Many rare CNVs that provide potential candidate regions for ARM were identified in 
a genome-wide CNV study.34 However, information on de novo occurrence was lacking and 
no specific CNV was discovered in multiple patients with ARM, which may imply genetic 
heterogeneity. The authors also suggested a link between these rare CNVs and the WNT 
signaling pathway and cytoskeletal network using gene network analyses.139 The cytoskeletal 
network has a role in, for example, ciliogenesis and cell movement and is regulated by WNT 
signaling. Furthermore, a few studies showed the importance of thorough phenotypic 
characterization and analyses in phenotypic subgroups of ARM. SNPs in the EDNRB gene, 
which induces smooth muscle differentiation, seemed to increase the risks of specific 
phenotypes of ARM only. Moreover, increased heritability of ARM was found among 
patients with perineal or vestibular fistulas,23 and SHH, GLI2, BMP4, and CDX1 were 
identified as candidate genes for mainly high-located ARM.27,35  
Several non-genetic risk factors for ARM have been studied as well, but only a few 
factors were consistently found to be associated with ARM: assisted reproduction, multiple 
pregnancy, preterm delivery, low birth weight, maternal overweight or obesity and pre-
existing diabetes. Regarding assisted reproduction, the true causal factor remains unclear. Is 
it hormonal treatment, the handling of oocytes and sperm, and/or the underlying parental 
subfertility? Low birth weight may be a consequence of fetal hypoxemia and decreased 
nutrient supply, which may in turn be due to alterations in placental development.140 Similar 
circumstances may occur in multiple and nulliparous pregnancies141 and may contribute to 
preeclampsia. Although associations found between ARM and nulliparity and preeclampsia 
still need confirmation, we hypothesize that placental insufficiency in early pregnancy may 
be involved in the etiology of ARM. Shared metabolic alternations, such as hyperglycemia, in 
overweight, obese, and diabetic mothers may clarify the associations with ARM for these 
factors.66 A previous study showed that adverse pregnancy outcomes mainly occurred in 
mothers with poor glycemic control during the critical phase of embryogenesis,142 which is 
the case in obese women with undiagnosed diabetes in particular. These studies consistently 
found that non-genetic risk factors are not unique for ARM, as assisted reproduction, 
multiple pregnancy, preterm delivery, low birth weight, preeclampsia, overweight or obesity, 
and pre-existing diabetes were also found to be associated with other congenital 
malformations, such as cardiac defects, neural tube defects, and hypospadias.49,63-
43 
65,67,70,143,144 This may point to nonspecificity or the relevance of timing of exposure during 
embryonic development, although the latter seems to be less applicable to these specific 
risk factors. It is impossible to draw conclusions about the involvement of most other 
maternal illnesses, medical drug use, and parental occupational or lifestyle factors in the 
etiology of ARM as results were inconsistent or derived from single studies only.  
Overall, most studies were limited by small samples sizes due to the relatively rare 
occurrence of ARM. Therefore, future studies should focus on the collection of data in large 
cohorts of patients with ARM, for which national and international collaborations seem 
essential.24 This will also enable analyses on specific phenotypes of ARM to elucidate the 
potentially heterogeneous etiology. Additional challenges for future research may lie in 
studying the role of complex gene-gene and gene-environment interactions in the etiology 
of ARM. Ideally, increased knowledge on the pathogenesis of ARM will lead to better 
guidance of patients and their families, more precise estimation of recurrence risks, 
identification of high-risk groups, and tailored preventive strategies.  
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guidance of patients and their families, more precise estimation of recurrence risks, 
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Abstract  
 
Purpose The recently established International Consortium on Anorectal Malformations 
aims to identify genetic and environmental risk factors in the etiology of syndromic and 
nonsyndromic anorectal malformations (ARM) by promoting collaboration through data 
sharing and combined research activities.  
 
Methods The consortium attempts to recruit at least 1,000 ARM cases. DNA samples are 
collected from case-parent triads to identify genetic factors involved in ARM. Several genetic 
techniques will be applied, including SNP arrays, gene and whole exome sequencing, and a 
genome-wide association study. Questionnaires inquiring about circumstances before and 
during pregnancy will be used to obtain environmental risk factor data. 
 
Results Currently, 701 ARM cases have been recruited throughout Europe. Clinical data are 
available from all cases, and DNA samples and questionnaire data mainly from the Dutch and 
German cases. Preliminary analyses on environmental risk factors in the Dutch and German 
cohort found associations between ARM and family history of ARM, fever during first 
trimester of pregnancy, and maternal job exposure to cleaning agents and solvents. 
 
Conclusion First results show that both genetic and environmental factors may contribute to 
the multifactorial etiology of ARM. The International Consortium on Anorectal 
Malformations will provide possibilities to study and detect important genes and 
environmental risk factors for ARM, ultimately resulting in better genetic counseling, 
improved therapies, and primary prevention.  
87 
Introduction 
Congenital anorectal malformations (ARM) are rare disorders, occurring in approximately 1 
in 5000 to 1 in 1500 live births worldwide.1 These disorders usually require surgical 
interventions in the neonatal period and postoperative follow-up and treatment to obtain 
and maintain fecal and urinary continence. Sequelae of ARM continue into adulthood and 
may include fecal incontinence and sexual dysfunction. All these issues cause major concerns 
for parents and children at school age and in later life, and pose a large social problem 
connected with acceptance of the population suffering from these problems. Clinical 
outcomes of ARM, such as functional stooling problems, are found to be directly associated 
with poor quality of life in ARM patients.2,3 These outcomes often deteriorate with age, 
which emphasizes the need for long-term follow-up and psychosocial treatment.2,3 As 
experience concerning ARM is scattered in many different hospitals in most European 
countries,4 regional differences in clinical outcome and quality of life have been reported. 
Moreover, case comparison is difficult, as a detailed diagnosis according to Krickenbeck is 
often not stated in discharge letters.5 
Despite the great physical and social burden on ARM patients and their parents, the 
etiology is largely unknown. In rare cases, ARM can be explained by chromosomal 
abnormalities or is part of a well-known syndrome. Townes-Brocks syndrome, comprising 
ear, limb, anal, renal, and heart anomalies, is caused by mutations in the SALL1 gene,6,7 
whereas mutations in the homeobox gene HLXB9 lead to Currarino syndrome, a combination 
of sacral agenesis, presacral mass, and ARM.8-10 However, clinical manifestations of 
syndromic forms of ARM may vary and genetics and underlying mechanisms remain elusive. 
The majority of ARM cases are not part of a syndrome and their etiology is assumed to be 
multifactorial with a causal interplay of genetic and environmental factors. Evidence for 
genetic factors involved in the anorectal development is mainly derived from syndromic 
ARM and animal studies rather than from studies on nonsyndromic ARM. In addition to 
genetic factors, an essential role is expected for environmental factors as ARM rarely 
aggregates in families.11 Some researchers studied environmental hazards and found 
associations between ARM and maternal alcohol intake,12 tobacco smoke and caffeine,13 the 
benzodiazepine lorazepam,14 paternal exposure to occupational hazards,15,16 and folic acid 
supplementation.17 In addition to these factors, increased risks were found after in vitro 
fertilization.18-20 However, strong evidence is still scarce as most potential risk factors were 
found in only one study and the majority of the studies had low power.  
To summarize, large scale studies on genetic and environmental risk factors with 
human ARM cases have not yet been performed, but could provide substantial clues on the 
pathogenesis of ARM. ARM would benefit from prevention, accurate diagnosis, and outlined 
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trimester of pregnancy, and maternal job exposure to cleaning agents and solvents. 
 
Conclusion First results show that both genetic and environmental factors may contribute to 
the multifactorial etiology of ARM. The International Consortium on Anorectal 
Malformations will provide possibilities to study and detect important genes and 
environmental risk factors for ARM, ultimately resulting in better genetic counseling, 
improved therapies, and primary prevention.  
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Introduction 
Congenital anorectal malformations (ARM) are rare disorders, occurring in approximately 1 
in 5000 to 1 in 1500 live births worldwide.1 These disorders usually require surgical 
interventions in the neonatal period and postoperative follow-up and treatment to obtain 
and maintain fecal and urinary continence. Sequelae of ARM continue into adulthood and 
may include fecal incontinence and sexual dysfunction. All these issues cause major concerns 
for parents and children at school age and in later life, and pose a large social problem 
connected with acceptance of the population suffering from these problems. Clinical 
outcomes of ARM, such as functional stooling problems, are found to be directly associated 
with poor quality of life in ARM patients.2,3 These outcomes often deteriorate with age, 
which emphasizes the need for long-term follow-up and psychosocial treatment.2,3 As 
experience concerning ARM is scattered in many different hospitals in most European 
countries,4 regional differences in clinical outcome and quality of life have been reported. 
Moreover, case comparison is difficult, as a detailed diagnosis according to Krickenbeck is 
often not stated in discharge letters.5 
Despite the great physical and social burden on ARM patients and their parents, the 
etiology is largely unknown. In rare cases, ARM can be explained by chromosomal 
abnormalities or is part of a well-known syndrome. Townes-Brocks syndrome, comprising 
ear, limb, anal, renal, and heart anomalies, is caused by mutations in the SALL1 gene,6,7 
whereas mutations in the homeobox gene HLXB9 lead to Currarino syndrome, a combination 
of sacral agenesis, presacral mass, and ARM.8-10 However, clinical manifestations of 
syndromic forms of ARM may vary and genetics and underlying mechanisms remain elusive. 
The majority of ARM cases are not part of a syndrome and their etiology is assumed to be 
multifactorial with a causal interplay of genetic and environmental factors. Evidence for 
genetic factors involved in the anorectal development is mainly derived from syndromic 
ARM and animal studies rather than from studies on nonsyndromic ARM. In addition to 
genetic factors, an essential role is expected for environmental factors as ARM rarely 
aggregates in families.11 Some researchers studied environmental hazards and found 
associations between ARM and maternal alcohol intake,12 tobacco smoke and caffeine,13 the 
benzodiazepine lorazepam,14 paternal exposure to occupational hazards,15,16 and folic acid 
supplementation.17 In addition to these factors, increased risks were found after in vitro 
fertilization.18-20 However, strong evidence is still scarce as most potential risk factors were 
found in only one study and the majority of the studies had low power.  
To summarize, large scale studies on genetic and environmental risk factors with 
human ARM cases have not yet been performed, but could provide substantial clues on the 
pathogenesis of ARM. ARM would benefit from prevention, accurate diagnosis, and outlined 
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clinical treatment. Clinical research on regional differences in clinical outcome and quality of 
life may contribute to improvements in patient care. Recently, the International Consortium 
on Anorectal Malformations, consisting of the Dutch AGORA-project (Aetiologic research 
into Genetic, Occupational and environmental Risk factors for Anomalies in children), the 
German CURE-NET (German Network for Congenital Uro-REctal Malformations), the Italian 
MUGAR-Net (Network for Uro-Genito-Ano-Rectal malformations in Italy), and the French 
MAREP (National Center for AnoRectal Malformations and rare Pelvic Anomalies), has been 
established for etiologic and clinical research. Our multidisciplinary consortium of 
geneticists, epidemiologists, and clinician-scientists strongly believes that a fundamental 
prerequisite for progress in the field of rare developmental disorders, such as ARM, will be 
to strengthen the ties between clinical and basic research activities. In this report, our 
mission and specific research goals regarding the pathobiology of ARM will be addressed. In 
addition, the first results on environmental risk factors from the Dutch and German ARM 
cohort will be presented. 
 
Methods 
Consortium on Anorectal Malformations 
Researchers from the participating countries initiated the establishment of an International 
Consortium on Anorectal Malformations. Our common goal is to collaborate and exchange 
knowledge on a research topic that is still in its infancy. We aim to perform high quality 
etiologic research on ARM and to standardize diagnostic classifications and clinical outcomes 
of ARM patients throughout Europe. The consortium will create a registry of ARM patients, 
which will serve as a base for all research on ARM. This registry is essential for etiologic 
research, which needs adequately registered diagnoses of ARM patients, as different 
phenotypes of ARM may originate from different pathogenic processes. 
At the current stage of research, more and more emphasis is placed on large 
numbers of patients and development of biobanks for both rare and frequently occurring 
disorders. Therefore, the participants in this consortium consider it of utmost importance to 
collect a critical mass of clinical data and biomaterials from children affected by ARM and 
their parents in a collaborative effort. The international collaboration will create case series 
of patients with data and biomaterials that would be hard to achieve on a national scale in 
any country. We aim to recruit at least 1,000 ARM cases within the countries participating in 
the consortium. Blood or saliva samples are collected from case-parent triads for genetic 
analyses. Questionnaires inquiring about circumstances three months before and during 
pregnancy will be used to obtain environmental risk factor data from the parents. Potential 
environmental risk factors are those that are capable of affecting the formation of oocytes 
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and spermatozoa and/or may influence the development of the embryo. A special database 
for questionnaire and clinical data will be set up that can be used for data entry in all 
participating countries. Professional data management will facilitate ongoing clinical 
collaborative projects ensuring data quality and compatibility. The following paragraphs 
describe the existing projects of patient and data collection in the currently participating 
countries of the consortium.   
 
AGORA - The Netherlands  
AGORA (Aetiologic research on Genetic, Occupational and environmental Risk factors for 
Anomalies in children) started at the Radboud University Nijmegen Medical Centre 
(RUNMC), Nijmegen, The Netherlands in 2005. Several disciplines collaborate in AGORA, 
namely genetic, epidemiologic, and pediatric departments, with the common aim to study 
the role of genetic and environmental risk factors in the etiology of a variety of congenital 
malformations, including ARM. Blood or saliva samples and environmental data are routinely 
collected from case-parent-triads during diagnostic or surgical procedures. The ideal control 
group, which consists of a random sample of the Dutch population in the relevant age group, 
will also be recruited to perform research on all congenital malformation patient groups 
within AGORA.   
 
CURE-NET - Germany 
The German Network for Congenital Uro-REctal Malformations (CURE-Net) represents the 
first systematic approach in Germany to investigate the molecular causes of congenital uro-
rectal malformations, employing an integrated network structure that involves basic 
research disciplines, and to establish the first prospective multicenter study into the clinical 
implications and psychosocial outcome of these disorders. CURE-NET was founded in 2008 
with federal funding by the German Federal Ministry of Education and Research (BMBF) 
starting in 2009. To ensure efficient recruitment of patients and their families, central 
recruitment has been established with all participating families being assessed in person by 
one of four physicians specialized in clinical genetics and/or pediatric surgery. DNA samples 
of each participating individual are stored in a central DNA biomaterial bank (DNA-BMB). The 
phenotypic information is documented in a nationwide register.  
 
MUGAR-Net - Italy 
The MUGAR-Net project (Network for Uro-Genito-Ano-Rectal malformations in Italy) is an 
ongoing project that does not exist in Italy at the moment, which aims to set up an Italian 
registry for urogenital and anorectal malformations. The registry will allow us to perform 
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the role of genetic and environmental risk factors in the etiology of a variety of congenital 
malformations, including ARM. Blood or saliva samples and environmental data are routinely 
collected from case-parent-triads during diagnostic or surgical procedures. The ideal control 
group, which consists of a random sample of the Dutch population in the relevant age group, 
will also be recruited to perform research on all congenital malformation patient groups 
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first systematic approach in Germany to investigate the molecular causes of congenital uro-
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with federal funding by the German Federal Ministry of Education and Research (BMBF) 
starting in 2009. To ensure efficient recruitment of patients and their families, central 
recruitment has been established with all participating families being assessed in person by 
one of four physicians specialized in clinical genetics and/or pediatric surgery. DNA samples 
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MUGAR-Net - Italy 
The MUGAR-Net project (Network for Uro-Genito-Ano-Rectal malformations in Italy) is an 
ongoing project that does not exist in Italy at the moment, which aims to set up an Italian 
registry for urogenital and anorectal malformations. The registry will allow us to perform 
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epidemiological studies, make the healthcare workers aware of the problem, collect blood 
and saliva samples from affected patients in a biobank, and finally establish cooperation with 
other international centers.  
 
MAREP - France 
The national center for AnoRectal Malformations and rare Pelvic anomalies (MAREP) was 
created in 2007 as part of the National French Program for Rare Disease (2005–2008). Its 
main objectives are to develop a French registry gathering anatomical and clinical data, to 
edit guidelines for the optimal management and follow-up of patients with ARM, and to 
diffuse information to patients, families, and medical actors to ensure equality for 
diagnostics, treatment, and care. Genetic diseases screening, research development and 
European collaborations form a large part of our missions as well. Data are collected and 
recorded online in a database called CEMARA (for CEntre MAladies RAres), which interacts 
with the Orphanet database. Blood samples are already collected in syndromic forms and 
collection will be extended to all enrolled patients. This center is also the national referent 
for Currarino syndrome molecular sequencing, and 90 index cases have been recorded. 
MAREP currently collects about 50–60 new ARM cases per year and is thus ready to 
participate in the consortium. 
 
Research possibilities 
The substantial amount of data that will be obtained within the consortium offers many 
possibilities for ARM research. Due to rapid developments in the genetic field, existing 
techniques in performing genetic research have also changed rapidly. SNP arrays and new 
promising gene sequencing techniques are appropriate in performing research regarding 
syndromic forms of ARM. Identification of genes mediating syndromic forms of ARM may 
also provide suggestions for the role of genetic factors in the etiology of more isolated forms 
of ARM. At the current stage, however, indications for specific candidate genes involved in 
the more isolated forms of ARM are nearly absent. Therefore, hypothesis-free research on 
nonsyndromic ARM seems to be most appropriate. We intend to perform a genome-wide 
association study (GWAS) in a large cohort of more isolated nonsyndromic ARM cases. In this 
hypothesis-generating approach, the whole genome will be scanned to identify potential 
SNPs involved in nonsyndromic ARM. To identify specific environmental risk factors, 
questionnaire data will be investigated. Since this will be a unique and relatively large cohort 
of ARM cases, identification of environmental risk factors seems likely. In a GWAS with 1,000 
cases and controls and assuming 80% power, main genetic effects ≥ 1.5 can be identified for 
91 
genes with an allele frequency > 0.05. For environmental factors with an exposure 
prevalence of 0.1, main effects ≥ 1.5 can also be detected.   
 
Dutch and German studies on environmental risk factors 
In our first Dutch case-control study among 85 nonsyndromic ARM cases and 650 controls, 
potential environmental risk factors for ARM were studied.21 ARM cases with chromosomal 
anomalies, known syndromes, cloaca, and cloacal exstrophies were excluded. Parents of 
these cases and controls filled out questionnaires, concerning exposures just before and 
during pregnancy. Recently, we tried to replicate the findings of the Dutch case-control 
study in 79 nonsyndromic ARM cases from the German CURE-Net. Due to the close 
geographic proximity and the assumed analogy in ethnicity, controls were used from the 
Dutch case-control study. Dutch and German questionnaires were nearly similar with regard 
to the environmental risk factors studied, apart from time to pregnancy (TTP), which was 
only included in the Dutch questionnaire. 
 
Results 
Data collection within the International Consortium on Anorectal Malformations 
A relatively large amount of data has already been collected in Europe during the past few 
years. Currently, approximately 700 ARM cases have been recruited: 275 cases in the 
Netherlands, 172 cases in Germany, 140 cases in Italy, and 114 cases in France.  Clinical data 
are available for all these cases. The members of the consortium are currently harmonizing 
their case reports to combine these data. As Italy and France had just started data collection, 
DNA samples and questionnaire data were mainly collected from ARM cases in the 
Netherlands and Germany (Table 1). Some other potential (non-)European collaborators 
may also contribute data to increase the total number of ARM cases in the future. 
 
Table 1. Collected data of ARM cases per country. 
 Number of collected data of ARM cases Intend to 
collect in totalb  Clinical data DNA 
samples  
Environ-
mental data  
Netherlands (Nijmegen) 275 275 220    300 
Germany (Bonn and Heidelberg) 172 131 156    300 
Italy (Padua) 140   20   10    200 
France (Paris)  114   50 114a    200 
Total 701 476 500 1,000 
aPartial questionnaire data. 
bMinimum. 
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Results of Dutch case-control study 
In our Dutch case-control study among 85 nonsyndromic ARM cases, we found associations 
between ARM and family history of ARM, time to pregnancy > 6 months, pre-pregnancy BMI 
≥ 25 kg/m2, fever during first trimester of pregnancy, maternal job exposure to industrial 
cleaning agents and solvents, paternal smoking, and paternal job exposures to exhaust 
fumes (Table 2).21 
 
Table 2. Summary of results of our Dutch case-control study on risk factors of ARM.21  
Potential risk factors ARM  
(n=85) 
No. (%) 
Controls 
(n=650) 
No. (%)  
Adjusted OR  
(95% CI)  
Family history of ARM 1st and 2nd degree 6 (7.2) 1 (0.2) 33.9 (2.9–398) 
Time to pregnancy > 6 months 26 (32.9) 135 (21.4) 1.8 (1.1–3.0) 
Maternal risk factors    
BMI before pregnancy ≥ 25 kg/m2 32 (38.1) 160 (26.0) 1.8 (1.1–2.8) 
Fever 1st trimester pregnancy (> 38°C) 3 (3.7) 4 (0.6) 5.1 (0.9–28.1) 
Maternal job exposure to industrial cleaning 
agents and solvents 
5 6.0)        12 (1.9) 2.9 (0.9–9.3) 
Paternal risk factors (3 months prior to conception)   
Paternal smoking of cigarettes 41 (50.0) 210 (35.7) 1.8 (1.1–2.9) 
Paternal job exposure to exhaust fumes 14 (17.3) 59 (10.0) 1.9 (1.0–3.6) 
aResults derived from the article in Birth Defects Res A Clin Mol Teratol.21 
 
Preliminary results of the German CURE-Net 
The Dutch results were reanalyzed with 79 ARM cases of the German CURE-Net study. These 
cases were classified according to Krickenbeck.5 The most frequently occurring diagnoses 
were perineal fistula (total 19.0%; 9.3% in boys and 30.5% in girls), vestibular fistula in girls 
(36.1%), and rectourethral fistula in boys (51.1%). The preliminary results showed 
associations between ARM and family history of ARM, fever during first trimester of 
pregnancy, and maternal job exposure to industrial cleaning agents and solvents (Table 3). 
No associations were found between ARM and BMI before pregnancy ≥ 25 kg/m2, paternal 
smoking, and paternal job exposure to exhaust fumes. These results were not adjusted for 
confounders. 
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Table 3. Replication of results on environmental risk factors for ARM using German ARM cases. 
Potential risk factors        German 
ARM 
          (n=79) 
         No.(%) 
   Dutch   
Controls   
      (n=650) 
No. (%) 
 Crude OR 
      (95% CI) 
Family history of ARM 1st and 2nd degree 6 (7.6) 1 (0.2) 49.0 (5.8–412.6) 
 
Maternal risk factors    
BMI before pregnancy ≥ 25 kg/m2 20 (25.3) 160 (26.0) 1.0 (0.6–1.7) 
Fever 1st trimester pregnancy (> 38°C) 5 (6.3) 4 (0.6) 10.6 (2.8–40.4) 
Maternal job exposure to industrial cleaning 
agents and solvents 
10 (12.7) 12 (1.9) 7.4 (3.1–17.7) 
Paternal risk factors (3 months prior to conception)   
Paternal smoking of cigarettes 28 (35.4) 210 (35.7) 1.0 (0.6–1.6) 
Paternal job exposure to exhaust fumes 4 (5.1) 59 (10.0) 0.5 (0.2–1.4) 
 
Discussion 
The replication of the Dutch results using the German CURE-Net data shows the added value 
of our international consortium. Interestingly, associations between ARM and family history 
of ARM, fever during first trimester of pregnancy, and maternal job exposure to industrial 
cleaning agents and solvents could be replicated in the German cohort of ARM cases. Family 
history of ARM has consistently been identified as a risk factor for ARM,22 which argues for 
the importance of genetic factors involved in ARM. Maternal fever during first trimester of 
pregnancy was indicated as a potential risk factor for ARM in the Dutch case-control study 
for the first time. As this association was replicated in the German cohort, it seems 
extremely worthwhile to further study this potential risk factor in detail. It may be essential 
to incorporate maternal fever, maternal infections, and antifebrile treatment in the 
consortium questionnaire on environmental risk factors to explore the underlying 
mechanism of the association between ARM and fever. In previous studies and in the Dutch 
and German cohorts, some job exposures were found to be associated with ARM, such as 
organic solvents and metals.15,16 As it remains questionable whether the rather crude 
assessment of parental exposure to occupational agents reflects real exposure, we intend to 
analyze these occupational exposures in a more accurate way and in a larger cohort of ARM 
patients. Although the Dutch case-control study21 and previous studies23,24 found an 
association between ARM and BMI before pregnancy ≥ 25 kg/m2, it could not be confirmed 
in the German study. Associations between ARM and paternal smoking and paternal job 
exposure to exhaust fumes were not replicated in the German cohort either. These 
preliminary results have some limitations, which should also be considered. In the German 
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assessment of parental exposure to occupational agents reflects real exposure, we intend to 
analyze these occupational exposures in a more accurate way and in a larger cohort of ARM 
patients. Although the Dutch case-control study21 and previous studies23,24 found an 
association between ARM and BMI before pregnancy ≥ 25 kg/m2, it could not be confirmed 
in the German study. Associations between ARM and paternal smoking and paternal job 
exposure to exhaust fumes were not replicated in the German cohort either. These 
preliminary results have some limitations, which should also be considered. In the German 
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analyses, the control group of the Dutch case-control study was used. Although we expect 
that the Dutch and German population correspond for the most part with regard to social 
standards and lifestyle factors, some geographical differences may exist. In the future, we 
intend to recruit controls in all participating countries to achieve true geographical similarity 
between cases and controls. In addition, the small sample sizes of the two case series made 
it difficult to provide reliable findings for less frequently occurring risk factors. However, 
these findings encourage us to reanalyze the current findings in a larger international study 
population, in which other interesting environmental risk factors may be found as well. 
 
Conclusion 
The recently established International Consortium on Anorectal Malformations, uniting 
researchers from the Netherlands, Germany, Italy, and France, will collect a large amount of 
data available for ARM research. The ensuing large cohort of ARM cases will provide 
possibilities to study and detect important genes and environmental risk factors involved in 
the etiology of syndromic and nonsyndromic forms of ARM, finally combining these to 
identify gene-environment interaction as well. Consequently, it is expected that the etiology 
of ARM will gradually be unraveled in the future, which will also provide a substantial 
amount of information on the pathogenesis of ARM. This knowledge may result in better 
genetic counseling, perinatal care, and ultimately primary prevention of ARM. While the 
current research focus is on finding causative factors, clinical issues will also become 
important. The consortium brings together pediatric surgeons to harmonize diagnostic 
classifications, interventions, and follow-up and to improve quality of life of ARM patients. In 
the future, other international pediatric surgery, genetic or epidemiological research groups 
may be involved in the consortium. 
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Abstract 
 
Background The European consortium on anorectal malformations (ARM-NET) was 
established to improve the health care of patients and to identify genetic and environmental 
risk factors. The aim of the present study was to present the first results on clinical data of a 
large European cohort of ARM patients based on our registry.  
 
Methods In 2010, the registry was established including patient characteristics and data on 
diagnosis, surgical therapy, and outcome regarding complications. Patients born between 
2007 and 2012 were retrospectively added. A descriptive analysis of this cohort was 
performed.  
 
Results Two hundred and three ARM patients were included. Syndromes or chromosomal 
abnormalities were present in 9%. Perineal fistulas were seen most in boys (42%) and girls 
(29%). Rare forms of ARM were found in 4% of the male and in 14% of the female patients. 
Forty-five percent of the patients had additional urogenital abnormalities. However, 32% of 
the patients were never screened for bladder abnormalities. Eight percent were never 
screened for renal malformations. In the majority of patients (79%), a PSARP was performed 
for the definitive reconstruction.  
 
Conclusion This collaborative effort provides a representative basis to estimate incidence of 
ARM types, to discuss differences and similarities in treatment, and health consequences 
throughout Europe. 
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Introduction 
Congenital anorectal malformations (ARMs) are rare birth defects of the digestive system 
affecting 2–6 per 10,000 births worldwide with an estimated prevalence rate of 3.0 per 
10,000 births in Europe.1,2 ARMs are found as isolated congenital birth defects, as part of a 
syndrome or associated with other anomalies.3 Associated anomalies have been reported to 
occur in approximately 45%–65% of the patients, mostly of the urogenital tract, central 
nervous system, skeletal system (vertebrae) or the remaining gastrointestinal tract.4-6 The 
exact frequency of associated congenital anomalies is still unclear and often based on single 
center studies showing contradicting results. The largest series is a single center study by 
Levitt and Peña and may be biased because of its nationwide referral function as Colorectal 
Center in the US.7 
Almost all ARMs require surgery early in life.4 Several surgical procedures are 
performed to correct anorectal malformation. The spectrum of malformations sometimes 
mandates different techniques for different malformations but the preferred technique is 
also influenced by surgeon’s preference and surgical education. Although these surgical 
procedures generally take place in specialized surgical centers to provide optimal care, the 
surgical care does not always restore functionality completely accounting for substantial 
morbidity among ARM patients. Outcome parameters thus vary accordingly. These 
parameters also vary due to the use of different scoring systems for evaluation of functional 
outcome and the retrospective character of most studies. 
Therefore, in 2010 the ARM-NET Consortium was founded and withholds three main 
goals. First, the consortium collects epidemiological data and DNA specimens to elucidate 
the etiology of anorectal malformations. It further aims to represent and independently 
monitor frequencies of types of ARM, additional malformations, surgical procedures, 
complications and outcome, especially because presently the Krickenbeck classification for 
ARM is not established in the WHO-ICD-10 or EUROCAT registry. A third goal is to harmonize 
diagnostic classification, possible interventions and follow up to improve quality of life of 
ARM patients. Here, we present our first results on co-morbidity and surgical procedures of 
a comprehensive multicenter European cohort of ARM patients. 
 
Methods 
ARM-NET was founded in 2010 as a consortium to collaborate in genetic and epidemiological 
research as well as to set up an anonymized registry on all new ARM patients in the 
participating centers in Europe (http://www.arm-net.eu).8 The initiative was a joint 
approach of four national research projects and their collaborating national patient 
organizations: The German CURE-Net (German Network for Congenital Uro-REctal 
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Malformations), the Dutch AGORA project (Aetiologic research into Genetic, Occupational 
and environmental Risk factors for Anomalies in children), the Italian MUGAR-Net (Network 
for Uro-Genito-Ano-Rectal malformations in Italy), and the French MAREP project (National 
centre for AnoRectal Malformations and rare Pelvic anomalies). 
The studies were approved by all local Ethics Committees and informed consent has 
been obtained from all patients and/or their parents as legal representatives. The first 
participating centers were from the Netherlands (Nijmegen, Groningen), Germany 
(Wurzburg, Heidelberg, Bremen), France (Paris) and Italy (Padua). The consortium has now 
expanded with further centers from Italy (Milan and Rome), Spain (Madrid), Turkey (Ankara), 
Germany (Hannover), and Ukraine (Dnepropetrovsk). In every center one pediatric surgeon 
is responsible for data management, except for Padua and Paris in which there are two. 
A web-based registry was constructed to monitor anonymized background data 
(maternal age at birth, gender, twin pregnancy, family history), diagnostic data such as type 
of malformation, following the Krickenbeck classification,9 associated anomalies, surgical 
procedures, complications and outcome. The VACTERL association was defined as having at 
least three of the following congenital malformations: vertebral anomalies, anorectal 
malformation, cardiac anomalies, tracheo-esophageal fistula, renal anomalies and limb 
anomalies.10 For the current study newborns were also retrospectively included, to survey all 
ARM patients born between 2007 and 2012. All data were anonymized, filled in and 
confirmed by pediatric surgeons from the collaborating centers. 
Descriptive analyses of absolute and relative frequencies have been performed on patient 
characteristics, diagnostic classification of the anorectal malformation and associated 
malformations, and surgery characteristics. Statistical analyses were performed using the 
statistical package SPSS 20.0 for Windows (SPSS Inc., Chicago, IL). 
 
Results 
A total of 203 patients were eligible for this study, as centers with incomplete patient data 
were excluded. ARM occurred equally in boys and girls (Table 1). Of these patients, 9% were 
syndromic or part of a known chromosomal defect such as trisomy 21, Currarino syndrome, 
Casamassima syndrome, Cri-du-Chat, Cat Eye syndrome or 22q11 microdeletion syndrome.In 
male patients the largest proportion had perineal fistulas (43%) followed by urethral fistulas 
(29%) (Table 2). In females the largest group had perineal fistulas as well (41%) followed by 
vestibular fistulas (28%). No fistulas were found in 15% of the males and only in 4% of 
females. Anal stenosis was observed similarly in males (3%) as in females (5%). Rare types of 
anorectal malformations were found in 9% of cases: 4% in males and 14% in females. 
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Table 1. Basic characteristics of a representative European cohort of 203 newborns with an anorectal 
malformation. 
Age mother at childbirth, mean (SD) 32 (5.5) 
Twins, no. (%) 11 (5.4) 
Male : Female ratio 1:1 
Isolated ARM patients, no. (%) 57 (28) 
Syndromic or chromosomal defect, no. (%) 18 (8.9) 
 
 
Table 2. Incidence of type of anorectal malformation according to the Krickenbeck classification. 
Male 
(n=98)a 
No. %  Female 
(n=102) 
No. % 
Perineal 42 43  Perineal 42 41 
Rectourethral 
  bulbar 
  prostatic 
  unspecified 
28 
14 
12 
2 
29 
15 
12 
2 
 Vestibular 29 28 
Bladder neck 6 6  Cloaca  
  < 3cm common channel 
  > 3 cm common channel 
  unspecified 
8 
2 
2 
4 
8 
2 
2 
4 
No fistula 15 15  No fistula 4 4 
Anal stenosis 3 3  Anal stenosis 5 5 
Rare type* 4 4  Rare type* 14 14 
aFor 3 male patients the type of malformation was unknown. 
bRare type:  1 anterior ectopic syndrome, 2 cloacal extrophy, 1 rectal atresia, 1 rectal stenosis, 2 recto-
vaginal fistula, 2 H-type fistula, 3 pouch colon, 6 other. 
 
The majority of patients (72%) had associated anomalies, most often renal, cardiac, or 
skeletal anomalies (Table 3). Nine percent of the patients had an esophageal atresia. The 
majority of these patients (89%) were classified as Vogt 3b/Gross C. Other gastrointestinal 
anomalies were seen in 6% of the ARM patients including duodenal atresia, malrotation, 
omphalocele and one had a hepatoblastoma. Cardiac anomalies were observed in 31% of 
the patients, mostly atrial septal or ventricular septal defects. Almost the same proportion of 
patients were found to have renal abnormalities (29%): hydronephrosis in 6%, single kidney 
in 6%, dysplastic kidney in 3%, double system 5%, horseshoe kidney in 2%, ectopic kidney in 
1% and other anomalies in 9%. Only 68% of the patients were screened for bladder 
anomalies. Excluding bladder exstrophy, in 8% of these patients abnormalities were found. 
Six patients had a neurogenic bladder, one had megacystis, and another had bladder 
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characteristics, diagnostic classification of the anorectal malformation and associated 
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Results 
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Table 1. Basic characteristics of a representative European cohort of 203 newborns with an anorectal 
malformation. 
Age mother at childbirth, mean (SD) 32 (5.5) 
Twins, no. (%) 11 (5.4) 
Male : Female ratio 1:1 
Isolated ARM patients, no. (%) 57 (28) 
Syndromic or chromosomal defect, no. (%) 18 (8.9) 
 
 
Table 2. Incidence of type of anorectal malformation according to the Krickenbeck classification. 
Male 
(n=98)a 
No. %  Female 
(n=102) 
No. % 
Perineal 42 43  Perineal 42 41 
Rectourethral 
  bulbar 
  prostatic 
  unspecified 
28 
14 
12 
2 
29 
15 
12 
2 
 Vestibular 29 28 
Bladder neck 6 6  Cloaca  
  < 3cm common channel 
  > 3 cm common channel 
  unspecified 
8 
2 
2 
4 
8 
2 
2 
4 
No fistula 15 15  No fistula 4 4 
Anal stenosis 3 3  Anal stenosis 5 5 
Rare type* 4 4  Rare type* 14 14 
aFor 3 male patients the type of malformation was unknown. 
bRare type:  1 anterior ectopic syndrome, 2 cloacal extrophy, 1 rectal atresia, 1 rectal stenosis, 2 recto-
vaginal fistula, 2 H-type fistula, 3 pouch colon, 6 other. 
 
The majority of patients (72%) had associated anomalies, most often renal, cardiac, or 
skeletal anomalies (Table 3). Nine percent of the patients had an esophageal atresia. The 
majority of these patients (89%) were classified as Vogt 3b/Gross C. Other gastrointestinal 
anomalies were seen in 6% of the ARM patients including duodenal atresia, malrotation, 
omphalocele and one had a hepatoblastoma. Cardiac anomalies were observed in 31% of 
the patients, mostly atrial septal or ventricular septal defects. Almost the same proportion of 
patients were found to have renal abnormalities (29%): hydronephrosis in 6%, single kidney 
in 6%, dysplastic kidney in 3%, double system 5%, horseshoe kidney in 2%, ectopic kidney in 
1% and other anomalies in 9%. Only 68% of the patients were screened for bladder 
anomalies. Excluding bladder exstrophy, in 8% of these patients abnormalities were found. 
Six patients had a neurogenic bladder, one had megacystis, and another had bladder 
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agenesis with trigonal hypoplasia. Regarding all neurogenic bladders it was unknown 
whether these were congenital or acquired. 
Forty-five percent of the patients were screened for vesicourethral reflux (gr I-V) and 
17% of those patients presented some grade of vesicourethral reflux (63% grade I or II). 
Skeletal abnormalities of the upper limb were seen in 7% of the patients and abnormalities 
of the lower limb in 11% of the patients. Vertebral anomalies (other than sacral and coccyx 
region) were seen in 18% whereas sacral anomalies were observed in 17% of the patients. 
However, the sacral ratio was recorded (25%) in only one center. Spinal cord anomalies were 
seen in 18% of those patients who were screened for this (78%), including thickened filum, 
tethered cord, syrinx conus, intraspinal lipoma’s or masses and meningoceles. 
 
Table 3. Absolute and relative frequency of associated anomalies seen in newborns with anorectal 
malformations. 
Type of associated anomalies nanomaly/ntotal groupa % 
Esophageal atresia 18/195 9 
Other gastrointestinal anomalies 10/170 6 
Cardiac anomalies 57/185 31 
   VSDb 16/185 9 
   ASDb 18/185 10 
Renal anomalies 53/186 29 
   Hydronephrosisc 12/186 6 
   Single kidney 11/186 6 
   Dysplastic kidney 6/186 3 
   Double system 9/186 5 
   Horse shoe kidney 4/186 2 
   Ectopic kidney 2/186 1 
   Other 17/186 9 
Skeletal anomalies 73/203 36 
   Upper Limb 13/191 7 
   Lower Limb 21/192 11 
   Vertebra 
   (not sacral and coccyx region) 
29/164 18 
   Sacral anomalies 28/162 17 
   Coccyx anomalies  31/140 22 
Spinal canal/cord anomaly 29/158 18 
aTotal group of patients without missing data. 
bWith and without other cardiac anomalies. 
cWith and without other renal anomalies. 
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Forty percent of the patients were given an enterostomy of which 84% were divided 
colostomies (Table 4). In most cases (77%) stomas were placed at the end of the descending 
colon or at the beginning of sigmoid colon. In the other 23% of the patients the stoma was 
mostly placed at the transverse colon. In males, all bladder neck, recto-bulbar and recto-
prostatic fistulas were given a colostomy. In females, all patients with cloacas received a 
colostomy. Females with a vestibular fistula were given a colostomy in 27%. Male and 
female patients with a perineal fistula were given an enterostomy in only 4%. In 92% a 
definitive anorectal reconstruction was done. For the final surgery a posterior sagittal 
anorectoplasty (PSARP) was performed in 79% of the patients. Four percent of the patients 
were treated with an anoplasty or cutback procedure (perineal patients only) (Table 5). An 
anterior sagittal anorectoplasty (ASARP) was performed in 6% of the patients; four percent 
of the patients received a laparascopic anorectoplasty (mainly for bladder-neck fistulas). 
 
Table 4. Type and placement of enterostomy for anorectal malformations. 
 nanomaly/ntotal groupa % 
Enterostomy 79/198 40 
Type   
   Loop 
   Divided colostomy 
 
12/77 
65/77 
 
16 
84 
Place   
   Ileum    
   Transverse colon 
   Sigmoid-Descending 
 
3/75 
14/75 
57/75 
 
4 
19 
77 
aTotal group of patients without missing data. 
 
Table 5. Final reconstructive surgery for the anorectal malformation. 
 nanomaly/ntotal groupa % 
Cutback 3/168 2 
Anoplasty 4/168 2 
(mini)PSARP 42/168 25 
PSARP 90/168 54 
ASARP 10/168 6 
LAARP 6/168 4 
PSARVUP 1/168 0.6 
TUM 3/168 2 
PSARP: posterior sagittal anorectoplasty; ASARP: anterior sagittal anorectoplasty; LAARP: laparoscopic 
anorectoplasty; PSARVUP: posterior sagittal anorectal-vagino-urethroplasty; TUM: total urogenital 
mobilization. 
aTotal group of patients without missing data. 
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Discussion 
In this study we collected and analyzed anonymized data on newborns with ARM in five 
European pediatric surgical centers, representative for six consecutive years (2007–2012). 
Members of the ARM-NET Consortium are dedicated pediatric colorectal surgeons and 
representatives of patient organizations and as well as epidemiologists and geneticists. 
Despite this, we have noticed that the classification of ARM is still difficult and debatable in 
specific patients, e.g. urethral fistulas (bulbar or prostatic) in males or perineal fistulas in 
females. We have noticed this through the remarks added to the registry and after a 
collective discussion. Urethral fistulas in males, either bulbar or prostatic, are part of a 
spectrum of anorectal malformations as described by Levitt and Peña.4 In this spectrum 
there is a certain overlap in bulbar and prostatic fistulas and the diagnostic tool (high 
pressure colostogram) sometimes gives results in which some clinicians and radiologists see 
a bulbar fistula whereas others see a prostatic fistula. Although the importance of the 
difference may not appear to be so relevant, yet in some patients (prostatic fistula) the 
laparoscopic approach could be chosen whereas in other patients (bulbar fistula) the 
posterior sagittal approach would be appropriate. Furthermore, it is generally thought that 
the functional outcome of a bulbar fistula is far better than that of a prostatic fistula.7 
In male patients the incidence of patients without a fistula was rather high (15%) in 
comparison to previous reports. Although this may be a true observation, it could be related 
to a possible misdiagnosis. A improperly performed colostogram may not reveal the fistula. 
This will not only overestimate the group of no-fistula patients but would also have the 
consequence of leaving a fistula after a PSARP. Further follow up on outcome will show this 
to be the case. 
Another remarkable observation is the incidence of the different types of anorectal 
malformations. The majority of malformations in females were perineal fistulas. This is 
contradictory to one of the largest study published by Levitt and Peña that showed that 
vestibular fistulas were the most frequently seen type of anorectal malformations.7 The 
difference may be explained by the fact that the center of that study also functions as a 
national referral center in the U.S. and thus may have a bias towards more severe patients. 
Another remarkable observation was that we found a relatively high percentage of rare 
anorectal malformations, particularly in females (14%). If this survey could be considered as 
representative, and our peer-review proved the correct classification, the so-called rare 
types may occur more often than previously expected. These patients often need thorough 
clinical judgment, decision-making or complex surgical care. The clinical relevance of our 
observation suggests that these patients may need to go to specific pediatric surgical care 
centers (specialized in colorectal care). In most European countries this is under debate and 
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rules are now being made by the European Committee to have centralized care for certain 
rare diseases.11 Therefore the opportunity of an independent, voluntarily and anonymized 
comparison, which is offered by such a registry, is important. 
The frequencies of associated anomalies were more or less in the range observed by 
others.4-6 Although associated urogenital anomalies were seen most, a large group was not 
routinely screened for bladder anomalies or vesico-ureteral reflux. A large group of patients 
were only examined on the basis of clinical symptoms. Although 17% of the screened 
patients showed some sort of vesico-ureteral reflux, the significance of routine screening 
needs to be further examined particularly whether such a screening also leads to a better 
urogenital long-term outcome. For the present time we recommend routine ultrasound of 
the urinary tract and kidneys in every newborn with an ARM. Voiding cysto-urethrography 
can be reserved for patients with dilated upper urinary tracts, lumbosacral and spinal 
abnormalities, or in case of additional urinary tract infections. Similarly, urodynamic 
investigations should be reserved for patients with suspected neurogenic bladders, recurrent 
infections or urinary incontinence at an older age in the follow up. 
Another remarkable finding concerned the screening of the sacral ratio.6 In our group 
of patients a sacral X-ray, MRI or ultrasound was performed to find sacral and spinal 
anomalies. In the latter 2 investigations the sacrum is described as normal or abnormal. 
However, the sacral ratio was only measured in one center (25% of patients). The clinical 
importance has been shown,12,13 but confirmation and validation by other centers may be 
helpful. In our registry, the measurement of the sacral ratio was reported to be difficult in 
very young children and newborns, thus making the measurement of the ratio quite 
variable. Ultrasound is also a validated method to investigate malformations both of the 
sacrum and of the spinal canal in newborns and infants. Therefore, the sacrum was 
described as either being normal or abnormal on ultrasound exams in most of the centers. 
We do, however, recognize the clinical importance of the sacral abnormalities and sacral 
ratio and hope to report better registration in the future and maintain the item in the 
registry despite these initial difficulties. 
The posterior sagittal approach has become the standard of care for most patients 
regardless the center or country of care. Laparoscopy is sometimes used but this is mostly 
limited to (male) patients with bladder neck fistulas.14 In females a small group of patients 
with perineal and vestibular fistulas were operated using an ASARP.15 This procedure has the 
preference of some surgeons because it leaves the posterior part of the sphincter complex 
as one similar as the mini-PSARP. The difference with the mini-PSARP lies mainly in the 
positioning of the patient. The ASARP is in lithotomy position whereas the mini-PSARP is in 
prone position. Both ASARP and mini-PSARP are procedures with less exposure but also 
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reduced visibility during surgery. Whether these procedures result in differences in long 
term outcome remains to be elucidated. This will be one of the long-term outcome measure-
ments of our registry. 
In regards to the placement of a colostomy, vestibular fistulas in females are still the 
most controversial on whether to place one or not. In all bulbar-, prostatic, bladder-neck 
fistulas and cloacal malformations a colostomy was created soon after birth. In patients with 
a vestibular fistula approximately 27% were given an enterostomy whereas in the remaining 
73% the reconstruction was done with a short or long period of parenteral nutrition. 
Evidence for either one of the protective procedures is still lacking and the choice is fully 
case individual decided and based on personal preferences. It will be a challenge for the 
ARM-NET Consortium to start a randomized controlled trial to give evidence for either one 
of the perioperative options. 
The major limitation of this cross-sectional study lies in the fact that data were 
collected by several surgeons throughout different countries. Peer review or independent 
monitoring is needed to ensure that the same kind of diagnostic classification is used. The 
registration in different centers increases the variance and the need to collect more data of a 
larger group of patients before issues are proven. Simultaneously the multi-center and cross-
country character of our anonymized registry is a great strength and the first step for an 
independent and representative comparison. This registry delivers more precise phenotypic 
and surgical treatment data than general malformation registries and multi-center data and 
in the future it provides the possibility to assess outcome evaluation of anorectal 
malformations in Europe. 
Regarding this issue, it seems clear that an evaluation procedure independent of the 
surgeon treating the patient is best to be established, as was shown recently.16 The ARM-Net 
Consortium furthermore brings geneticists and epidemiologists together for a virtual 
biobank and opens possibilities for etiologic and pathobiological research into this rare 
malformation. Finally, several patient organizations are co-founder and member of this 
network and they are not only able to give a quality control on the surgical care, but in 
certain sense also have the moral authority to do so.16 
In conclusion, this collaborative effort of five European pediatric surgical centers brings 
national research projects together and gives a European, representative dataset of ARM 
patient. These first results show that basic screening of all patients entering our registry 
should improve and include e.g. sacral abnormalities and ultrasound screening of the urinary 
tract of every patient. The data provide a basis to discuss differences in treatment and 
health consequences in different types of ARM, but also shows the similarities in surgical 
treatment throughout different countries in Europe. 
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To the Editor 
 
Strict delineation and clear limits to the VACTERL association (OMIM 192350) have been 
debated since the first description of the VATER association in 1972.1 We welcome the 
presentation of a complete series of 60 patients presenting at least three component 
features of the VACTERL association by Solomon et al. in the September issue of the 
American Journal of Medical Genetics Part A.2 They mention among their cardinal findings 
that vertebral defects, cardiac malformations, and renal anomalies build the strongest 
cluster, suggesting that these three VACTERL component features tend to appear together 
more often than do any other component features (anorectal malformation (ARM), tracheo-
esophageal (TE) fistula with esophageal atresia, and limb dysplasia). However, we have 
serious doubts about the external validity of the study results and we are not convinced that 
these can be extrapolated to the overall group of VACTERL patients for several reasons. 
First, the authors claim the advantage of recruiting their patients based on a 
predefined association definition as inclusion criterion and not focusing on a population-
based registry. However, this may be the most important study limitation. We wonder about 
the effect of sampling bias on the results, as the authors already mentioned that more 
severely affected individuals are more likely to seek participation in their study. Moreover, 
without reliable genetic or epidemiological proof of concept regarding the classification of 
component features or inclusion criteria of clinical features for VACTERL, all further results 
may be arbitrary. Even the ostensible proof of inheritance of component features of the 
VACTERL association might be reduced to the inheritance of congenital anomalies of the 
VACTERL association spectrum among patients and families with TE.3 The current broad 
definition and classification of component features for the VACTERL association has not been 
supported by independent epidemiological studies. While the first population based 
studies4,5 used an extended definition of VACTERL according to Kaufman,6 later and more 
comprehensive analyses could not support this extension.7-9 
Secondly, to compare prevalence rates of the component features of the VACTERL 
association between independent studies, equal diagnostic criteria are desired, which was 
also stated by Solomon et al. However, vertebral, cardiac, renal, and limb defects are rather 
collective categories, which include a broad spectrum of anomalies differing in severity and 
timing of appearance, while ARM and TE are more specific defects, at least not differing in 
their timing of appearance. Here, we see certain shortcomings of the authors not providing a 
more detailed and specific description on their classification of component features. For 
example, the following defects might all occur during a certain phase of pre- or postnatal 
development but also tend to disappear again, without any need for intervention why most 
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of them are not considered real congenital defects, e.g., patent ductus arteriosus, patent 
foramen ovale, vesicouretral reflux, and secondary hydronephrosis, etc. Furthermore, it is 
not clear whether sacral dysplasia, a common component in ARM, is included in vertebral 
malformations. In this respect and in regards to limb defects, population based evidence 
exist only for upper preaxial (radial) defects.7-9 
To our opinion, the study results may thus be weakened by sampling bias and an 
unclear definition or classification of classic component features among patients with 
VACTERL association. Solomon et al. found the highest prevalence rates (70–80%) for 
vertebral, cardiac, and renal defects in their study compared to prevalence rates of 
approximately 50% of the other three component features of the VACTERL association. 
Hence, it is not surprising that they found vertebral, cardiac, and renal defects cluster 
together in hierarchical clustering analyses. Nevertheless, previous population based studies 
do not support their findings: Rittler et al.7 even found the lowest association rate 
(observed/expected) for the co-occurrence of vertebral, cardiac, and renal defects as 
multiple congenital anomalies (MCA). Even more, these population based studies8,9 do not 
count cardiac defects as part of the VACTERL association, as these defects do not seem to be 
more common among VACTERL patients than in other MCAs. 
To avoid sampling bias it is reasonable to focus on population based studies. In lack 
of such populations, another valid approach may be focusing on a reliable component 
feature like TE or ARM. The systematic screening for other component features of the 
VACTERL association in such cases excludes arbitrary feature patterns. Hence, we compared 
the presence of each component feature of the VACTERL association in the patients 
described by Solomon et al.2 to our Dutch (14 Triads, 10 Tetrads, 5 Pentads, and 1 Hexad) 
and German (25 Triads, 13 Tetrads, and 6 Pentads) cohorts of patients with VACTERL 
association all presenting with ARM (Table 1), recruited through pediatric surgeons and 
clinical geneticists. Patients with associated features suggestive of an alternate diagnosis 
were excluded as well. We used a rigid and conservative classification system of component 
features of the VACTERL association for our own patients and compared these with the 34 
patients with VACTERL association and ARM (33 patients plus patient #66) described by 
Solomon et al.2 Solomon et al.2 did not account patients #28 and #66 to have an ARM, which 
of course must be corrected according to standard classification system.10,11 Looking at the 
prevalence rates of cardiac and limb defects among patients with VACTERL association who 
all present an ARM, the cohort of Solomon et al. shows higher prevalences than in our 
cohorts (Table 1), demonstrating differences in component feature prevalences among 
VACTERL cohorts. 
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Table 1. Anorectal malformation and at least two further major component features. 
Component feature Solomon et al.2,  
(n=34)  
No. (%) 
German cohort,  
(n=44)  
No. (%) 
Dutch cohort, 
(n=30)  
No. (%) 
V 25 (74) 26 (59) 22 (73) 
A 34 (100) 44 (100) 30(100) 
C 27 (79) 29 (66) 18 (60) 
TE 15 (44) 18 (41) 14 (47) 
R 22 (65) 30 (68) 21 (70) 
L 14 (41) 13 (30) 8 (27) 
V, vertebral malformations; A, anorectal malformations; C, cardiac malformations; TE, tracheo-esophageal 
fistula; R, renal malformations; L, limb malformations, for the German and Dutch cohort only radial 
defects. 
 
Finally, we are confused with parts of the discussion of Figure 4. It is mentioned that Cluster 
1 has the lowest rate of anorectal defects, but this should be Cluster 2 according to the 
Figure. Although patients in Clusters 2 and 3 are stated to have low probability of TE defects, 
the probability of having these defects is the highest for patients in Cluster 2 according to 
the Figure. 
Overall accounting for the lack of nationwide active birth registries in most countries 
we want to stress the importance of multicenter and multidiscipline collaborations in the 
field of rare congenital anomalies comprising active and passive birth registries, pediatric 
surgeons, and geneticists to harmonize diagnostic classification systems and to avoid 
sampling bias. 
 
Acknowledgments 
Charlotte Wijers was supported by a grant from the Radboud University Nijmegen Medical 
Center. Ekkehart Jenetzky, Nadine Zwink, and Heiko Reutter are members of the “Network 
for Systematic Investigation of the Molecular Causes, Clinical Implications and Psychosocial 
Outcome of Congenital Uro-Rectal Malformations (CURE-Net)” supported by a research 
grant (01GM08107) from the German Federal Ministry of Education and Research 
(Bundesministerium für Bildung und Forschung, BMBF): http://www.cure-net.de. 
 
References 
1. Quan L, Smith DW. The VATER association: Vertebral defects, anal atresia, tracheoesophageal 
fistula with esophageal atresia, radial dysplasia. Birth Defects 1972;8:75-78. 
2. Solomon BD, Pineda-Alvarez DE, Raam MS, et al. Analysis of component findings in 79 patients 
diagnosed with VACTERL association. Am J Med Genet A 2010;152A:2236-2244. 
5112 
of them are not considered real congenital defects, e.g., patent ductus arteriosus, patent 
foramen ovale, vesicouretral reflux, and secondary hydronephrosis, etc. Furthermore, it is 
not clear whether sacral dysplasia, a common component in ARM, is included in vertebral 
malformations. In this respect and in regards to limb defects, population based evidence 
exist only for upper preaxial (radial) defects.7-9 
To our opinion, the study results may thus be weakened by sampling bias and an 
unclear definition or classification of classic component features among patients with 
VACTERL association. Solomon et al. found the highest prevalence rates (70–80%) for 
vertebral, cardiac, and renal defects in their study compared to prevalence rates of 
approximately 50% of the other three component features of the VACTERL association. 
Hence, it is not surprising that they found vertebral, cardiac, and renal defects cluster 
together in hierarchical clustering analyses. Nevertheless, previous population based studies 
do not support their findings: Rittler et al.7 even found the lowest association rate 
(observed/expected) for the co-occurrence of vertebral, cardiac, and renal defects as 
multiple congenital anomalies (MCA). Even more, these population based studies8,9 do not 
count cardiac defects as part of the VACTERL association, as these defects do not seem to be 
more common among VACTERL patients than in other MCAs. 
To avoid sampling bias it is reasonable to focus on population based studies. In lack 
of such populations, another valid approach may be focusing on a reliable component 
feature like TE or ARM. The systematic screening for other component features of the 
VACTERL association in such cases excludes arbitrary feature patterns. Hence, we compared 
the presence of each component feature of the VACTERL association in the patients 
described by Solomon et al.2 to our Dutch (14 Triads, 10 Tetrads, 5 Pentads, and 1 Hexad) 
and German (25 Triads, 13 Tetrads, and 6 Pentads) cohorts of patients with VACTERL 
association all presenting with ARM (Table 1), recruited through pediatric surgeons and 
clinical geneticists. Patients with associated features suggestive of an alternate diagnosis 
were excluded as well. We used a rigid and conservative classification system of component 
features of the VACTERL association for our own patients and compared these with the 34 
patients with VACTERL association and ARM (33 patients plus patient #66) described by 
Solomon et al.2 Solomon et al.2 did not account patients #28 and #66 to have an ARM, which 
of course must be corrected according to standard classification system.10,11 Looking at the 
prevalence rates of cardiac and limb defects among patients with VACTERL association who 
all present an ARM, the cohort of Solomon et al. shows higher prevalences than in our 
cohorts (Table 1), demonstrating differences in component feature prevalences among 
VACTERL cohorts. 
 
 
113 
Table 1. Anorectal malformation and at least two further major component features. 
Component feature Solomon et al.2,  
(n=34)  
No. (%) 
German cohort,  
(n=44)  
No. (%) 
Dutch cohort, 
(n=30)  
No. (%) 
V 25 (74) 26 (59) 22 (73) 
A 34 (100) 44 (100) 30(100) 
C 27 (79) 29 (66) 18 (60) 
TE 15 (44) 18 (41) 14 (47) 
R 22 (65) 30 (68) 21 (70) 
L 14 (41) 13 (30) 8 (27) 
V, vertebral malformations; A, anorectal malformations; C, cardiac malformations; TE, tracheo-esophageal 
fistula; R, renal malformations; L, limb malformations, for the German and Dutch cohort only radial 
defects. 
 
Finally, we are confused with parts of the discussion of Figure 4. It is mentioned that Cluster 
1 has the lowest rate of anorectal defects, but this should be Cluster 2 according to the 
Figure. Although patients in Clusters 2 and 3 are stated to have low probability of TE defects, 
the probability of having these defects is the highest for patients in Cluster 2 according to 
the Figure. 
Overall accounting for the lack of nationwide active birth registries in most countries 
we want to stress the importance of multicenter and multidiscipline collaborations in the 
field of rare congenital anomalies comprising active and passive birth registries, pediatric 
surgeons, and geneticists to harmonize diagnostic classification systems and to avoid 
sampling bias. 
 
Acknowledgments 
Charlotte Wijers was supported by a grant from the Radboud University Nijmegen Medical 
Center. Ekkehart Jenetzky, Nadine Zwink, and Heiko Reutter are members of the “Network 
for Systematic Investigation of the Molecular Causes, Clinical Implications and Psychosocial 
Outcome of Congenital Uro-Rectal Malformations (CURE-Net)” supported by a research 
grant (01GM08107) from the German Federal Ministry of Education and Research 
(Bundesministerium für Bildung und Forschung, BMBF): http://www.cure-net.de. 
 
References 
1. Quan L, Smith DW. The VATER association: Vertebral defects, anal atresia, tracheoesophageal 
fistula with esophageal atresia, radial dysplasia. Birth Defects 1972;8:75-78. 
2. Solomon BD, Pineda-Alvarez DE, Raam MS, et al. Analysis of component findings in 79 patients 
diagnosed with VACTERL association. Am J Med Genet A 2010;152A:2236-2244. 
114 
3. Solomon BD, Pineda-Alvarez DE, Raam MS, et al. Evidence for inheritance in patients with 
VACTERL association. Hum Genet 2010;127:731–733. 
4. Khoury MJ, Cordero JF, Greenberg F, et al. A population study of the VACTERL association: 
evidence for its etiologic heterogeneity. Pediatrics 1983;71:815-820. 
5. Czeizel AE, Ludányi I. VACTERL association. Acta Morphol Acad Sci Hung 1984;32:75-96. 
6. Kaufman RL. Birth defects and oral contraceptives. Lancet 1973;1:1396.  
7. Rittler M, Paz JE, Castilla EE. VACTERL association, epidemiologic definition and delineation. Am J 
Med Genet 1996;63:529-536. 
8. Botto LD, Khoury MJ, Mastroiacovo P, et al. The spectrum of congenital anomalies of the VATER 
association: an international study. Am J Med Genet 1997;71:8-15. 
9. Källén K, Mastroiacovo P, Castilla EE, et al. VATER non-random association of congenital 
malformations: study based on data from four malformation registers. Am J Med Genet 
2001;101:26-32. 
10. Holschneider A, Hutson J, Peña A, et al. Preliminary report on the International Conference for 
the Development of Standards for the Treatment of Anorectal Malformations. J Pediatr Surg 
2005;40:1521-1526. 
11. Levitt MA, Peña A. Anorectal malformations. Orphanet J Rare Dis 2007;2:33. 
 
 
 
5114 
3. Solomon BD, Pineda-Alvarez DE, Raam MS, et al. Evidence for inheritance in patients with 
VACTERL association. Hum Genet 2010;127:731–733. 
4. Khoury MJ, Cordero JF, Greenberg F, et al. A population study of the VACTERL association: 
evidence for its etiologic heterogeneity. Pediatrics 1983;71:815-820. 
5. Czeizel AE, Ludányi I. VACTERL association. Acta Morphol Acad Sci Hung 1984;32:75-96. 
6. Kaufman RL. Birth defects and oral contraceptives. Lancet 1973;1:1396.  
7. Rittler M, Paz JE, Castilla EE. VACTERL association, epidemiologic definition and delineation. Am J 
Med Genet 1996;63:529-536. 
8. Botto LD, Khoury MJ, Mastroiacovo P, et al. The spectrum of congenital anomalies of the VATER 
association: an international study. Am J Med Genet 1997;71:8-15. 
9. Källén K, Mastroiacovo P, Castilla EE, et al. VATER non-random association of congenital 
malformations: study based on data from four malformation registers. Am J Med Genet 
2001;101:26-32. 
10. Holschneider A, Hutson J, Peña A, et al. Preliminary report on the International Conference for 
the Development of Standards for the Treatment of Anorectal Malformations. J Pediatr Surg 
2005;40:1521-1526. 
11. Levitt MA, Peña A. Anorectal malformations. Orphanet J Rare Dis 2007;2:33. 
 
 
 
 
 
 
 
Part 2 
Non-genetic factors 
 
 
 
 
 
 
 
Part 2 
Non-genetic factors 
 
 
 
 
 
 
 
Chapter 6 
 
Anorectal malformations and pregnancy-related 
disorders: a registry-based case-control study  
in 17 European regions 
 
Charlotte HW Wijers, Iris ALM van Rooij, Marian K Bakker,  
Carlo LM Marcelis, Marie-Claude Addor, Ingeborg Barisic, Judit Béres, 
Sebastiano Bianca, Fabrizio Bianchi, Elisa Calzolari, Ruth Greenlees, 
Nathalie Lelong, Anna Latos-Bielenska, Carlos Matias Dias,  
Robert McDonnell, Carmel Mullaney, Vera Nelen, Mary O’Mahony, 
Annette Queisser-Luft, Judith Rankin, Natalia Zymak-Zakutnia,  
Ivo de Blaauw, Nel Roeleveld, Hermien EK de Walle 
 
BJOG  
2013;120:1066-1074 
 
 
 
 
Chapter 6 
 
Anorectal malformations and pregnancy-related 
disorders: a registry-based case-control study  
in 17 European regions 
 
Charlotte HW Wijers, Iris ALM van Rooij, Marian K Bakker,  
Carlo LM Marcelis, Marie-Claude Addor, Ingeborg Barisic, Judit Béres, 
Sebastiano Bianca, Fabrizio Bianchi, Elisa Calzolari, Ruth Greenlees, 
Nathalie Lelong, Anna Latos-Bielenska, Carlos Matias Dias,  
Robert McDonnell, Carmel Mullaney, Vera Nelen, Mary O’Mahony, 
Annette Queisser-Luft, Judith Rankin, Natalia Zymak-Zakutnia,  
Ivo de Blaauw, Nel Roeleveld, Hermien EK de Walle 
 
BJOG  
2013;120:1066-1074 
120 
Abstract 
 
Objective To identify pregnancy-related risk factors for different manifestations of 
congenital anorectal malformations (ARM). 
 
Design A population-based case-control study.  
 
Setting Seventeen EUROCAT (European Surveillance of Congenital Anomalies) registries, 
1980–2008.  
 
Population The study population consisted of 1,417 cases with ARM, including 648 isolated 
ARM cases, 601 ARM cases with additional congenital anomalies and 168 ARM-VACTERL 
(Vertebral, Anal, Cardiac, Tracheo-Esophageal, Renal, and Limb defects) cases, and 13,371 
controls with recognized syndromes or chromosomal abnormalities.  
 
Methods Multiple logistic regression analyses were used to calculate adjusted odds ratios 
(OR) for potential risk factors for ARM, such as fertility treatment, multiple pregnancy, 
primiparity, maternal illnesses during pregnancy, and pregnancy-related complications. 
 
Main outcome measures Adjusted ORs for pregnancy-related risk factors for ARM. 
 
Results ARM cases were more likely to be firstborn than controls (OR 1.6,  95% CI  1.4–1.8). 
Fertility treatment and being part of a twin or triplet seemed to increase the risk of ARM in 
cases with additional congenital anomalies or VACTERL (ORs ranging from 1.6 to 2.5). 
Maternal fever during pregnancy and preeclampsia were only associated with ARM when 
additional congenital anomalies were present (OR 3.9, 95% CI 1.3–11.6 and OR 3.4, 95% CI 
1.6–7.1, respectively), whereas maternal epilepsy during pregnancy resulted in a fivefold 
elevated risk of all manifestations of ARM (OR 5.1, 95% CI 1.7–15.6).  
 
Conclusions This large European study identified maternal epilepsy, fertility treatment, 
multiple pregnancy, primiparity, preeclampsia, and maternal fever during pregnancy as 
potential risk factors primarily for complex manifestations of ARM with additional congenital 
anomalies and VACTERL. 
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Introduction 
Congenital anorectal malformations (ARM) are the most frequently occurring birth defects 
of the digestive system affecting 2–6 per 10,000 births worldwide.1 ARM is characterized by 
a narrowing of the anorectal canal or anal atresia with or without fistula to neighboring 
organs. Surgical procedures are often required at a very early age, but may not restore 
functionality completely, accounting for substantial physical and social morbidity among 
patients and their families. ARM can occur in isolation, but additional anomalies are present 
in approximately 50% of cases, especially as components of the VACTERL (Vertebral, Anal, 
Cardiac, Tracheo-Esophageal, Renal, and Limb) association.2,3 
Although the diversity in phenotypes and the presence of associated malformations 
indicate causal heterogeneity, most etiological studies analyzed all ARM types collectively. 
These studies showed contradictory results for associations between ARM and parental 
lifestyle factors, such as alcohol intake and smoking.4-7 Several studies have been undertaken 
to investigate other aetiological parameters for ARM, suggesting risk factors, such as 
maternal pre-pregnancy overweight or obesity [6,8,9], pre-existing and/or gestational 
diabetes,10,11 prolonged time to pregnancy,6 and use of assisted reproductive techniques.12-14 
In addition, indications exist for a role of maternal fever during pregnancy,6,15 maternal drug 
use (anti-asthmatic drugs,16 thyroid medication,17 and the benzodiazepine lorazepam18), folic 
acid supplementation,19 and parental occupational hazards.6,20 Scientific evidence for the 
above-mentioned potential risk factors for ARM is still growing, but most studies lack power 
to perform subanalyses on different manifestations of ARM. For these analyses, large 
population-based case-control studies are most appropriate.  
The European Surveillance of Congenital Anomalies (EUROCAT) is a network of 
population-based congenital anomalies registries in Europe covering more than 1.7 million 
births per year collecting data on congenital anomalies for public health, preventive, and 
epidemiologic purposes.21 The EUROCAT database enabled us to conduct a case-control 
study for ARM in a large study sample, using information from multiple sources from 17 
EUROCAT registries to study potential pregnancy-related risk factors for ARM and especially 
for subgroups with different manifestations of ARM.  
 
Methods 
EUROCAT 
The EUROCAT database contains standardized data about congenital anomalies recorded by 
each registry using uniform definitions and coding, which are described elsewhere.22-24 The 
data used in this study were routinely collected between 1980 and 2008 by 17 EUROCAT 
registries in 13 countries (Figure 1), including live births, stillbirths from 20 weeks of 
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Introduction 
Congenital anorectal malformations (ARM) are the most frequently occurring birth defects 
of the digestive system affecting 2–6 per 10,000 births worldwide.1 ARM is characterized by 
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in approximately 50% of cases, especially as components of the VACTERL (Vertebral, Anal, 
Cardiac, Tracheo-Esophageal, Renal, and Limb) association.2,3 
Although the diversity in phenotypes and the presence of associated malformations 
indicate causal heterogeneity, most etiological studies analyzed all ARM types collectively. 
These studies showed contradictory results for associations between ARM and parental 
lifestyle factors, such as alcohol intake and smoking.4-7 Several studies have been undertaken 
to investigate other aetiological parameters for ARM, suggesting risk factors, such as 
maternal pre-pregnancy overweight or obesity [6,8,9], pre-existing and/or gestational 
diabetes,10,11 prolonged time to pregnancy,6 and use of assisted reproductive techniques.12-14 
In addition, indications exist for a role of maternal fever during pregnancy,6,15 maternal drug 
use (anti-asthmatic drugs,16 thyroid medication,17 and the benzodiazepine lorazepam18), folic 
acid supplementation,19 and parental occupational hazards.6,20 Scientific evidence for the 
above-mentioned potential risk factors for ARM is still growing, but most studies lack power 
to perform subanalyses on different manifestations of ARM. For these analyses, large 
population-based case-control studies are most appropriate.  
The European Surveillance of Congenital Anomalies (EUROCAT) is a network of 
population-based congenital anomalies registries in Europe covering more than 1.7 million 
births per year collecting data on congenital anomalies for public health, preventive, and 
epidemiologic purposes.21 The EUROCAT database enabled us to conduct a case-control 
study for ARM in a large study sample, using information from multiple sources from 17 
EUROCAT registries to study potential pregnancy-related risk factors for ARM and especially 
for subgroups with different manifestations of ARM.  
 
Methods 
EUROCAT 
The EUROCAT database contains standardized data about congenital anomalies recorded by 
each registry using uniform definitions and coding, which are described elsewhere.22-24 The 
data used in this study were routinely collected between 1980 and 2008 by 17 EUROCAT 
registries in 13 countries (Figure 1), including live births, stillbirths from 20 weeks of 
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gestation onwards, and terminations of pregnancy for fetal anomaly following prenatal 
diagnosis. Major malformations, syndromes, and chromosomal abnormalities were coded 
according to the International Classification of Diseases (ICD) version 9 or 10, whereas 
specified minor anomalies were excluded according to the EUROCAT classification.23  
 
 
 
Figure 1. Map of 17 participating EUROCAT registries with the birth years in the registries and the 
total numbers of cases and controls. 
 
Case and control definitions 
The study population consisted of 21,606 fetuses or infants with ARM, syndromes, and/or 
chromosomal abnormalities. Cases were defined as live births, stillbirths, and prenatally 
diagnosed fetuses with subsequent terminations of pregnancy with all phenotypes of ARM. 
Fetuses or infants with ARM being part of a recognized syndrome or the result of a 
chromosomal abnormality, as well as with exstrophy of the cloaca or bladder were excluded 
(n=268). Excluded syndromes or chromosomal abnormalities (n=217; 13% of ARM cases) 
mainly comprised trisomy 21 (26%), sirenomelia (11%), and trisomy 18 (8%) as well as many 
others. We divided the case group into three different manifestations of ARM: isolated ARM 
(if ARM was the only malformation); ARM and one or more other major congenital 
anomalies; and ARM cases with the VACTERL association (ARM-VACTERL). Associated 
anomalies in the latter two manifestations of ARM are shown in Table 1. The VACTERL 
association includes vertebral defects (only thoracic and lumbar defects), anorectal 
malformations, cardiac defects (mainly atrial septal defect, ventricular septal defect, and 
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tetralogy of Fallot), tracheo-esophageal atresia, renal malformations, and radial limb defects. 
ARM-VACTERL was defined as ARM and at least two of the additional congenital anomalies 
included in the VACTERL association, which corresponds with the VACTERL definition of the 
presence of at least three of the associated malformations.25 Diagnoses of ARM-VACTERL 
were assigned by the first author (C.W.) based on this definition and confirmed by a clinical 
geneticist (C.M.). Because no healthy controls are included in the EUROCAT registries, by 
convention the control group included live births, stillbirths, and prenatally diagnosed 
fetuses with subsequent terminations of pregnancy with recognized syndromes (mostly 
single gene disorders) or chromosomal anomalies, excluding ARM and VACTERL (n=45). 
Frequently occurring syndromes or chromosomal abnormalities among controls were 
trisomy 21 (54%), trisomy 18 (8%), and Turner syndrome (4%). As some pregnancy-related 
factors, such as preeclampsia and gestational diabetes, are normally not yet diagnosed 
before termination of pregnancy, the proportion of terminated pregnancies after prenatal 
diagnosis in the control group was reduced to the proportion in the case group for reasons 
of comparability, by randomly excluding part of these controls (n=6,505).  
 
Determinant definitions 
In the EUROCAT database, information was recorded after birth of the child using multiple 
sources, such as hospital records, birth and death certificates, and post mortem 
examinations using uniform definitions and coding.23 A few registries also incorporated 
maternal interviews after birth. Several fetus/infant characteristics, including gender, 
survival (beyond one week of age), gestational age (in completed weeks) and birth weight (in 
grams) were recorded in the database. In addition, information was available on maternal 
age at delivery, fertility treatment (including hormonal treatment, artificial insemination, in 
vitro fertilization [IVF], intracytoplasmic sperm injection [ICSI], and gamete intra-fallopian 
transfer [GIFT]), multiple pregnancy (twin or triplet), parity (no vs one or more previous 
pregnancies), maternal chronic illnesses, maternal illnesses during first four months of 
pregnancy, and pregnancy complications. The latter three were coded according to the ICD-9 
or ICD-10 and we included pre-existing and gestational diabetes mellitus, chronic obstructive 
lower pulmonary diseases (e.g. asthma and bronchitis), epilepsy, mental disorders (e.g. 
depressive and anxiety disorders), fever (>38°C) during first four months of pregnancy, and 
preeclampsia, also including eclampsia, as a proxy for placental dysfunction in this study. 
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Table 1. Anomalies among anorectal malformation cases with additional congenital anomalies and 
ARM-VACTERL cases (17 EUROCAT registries; 1980-2008). 
 ARM and other 
defects  
(n= 601) 
ARM-VACTERL  
 
(n= 168) 
All ARM casesa 
 
(n= 1,417) 
 No. % No. % No. % 
Skeletal anomalies    125 20.8 87 51.8 212 15.0 
   Vertebral anomaliesb 20 3.3 57 33.9 77 5.4 
   Other musculo-skeletal anomalies 113 18.8 48 28.6 161 11.4 
Congenital heart defects    137 22.8 98 58.3 235 16.6 
   Cardiac defectsb 97 16.1 87 51.8 184 13.0 
   Other cardiovascular anomalies 53 8.8 29 17.3 82 5.8 
Tracheo-Esophageal atresiab 62 10.3 80 47.6 142 10.0 
Urological anomalies   236 39.3 122 72.6 358 25.3 
   Renal anomaliesb 126 21.0 107 63.7 233 16.4 
   Urinary tract anomalies 136 22.6 36 21.4 172 12.1 
Limb defects     121 20.1 68 40.5 189 13.3 
   Radial Limb defectsb 33 5.5 50 29.8 83 5.9 
   Other limb defects 101 16.8 28 16.7 129 9.1 
Central nervous system anomalies 89 14.8 13 7.7 102 7.2 
Respiratory anomalies 50 8.3 15 8.9 65 4.6 
Orofacial clefts 35 5.8 4 2.4 39 2.8 
Other facial anomalies 66 11.0 20 11.9 86 6.1 
Gastro-intestinal anomalies 60 10.0 21 12.5 81 5.7 
Abdominal wall defects 32 5.3 0 0.0 32 2.3 
Genital anomalies 148 24.6 34 20.2 182 12.8 
aIncluding isolated ARM cases, ARM cases with additional congenital anomalies, and ARM-VACTERL cases. 
bOnly including defects belonging to the VACTERL association. 
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Statistical analyses 
Statistical analyses were performed using the statistical package SPSS 18.0 for Windows 
(SPSS Inc., Chicago, IL). We calculated crude odds ratios (ORs) with 95% confidence intervals 
(CIs) for potential risk factors for ARM, namely fertility treatment, multiple pregnancy, 
primiparity, and the above-mentioned maternal illnesses and pregnancy complications. 
Multiple logistic regression analyses were used to calculate adjusted ORs when at least three 
cases were exposed. We defined confounders as those factors that were either causally or 
accidentally associated with both ARM and the determinant. The reporting registry was 
selected as a priori confounder and was included in every model. In addition, maternal age 
at delivery (divided into ≤35 vs >35 years), year of birth, fertility treatment, multiple 
pregnancy, primiparity, preeclampsia, and maternal epilepsy were considered as potential 
confounding factors when they were not the primary factor of interest. All factors that 
changed the ORs in bivariable models were included in the full models, from which they 
were excluded if the OR did not change more than 10% upon removal. None of the potential 
confounders proved to be true confounders, except for maternal age at delivery, primiparity, 
and year of birth on only a few occasions. Subanalyses were performed for the different 
manifestations of ARM. Registries were excluded from specific analyses when data on 
certain determinants were not collected.  
 
Results 
A total of 1,417 cases and 13,371 controls were eligible for this case-control study. Of the 
cases, 648 had isolated ARM (46%), 601 had ARM with one or more major congenital 
anomalies (42%), and 168 were ARM-VACTERL cases (12%). Most ARM cases with associated 
anomalies had urological (25%), cardiac (17%), skeletal (15%), limb (13%), or genital (13%) 
anomalies (Table 1). Cases were more often boys than girls, whereas the proportions of 
control boys and girls were almost equal (Table 2). Approximately 87% of the cases were 
live-born, 3% were stillborn, and 10% of the pregnancies were terminated after prenatal 
diagnosis. Survival after one week of age was 90% among all live-born ARM cases, 99% 
among live-born isolated ARM cases, 84% among live-born ARM cases with other anomalies, 
and 73% among live-born ARM-VACTERL cases. The proportions of mothers whose children 
were delivered preterm and/or had low birth weight were almost the same for live-born 
cases and controls. Case mothers were slightly younger than control mother (28.9 years and 
32.2 years, respectively), of which a larger proportion was over 35 years of age, because of 
the selection of controls, which included many infants or fetuses with Down syndrome.  
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Table 2. Characteristics of anorectal malformation cases and controls and their mothers (17 
EUROCAT registries; 1980-2008). 
 ARM cases  
(n= 1,417) 
No.a (%) 
Controls  
(n= 13,371)  
No.a (%) 
Gender   
   Male 894 (63.5) 6,748 (50.8) 
   Female 490 (34.8) 6,487 (48.9) 
   Indeterminate 24 (1.7) 37 (0.3) 
Birth type        
   Live birth 1,228 (86.7) 11,210 (84.0) 
   Stillbirth 45 (3.2) 793 (5.9) 
   Termination of pregnancy 143 (10.1) 1,349 (10.1)b 
Survival (>one week of age)c 827 (90.3) 8,551 (92.4) 
Preterm delivery (<37 weeks)c 242 (21.3) 2,125 (20.3) 
Low birth weight (<2500 gr)c 294 (24.9) 2,915 (26.9) 
Maternal age at delivery (>35 years) 180 (13.7) 4,264 (33.2) 
aNumbers do not add up to total number due to missing values. 
bArtificially reduced to the same percentage as the cases. 
cOnly calculated for live births. 
 
Tables 3 and 4 show the associations between ARM and fertility treatment, multiple 
pregnancy, primiparity, and maternal chronic illnesses, maternal illnesses during the first 
four months of pregnancy and pregnancy complications. ARM seemed to be weakly 
associated with fertility treatment (OR 1.3, 95% CI 0.9–1.8). No association was found 
between isolated ARM and fertility treatment (OR 0.8, 95% CI 0.4–1.5), but an increased risk 
was observed for ARM and other congenital anomalies (OR 1.6, 95% CI 1.0–2.4) and possibly 
for ARM-VACTERL (OR 1.6, 95% CI 0.8–3.3). Comparable odds ratios were found when 
multiple pregnancies were excluded from the analyses. Among the parents who received 
fertility treatment, 118 mothers were given hormonal treatment only (21 case and 97 
control mothers), 87 mothers were artificially inseminated (ten case and 77 control 
mothers), 109 parents underwent IVF (seven case and 102 control parents), 14 parents 
conceived through ICSI (zero case and 14 control parents), 16 pregnancies resulted from 
GIFT (three cases and 13 controls), and other unspecified techniques were used 38 times. In 
fact, the only effect was observed for hormonal treatment (OR 2.1, 95% CI 1.3–3.4), whereas 
no association was seen between ARM and IVF, ICSI, and GIFT taken together (OR 0.8, 95% 
CI 0.4–1.5). In total, 398 multiple pregnancies occurred, of which 388 were twin pregnancies 
and ten were triplet pregnancies. Cases were more likely to be part of a twin or triplet than 
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controls (OR 1.6, 95% CI 1.2–2.1), but this was only seen among ARM cases with other 
congenital anomalies and ARM-VACTERL cases (OR 1.8, 95% CI 1.2–2.8 and OR 2.5, 95% CI 
1.3–4.7, respectively). We found comparable results when the analyses were restricted to 
infants whose parents did not receive fertility treatment, but the association between ARM-
VACTERL and multiple pregnancy disappeared (OR 0.5, 95% CI 0.1–3.6). Primiparity was 
associated with an approximately 1.5-fold elevated risk of all manifestations of ARM. We 
found preeclampsia to be associated with ARM (OR 2.2, 95% CI 1.2–4.0), but only among 
ARM cases with other congenital anomalies (OR 3.4, 95% CI 1.6–7.1). Similar risk estimates 
were seen for ARM patients whose mothers had fever during the first four months of 
pregnancy (OR 2.2, 95% CI 0.8–5.7 and OR 3.9, 95% CI 1.3–11.6, respectively). The risks of all 
manifestations of ARM were approximately five times increased when the mother suffered 
from epilepsy during pregnancy. In total, 14 mothers had epilepsy during pregnancy (five 
cases and nine controls), of whom at least ten mothers reported antiepileptic drug use 
during the first four months of pregnancy (five case and five control mothers). We did not 
have information on type and dose of the antiepileptic drugs. Finally, pre-existing and 
gestational diabetes, maternal chronic obstructive lower pulmonary diseases (e.g. asthma 
and bronchitis), and mental disorders (e.g. depressive and anxiety disorders) during the first 
four months of pregnancy were not associated with ARM. Subanalyses including only live 
births resulted in ORs which were very similar to those in Tables 3 and 4 for all pregnancy-
related disorders (data not shown). 
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Table 3. Associations between anorectal malformations and pregnancy-related disorders (17 
EUROCAT registries; 1980-2008). 
 Cases  
(n= 1,417) 
No. (%) 
Controls 
(n= 13,371) 
No. (%) 
Crude OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Fertility treatmenta 45 (6.0) 337 (4.8) 1.3 (0.9–1.8) 1.3 (0.9–1.8) 
Multiple pregnancy (twin or triplet) 56 (4.0) 342 (2.6) 1.6 (1.2–2.1) 1.6 (1.2–2.1) 
Primiparityb 472 (43.2) 3,472 (32.5) 1.6 (1.4–1.8) 1.6 (1.4–1.8) 
Preeclampsiac 14 (2.2) 71 (1.3) 1.7 (1.0–3.1) 2.2 (1.2–4.0) 
Fever during the first 4 months of 
pregnancyc 
5 (0.8) 30 (0.5) 1.5 (0.6–3.8) 2.2 (0.8–5.7)d 
Diabetes mellitusc      
   Pre-existing 8 (1.1) 85 (1.4) 0.8 (0.4–1.7) 0.8 (0.4–1.7) 
   Gestational 1 (0.1) 37 (0.6) 0.2 (0.0–1.7) – 
Chronic lower obstructive pulmonary 
diseasec 
17 (2.4) 128 (2.1) 1.2 (0.7–1.9) 1.4 (0.8–2.3) 
Epilepsy during pregnancyc 5 (0.8) 9 (0.2) 4.9 (1.6–14.6) 5.1 (1.7–15.6) 
Mental disorder during the first 4 
months of pregnancyc 
3 (0.5) 28 (0.5) 0.9 (0.3–3.1) 1.3 (0.4–4.3)  
Maternal age at delivery, year of birth, fertility treatment, multiple pregnancy, primiparity, preeclampsia, 
and maternal epilepsy were included as potential confounders, but they were excluded from the models if 
their removal did not change the OR by more than 10%. All factors were adjusted for registry. Adjusted 
OR was calculated if >2 cases were exposed.  
aFive registries were excluded as data were not available, leaving 1,071 cases and 10,518 controls. 
bOne registry was excluded as data were not available, leaving 1,325 cases and 12,774 controls. 
cSix registries were excluded as data were not available, leaving 918 cases and 8,347 controls. 
dAdjusted for registry and year of birth. 
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Table 3. Associations between anorectal malformations and pregnancy-related disorders (17 
EUROCAT registries; 1980-2008). 
 Cases  
(n= 1,417) 
No. (%) 
Controls 
(n= 13,371) 
No. (%) 
Crude OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Fertility treatmenta 45 (6.0) 337 (4.8) 1.3 (0.9–1.8) 1.3 (0.9–1.8) 
Multiple pregnancy (twin or triplet) 56 (4.0) 342 (2.6) 1.6 (1.2–2.1) 1.6 (1.2–2.1) 
Primiparityb 472 (43.2) 3,472 (32.5) 1.6 (1.4–1.8) 1.6 (1.4–1.8) 
Preeclampsiac 14 (2.2) 71 (1.3) 1.7 (1.0–3.1) 2.2 (1.2–4.0) 
Fever during the first 4 months of 
pregnancyc 
5 (0.8) 30 (0.5) 1.5 (0.6–3.8) 2.2 (0.8–5.7)d 
Diabetes mellitusc      
   Pre-existing 8 (1.1) 85 (1.4) 0.8 (0.4–1.7) 0.8 (0.4–1.7) 
   Gestational 1 (0.1) 37 (0.6) 0.2 (0.0–1.7) – 
Chronic lower obstructive pulmonary 
diseasec 
17 (2.4) 128 (2.1) 1.2 (0.7–1.9) 1.4 (0.8–2.3) 
Epilepsy during pregnancyc 5 (0.8) 9 (0.2) 4.9 (1.6–14.6) 5.1 (1.7–15.6) 
Mental disorder during the first 4 
months of pregnancyc 
3 (0.5) 28 (0.5) 0.9 (0.3–3.1) 1.3 (0.4–4.3)  
Maternal age at delivery, year of birth, fertility treatment, multiple pregnancy, primiparity, preeclampsia, 
and maternal epilepsy were included as potential confounders, but they were excluded from the models if 
their removal did not change the OR by more than 10%. All factors were adjusted for registry. Adjusted 
OR was calculated if >2 cases were exposed.  
aFive registries were excluded as data were not available, leaving 1,071 cases and 10,518 controls. 
bOne registry was excluded as data were not available, leaving 1,325 cases and 12,774 controls. 
cSix registries were excluded as data were not available, leaving 918 cases and 8,347 controls. 
dAdjusted for registry and year of birth. 
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Discussion 
In this large European registry-based case-control study, the risk of ARM appeared to be 
associated with fertility treatment, multiple pregnancy, primiparity, preeclampsia, maternal 
fever during the first four months of pregnancy, and epilepsy during pregnancy. These 
pregnancy-related disorders were mainly found to increase the risk of ARM when ARM 
occurred in combination with other anomalies, whether or not belonging to the VACTERL 
association.  
The EUROCAT network provides many possibilities for large-scale epidemiologic 
studies on congenital anomalies. The study sample of 1,417 ARM cases was the largest 
sample ever studied, which made it possible to investigate different manifestations of ARM. 
The importance of performing these subanalyses was emphasized by risk estimates that 
varied between different manifestations of ARM. Causal heterogeneity may exist due to 
differences in the time windows of exposure or the underlying biological mechanisms. 
Despite the large study sample, the power may have been insufficient to detect moderate 
effects of specific risk factors for ARM, especially in ARM-VACTERL cases. As EUROCAT only 
collects data on pregnancies of affected infants/fetuses, we used controls that had 
malformations instead of controls without malformations. Teratogenicity non-specificity bias 
may occur when a certain exposure leads to malformations in both cases and controls. To 
reduce this type of bias, only controls with recognized syndromes or chromosomal 
abnormalities were included, under the assumption that these abnormalities originated due 
to genetic defects only. Because these syndromes and chromosomal abnormalities arise 
before or during conception, it is not likely that pregnancy-related factors influenced their 
occurrence. Furthermore, previous studies argued that these types of congenital anomalies 
are suitable and representative sources of controls.26,27 A few potential risk factors, including 
gestational diabetes mellitus, chronic lower obstructive pulmonary disease and mental 
disorders, seemed to be underreported in mothers of both cases and controls, but the 
figures for most determinants in controls were similar to those found in the general 
pregnant population.28,29 As post mortem examination after a stillbirth or for prenatally 
diagnosed fetuses with subsequent termination of pregnancy was not always performed, 
some controls may have had ARM. This could have resulted in dilution of the effects that 
were found. Differential misclassification of exposure status because of poorer recording of 
exposures for controls compared with cases is unlikely, as information on pregnancy-related 
factors was obtained from hospital records by the EUROCAT registry, with already existing 
data gathered prospectively during pregnancy for most infants in our study, regardless of the 
type of malformation. Only a few registries used maternal interviews after birth, but 
pregnancy-related factors, such as fertility treatment, multiple pregnancy, primiparity, 
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Discussion 
In this large European registry-based case-control study, the risk of ARM appeared to be 
associated with fertility treatment, multiple pregnancy, primiparity, preeclampsia, maternal 
fever during the first four months of pregnancy, and epilepsy during pregnancy. These 
pregnancy-related disorders were mainly found to increase the risk of ARM when ARM 
occurred in combination with other anomalies, whether or not belonging to the VACTERL 
association.  
The EUROCAT network provides many possibilities for large-scale epidemiologic 
studies on congenital anomalies. The study sample of 1,417 ARM cases was the largest 
sample ever studied, which made it possible to investigate different manifestations of ARM. 
The importance of performing these subanalyses was emphasized by risk estimates that 
varied between different manifestations of ARM. Causal heterogeneity may exist due to 
differences in the time windows of exposure or the underlying biological mechanisms. 
Despite the large study sample, the power may have been insufficient to detect moderate 
effects of specific risk factors for ARM, especially in ARM-VACTERL cases. As EUROCAT only 
collects data on pregnancies of affected infants/fetuses, we used controls that had 
malformations instead of controls without malformations. Teratogenicity non-specificity bias 
may occur when a certain exposure leads to malformations in both cases and controls. To 
reduce this type of bias, only controls with recognized syndromes or chromosomal 
abnormalities were included, under the assumption that these abnormalities originated due 
to genetic defects only. Because these syndromes and chromosomal abnormalities arise 
before or during conception, it is not likely that pregnancy-related factors influenced their 
occurrence. Furthermore, previous studies argued that these types of congenital anomalies 
are suitable and representative sources of controls.26,27 A few potential risk factors, including 
gestational diabetes mellitus, chronic lower obstructive pulmonary disease and mental 
disorders, seemed to be underreported in mothers of both cases and controls, but the 
figures for most determinants in controls were similar to those found in the general 
pregnant population.28,29 As post mortem examination after a stillbirth or for prenatally 
diagnosed fetuses with subsequent termination of pregnancy was not always performed, 
some controls may have had ARM. This could have resulted in dilution of the effects that 
were found. Differential misclassification of exposure status because of poorer recording of 
exposures for controls compared with cases is unlikely, as information on pregnancy-related 
factors was obtained from hospital records by the EUROCAT registry, with already existing 
data gathered prospectively during pregnancy for most infants in our study, regardless of the 
type of malformation. Only a few registries used maternal interviews after birth, but 
pregnancy-related factors, such as fertility treatment, multiple pregnancy, primiparity, 
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preeclampsia, and other maternal disorders, are not expected to be prone to recall bias. A 
limitation of this registry-based study was the lack of information on parental lifestyle 
factors and of detailed information on certain potential risk factors, such as zygosity in 
multiple pregnancies, the type of fertility problems of the parents, and specific information 
on illnesses and drug use. Therefore, residual confounding cannot be excluded. All 
associations were adjusted for registry, which was appropriate as small differences existed 
between the EUROCAT registries included. Although we described some potential biases 
that are usually associated with observational studies, we expect that these biases only 
influenced our findings to a minimal extent. 
Approximately 54% of the ARM cases without syndromes, chromosomal abnor-
malities, or cloacal or bladder exstrophy had one or more additional congenital anomalies. 
Among all ARM cases up to 62% had additional congenital anomalies. This is in line with 
previous studies that reported percentages between 40% and 70%, usually including 
syndromes and chromosomal abnormalities.2,30 Urological (25%) and cardiac (17%) 
malformations appeared to be the most prevalent additional malformations, which also 
confirms other studies.2,30 The male/female ratio of 1.8 among ARM cases was higher than 
previously described ratios of 1.2–1.4.6,30 Females more often suffer from mild and 
unrecognized phenotypes of ARM without clinical symptoms than males. In this registry-
based study, diagnoses of these mild phenotypes of ARM may have been missed or delayed, 
which could have led to a relatively high male/female ratio.  
To our knowledge, this is the first study to perform subanalyses on associations 
between fertility treatment and different manifestations of ARM. Even after adjustment for 
multiple pregnancy, we found fertility treatment to be associated with ARM in combination 
with other defects only and we found an effect for hormonal treatment without IVF or ICSI in 
general. In contrast, clomiphene citrate, a hormonal drug for subfertility treatment, was not 
found to be associated with ARM in a study on the effect of this drug on major birth 
defects.31 Other studies showed that assisted reproductive techniques, including IVF and 
ICSI, increased the risk of several major birth defects, including ARM.12-14 However, these 
studies did not perform subanalyses for different manifestations of ARM. Although 
contrasting, all of these findings seem to point towards an association between ARM and 
fertility treatment. This may be due to epigenetic mechanisms, which were also described 
for associations between fertility treatment and certain syndromes (e.g. Beckwith-
Wiedemann syndrome).32,33 However, it may also indicate that the underlying subfertility of 
the parents is the main risk factor in the etiology of ARM.  
We found an over-representation of ARM with additional congenital anomalies and 
ARM-VACTERL among multiple pregnancies, whereas few other researchers found increased 
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numbers of heterogeneous groups of gastro-intestinal atresias, including ARM, in multiple 
pregnancies.34,35 Doyle et al. showed the proportion of chromosomal abnormalities to be 
lower in multiple pregnancies,34 which could correspond with a decreased number of 
multiple pregnancies among our controls. Since more recent studies did not confirm this 
result, it is debatable whether our ORs for multiple pregnancies were overestimated.35,36 
Primiparity was associated with all manifestations of ARM and preeclampsia with ARM and 
additional congenital anomalies only, although the risk estimates for primiparity may be 
slightly inflated as firstborns are relatively uncommon among controls with Down 
syndrome.37. Interestingly, multiple pregnancy, primiparity, and preeclampsia are all factors 
that may reflect situations in which the placenta supplies the fetus with nutrients and 
hormones insufficiently. Therefore, we hypothesize placental insufficiency in early 
pregnancy to partly explain the associations found, especially those for ARM occurring in 
combination with other congenital anomalies. Similar results have been found for 
hypospadias, a frequently occurring congenital malformation among boys.38 Although the 
rates of low birth weight among cases and controls were almost equal, these were high 
compared with non-malformed controls.28 Low birth weight may also be a consequence of 
placental insufficiency, which strengthens our placental insufficiency hypothesis. Another 
biological mechanism underlying the associations between ARM and multiple pregnancy and 
primiparity may be a disturbed androgen/estrogen balance, as endogenous levels of free 
oestradiol are increased in first and multiple pregnancies.39 Free oestradiol levels also 
increase with increasing body mass index of the mother,40 and maternal overweight and 
obesity have consistently been identified as risk factors for ARM.41  
Although adverse effects of maternal epilepsy and/or antiepileptic drug use on birth 
defects have already been shown,42 we found a five times increased risk of ARM in 
infants/fetuses of mothers with epilepsy during pregnancy. Unfortunately, we were not able 
to study associations between ARM and the different types and doses of antiepileptic drugs, 
as no information was available. It is unclear whether congenital anomalies result from 
teratogenic effects of antiepileptic drugs alone, or are partly the result of the underlying 
epilepsy itself. Previously, a reduced risk of ARM was shown after periconceptional folic acid 
supplementation.19 This may explain the association between ARM and maternal epilepsy 
during pregnancy as treatment with most antiepileptic drugs was associated with reduced 
folate serum levels.43 In agreement with our previous studies on parental risk factors for 
ARM,6,15 maternal fever during the first four months of pregnancy was found to be 
associated with ARM, mainly in infants/fetuses with additional congenital anomalies. A 
recent meta-analysis reported an increased risk of ARM for maternal pre-existing or 
gestational diabetes mellitus,41 but we could not confirm these findings, possibly because of 
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preeclampsia, and other maternal disorders, are not expected to be prone to recall bias. A 
limitation of this registry-based study was the lack of information on parental lifestyle 
factors and of detailed information on certain potential risk factors, such as zygosity in 
multiple pregnancies, the type of fertility problems of the parents, and specific information 
on illnesses and drug use. Therefore, residual confounding cannot be excluded. All 
associations were adjusted for registry, which was appropriate as small differences existed 
between the EUROCAT registries included. Although we described some potential biases 
that are usually associated with observational studies, we expect that these biases only 
influenced our findings to a minimal extent. 
Approximately 54% of the ARM cases without syndromes, chromosomal abnor-
malities, or cloacal or bladder exstrophy had one or more additional congenital anomalies. 
Among all ARM cases up to 62% had additional congenital anomalies. This is in line with 
previous studies that reported percentages between 40% and 70%, usually including 
syndromes and chromosomal abnormalities.2,30 Urological (25%) and cardiac (17%) 
malformations appeared to be the most prevalent additional malformations, which also 
confirms other studies.2,30 The male/female ratio of 1.8 among ARM cases was higher than 
previously described ratios of 1.2–1.4.6,30 Females more often suffer from mild and 
unrecognized phenotypes of ARM without clinical symptoms than males. In this registry-
based study, diagnoses of these mild phenotypes of ARM may have been missed or delayed, 
which could have led to a relatively high male/female ratio.  
To our knowledge, this is the first study to perform subanalyses on associations 
between fertility treatment and different manifestations of ARM. Even after adjustment for 
multiple pregnancy, we found fertility treatment to be associated with ARM in combination 
with other defects only and we found an effect for hormonal treatment without IVF or ICSI in 
general. In contrast, clomiphene citrate, a hormonal drug for subfertility treatment, was not 
found to be associated with ARM in a study on the effect of this drug on major birth 
defects.31 Other studies showed that assisted reproductive techniques, including IVF and 
ICSI, increased the risk of several major birth defects, including ARM.12-14 However, these 
studies did not perform subanalyses for different manifestations of ARM. Although 
contrasting, all of these findings seem to point towards an association between ARM and 
fertility treatment. This may be due to epigenetic mechanisms, which were also described 
for associations between fertility treatment and certain syndromes (e.g. Beckwith-
Wiedemann syndrome).32,33 However, it may also indicate that the underlying subfertility of 
the parents is the main risk factor in the etiology of ARM.  
We found an over-representation of ARM with additional congenital anomalies and 
ARM-VACTERL among multiple pregnancies, whereas few other researchers found increased 
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numbers of heterogeneous groups of gastro-intestinal atresias, including ARM, in multiple 
pregnancies.34,35 Doyle et al. showed the proportion of chromosomal abnormalities to be 
lower in multiple pregnancies,34 which could correspond with a decreased number of 
multiple pregnancies among our controls. Since more recent studies did not confirm this 
result, it is debatable whether our ORs for multiple pregnancies were overestimated.35,36 
Primiparity was associated with all manifestations of ARM and preeclampsia with ARM and 
additional congenital anomalies only, although the risk estimates for primiparity may be 
slightly inflated as firstborns are relatively uncommon among controls with Down 
syndrome.37. Interestingly, multiple pregnancy, primiparity, and preeclampsia are all factors 
that may reflect situations in which the placenta supplies the fetus with nutrients and 
hormones insufficiently. Therefore, we hypothesize placental insufficiency in early 
pregnancy to partly explain the associations found, especially those for ARM occurring in 
combination with other congenital anomalies. Similar results have been found for 
hypospadias, a frequently occurring congenital malformation among boys.38 Although the 
rates of low birth weight among cases and controls were almost equal, these were high 
compared with non-malformed controls.28 Low birth weight may also be a consequence of 
placental insufficiency, which strengthens our placental insufficiency hypothesis. Another 
biological mechanism underlying the associations between ARM and multiple pregnancy and 
primiparity may be a disturbed androgen/estrogen balance, as endogenous levels of free 
oestradiol are increased in first and multiple pregnancies.39 Free oestradiol levels also 
increase with increasing body mass index of the mother,40 and maternal overweight and 
obesity have consistently been identified as risk factors for ARM.41  
Although adverse effects of maternal epilepsy and/or antiepileptic drug use on birth 
defects have already been shown,42 we found a five times increased risk of ARM in 
infants/fetuses of mothers with epilepsy during pregnancy. Unfortunately, we were not able 
to study associations between ARM and the different types and doses of antiepileptic drugs, 
as no information was available. It is unclear whether congenital anomalies result from 
teratogenic effects of antiepileptic drugs alone, or are partly the result of the underlying 
epilepsy itself. Previously, a reduced risk of ARM was shown after periconceptional folic acid 
supplementation.19 This may explain the association between ARM and maternal epilepsy 
during pregnancy as treatment with most antiepileptic drugs was associated with reduced 
folate serum levels.43 In agreement with our previous studies on parental risk factors for 
ARM,6,15 maternal fever during the first four months of pregnancy was found to be 
associated with ARM, mainly in infants/fetuses with additional congenital anomalies. A 
recent meta-analysis reported an increased risk of ARM for maternal pre-existing or 
gestational diabetes mellitus,41 but we could not confirm these findings, possibly because of 
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under-reporting of pre-existing or gestational diabetes among cases and controls and small 
numbers in the case groups.  
 
Conclusion 
This is the first study emphasizing the importance of performing subanalyses on different 
manifestations of ARM. Our findings suggest the involvement of multiple pregnancy, 
primiparity, and preeclampsia, factors that are possibly related to placental insufficiency or a 
disturbed androgen/estrogen balance, as well as fertility treatment, maternal epilepsy, and 
fever during the first four months of pregnancy in the etiology of ARM. These pregnancy-
related disorders mainly seem to play a role in complex phenotypes of ARM in which 
additional congenital anomalies are present. Only maternal epilepsy and primiparity were 
found to be involved in the occurrence of isolated ARM. Although these factors increased 
the risk of ARM 1.5 to 5 times, the absolute risks of having a child with ARM were relatively 
low, ranging between 0.05% and 0.26% for each potential risk factor. In addition to relative 
and absolute risks, however, these findings also provide clues about the pathophysiological 
mechanisms involved in the etiology of ARM, which may in turn guide further research, 
preventive strategies and health care for ARM patients in the future. 
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Abstract 
 
Background Anorectal malformations (ARM) are major congenital malformations that 
usually require a multitude of surgical procedures at very early age and have a large impact 
on the lives of patients and their parents. The causes of ARM are still largerly unknown, but 
it is assumed to have a multifactorial etiology. A few studies focused on environmental risk 
factors, but evidence is still scarce.  
 
Methods In this Dutch case-control study (1996-2008), we investigated the role of maternal 
and paternal risk factors in the etiology of ARM. Parents of 85 ARM cases and 650 controls 
filled in a questionnaire. Controls were children treated with ear ventilation tubes.  
 
Results A higher occurrence of fever during the first trimester of pregnancy was found for 
case mothers compared to control mothers (odds ratio (OR), 5.1; 95% Confidence Interval 
(CI), 0.9, 28.1). Maternal occupational exposure to industrial cleaning agents and solvents 
increased the risk of ARM three times (OR, 2.9; 95% CI, 0.9, 9.3). Overweight (Body Mass 
Index (BMI) ≥ 25 kg/m2) before pregnancy also seemed to be associated with ARM (OR, 1.8; 
95% CI, 1.1, 2.8), as well as maternal multivitamin use during pregnancy (OR, 1.6; 95% CI, 
1.0, 2.7), paternal smoking (OR, 1.8; 95% CI, 1.1, 2.9) and paternal occupational exposure to 
exhaust fumes (OR, 1.9; 95% CI, 1.0, 3.6). Reported ARM in at least one first or second 
degree family member greatly increased the risk of having a child with ARM (OR, 40.3; 95% 
CI, 4.8, 342.8).  
 
Conclusions This study revealed potential risk factors for ARM, including fever during 
pregnancy, maternal overweight, use of multivitamins, paternal smoking, and occupational 
exposures, but a familial component seems important as well. 
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Introduction 
Congenital anorectal malformations (ARM) are the most common gastrointestinal anomalies 
at birth. The worldwide prevalence of ARM is estimated to be 1 in 1500 to 1 in 5000 live 
births.1 Anorectal anomalies include a wide range of phenotypes depending on location and 
size of the defect. They usually require multiple surgical procedures at very early age and 
have a major impact on the lives of patients and their parents. Additional congenital 
anomalies are present in approximately 50% of ARM cases, especially anomalies of the 
heart, kidneys, spine, urogenital tract, and other gastrointestinal atresias, in particular as 
components of the VACTERL association (Vertebral defects, Anal atresia, Cardiac defects, 
Tracheo-Esophageal fistula, Renal anomalies, Radial dysplasia, and Limb defects). Not much 
is known about the etiology of ARM, apart from a few identified genes that have been 
implicated in syndromes including ARM or were derived from animal studies. Townes-Brocks 
syndrome, with combinations of anal, renal, limb, and ear anomalies, is caused by mutations 
in the SALL1 zinc-finger protein.2 Linkage and mutational analyses in patients with the 
Currarino syndrome, in which sacral malformations are found along with ARM, identified the 
homeobox gene HLXB9 as a major locus.3 Mutant mice with various defects in the signaling 
pathway of sonic hedgehog exhibit a spectrum of distal hindgut defects mimicking human 
ARM, while mutant mice lacking Gli2 or Gli3 show imperforate anus with recto-urethral 
fistula and anal stenosis.4,5 
Although evidence exists for genetic contribution to ARM based on these studies, 
nonsyndromic anorectal anomalies rarely aggregate in families.6 This points towards a 
substantial role for environmental risk factors. A Japanese study suggested maternal alcohol 
drinking in early pregnancy as a risk factor for isolated anal atresia,7 that could not be 
confirmed by others.8,9 Cigarette smoking and caffeine intake were found to be associated 
with anal atresia in the US,9 whereas in France and Spain, associations with medical drug use 
during pregnancy were found,8 in particular use of the benzodiazepine lorazepam.10 Paternal 
exposure to occupational hazards, such as organic solvents and metals in vehicle 
manufacturers seemed to be associated with anal atresia as well.8,11 Based on a single study 
in China, it has been suggested that periconceptional folic acid supplementation may reduce 
the risk of anal atresia.12 Most of these potential risk factors stem from only one 
epidemiologic study per risk factor, which is not sufficient for conclusions about causality. 
Moreover, none of these studies investigated all potential risk factors simultaneously in a 
structured manner allowing adjustment for confounders. Therefore, the aim of this case-
control study was to identify risk factors for ARM among a wide spectrum of familial, 
pregnancy-related, lifestyle, and occupational factors in both mothers and fathers.  
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Abstract 
 
Background Anorectal malformations (ARM) are major congenital malformations that 
usually require a multitude of surgical procedures at very early age and have a large impact 
on the lives of patients and their parents. The causes of ARM are still largerly unknown, but 
it is assumed to have a multifactorial etiology. A few studies focused on environmental risk 
factors, but evidence is still scarce.  
 
Methods In this Dutch case-control study (1996-2008), we investigated the role of maternal 
and paternal risk factors in the etiology of ARM. Parents of 85 ARM cases and 650 controls 
filled in a questionnaire. Controls were children treated with ear ventilation tubes.  
 
Results A higher occurrence of fever during the first trimester of pregnancy was found for 
case mothers compared to control mothers (odds ratio (OR), 5.1; 95% Confidence Interval 
(CI), 0.9, 28.1). Maternal occupational exposure to industrial cleaning agents and solvents 
increased the risk of ARM three times (OR, 2.9; 95% CI, 0.9, 9.3). Overweight (Body Mass 
Index (BMI) ≥ 25 kg/m2) before pregnancy also seemed to be associated with ARM (OR, 1.8; 
95% CI, 1.1, 2.8), as well as maternal multivitamin use during pregnancy (OR, 1.6; 95% CI, 
1.0, 2.7), paternal smoking (OR, 1.8; 95% CI, 1.1, 2.9) and paternal occupational exposure to 
exhaust fumes (OR, 1.9; 95% CI, 1.0, 3.6). Reported ARM in at least one first or second 
degree family member greatly increased the risk of having a child with ARM (OR, 40.3; 95% 
CI, 4.8, 342.8).  
 
Conclusions This study revealed potential risk factors for ARM, including fever during 
pregnancy, maternal overweight, use of multivitamins, paternal smoking, and occupational 
exposures, but a familial component seems important as well. 
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Materials and methods 
Study population 
Children born between January 1996 and April 2008 who were treated for ARM at the 
department of Pediatric Surgery of the Radboud University Nijmegen Medical Centre 
(RUNMC) in the Netherlands were eligible for this study. The medical records were reviewed 
to retrieve anomaly-specific information to classify ARM according to Levitt and Peña.13 For 
boys, the malformations were categorized into perineal fistulas, recto-urethral fistulas 
(bulbar or prostate), recto-bladderneck fistulas and imperforate anus without fistula and for 
girls into perineal and vestibular fistulas, and imperforate anus without fistula. Two less 
common defects, rectal atresia and anal stenosis, were also identified and included. For the 
diagnosis of the VACTERL association, we used the presence of ARM and at least two 
additional defects of the VACTERL spectrum as described by Jong et al.14 and named it ARM-
VACTERL in this study. In total, the parents of 132 ARM cases were asked to participate in 
the study.  
The control group was derived from a study on hypospadias15 and recruited at the 
Otorhinolaryngology departments of the RUNMC and three general hospitals in the 
surroundings of Nijmegen, covering the referral area of the ARM cases. All controls were 
boys with persistent middle ear infection treated with ventilation tubes and born between 
1996 and 2004. We randomly selected 1000 controls without major birth defects. This 
control group was chosen to avoid selective non-response and information bias since they 
were not informed about their control status. Because middle ear infection is one of the 
most common diseases in childhood, the control group is likely to be representative of the 
general population in the area.  
 
Data collection 
Between February 2005 and December 2006, the parents of cases and controls known to be 
alive were sent almost identical questionnaires and similar information letters and leaflets, 
followed by two reminders after three and seven weeks to increase the response rate. From 
2007 onwards, parents of ARM cases were asked to participate in the AGORA project 
(Aetiologic research into Genetic and Occupational/ Environmental Risk Factors for 
Anomalies in Children) of the RUNMC at the child’s first admission to the hospital. This 
project aims at building a data- and biobank for questionnaire data and DNA from cases 
treated for a congenital disorder and their parents.   
The questionnaire contained questions about demographic factors, family history of 
birth defects, and pregnancy history. Questions about health status, prescribed medication, 
lifestyle, and various exposures at work or during leisure time activities were asked 
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concerning the three months before conception and during pregnancy for mothers and 
concerning the three months period before conception for fathers. The specific time 
windows of exposure during pregnancy were asked for all maternal items. Compared to the 
questionnaires of controls, those of cases contained a few more items on stress, extreme 
nausea, caffeine intake, and vaccination during pregnancy, and for some questions, such as 
dietary intake, different answer categories were used resulting in noncomparability. 
Therefore, these items were not taken into account in the analyses. Variables included in the 
analyses were age at childbirth (< or ≥ 35 years), ethnicity, educational level (low: 
no/primary/lower vocational/intermediate secondary/intermediate vocational education), 
Body Mass Index (BMI) (< or ≥ 25 kg/m2), family history of birth defects, defined as two or 
more 1st or 2nd degree relatives with a birth defect, family history of ARM, defined as one or 
more 1st or 2nd degree relatives with ARM, time to pregnancy (TTP) (≤  or > 6 months), 
fertility problems established by a medical doctor, conception with medical treatment, 
preterm delivery (< 37 weeks), birth weight (≤  or > 2500 grams), parity, chronic diseases, 
use of folic acid, multivitamins, alcohol (including number of glasses per week), cigarettes 
(including number per day), and medication (including type of medication) before or during 
pregnancy, fever (> 38°C) in first trimester of pregnancy, and job exposure during pregnancy 
to X-rays, cytostatics, anesthetics, industrial cleaning agents and solvents, disinfectants, 
cosmetics, exhaust fumes, paint/varnish/adhesives/ink/thinner, welding fumes, and 
pesticides. For certain occupational exposure data, adjustments were made when data 
indicated that occupational exposure was confused with private use of products, for 
example pesticides.  
The study protocol was approved by the regional Committee on Research Involving 
Human Subjects and written informed consent was obtained from the parents of all cases 
and controls.  
 
Statistical analyses 
Chi-square tests were used to compare the frequency distributions of background variables 
among cases and controls. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were 
calculated for all potential maternal and paternal risk factors using unconditional logistic 
regression analyses. The variables considered as potential confounders included all 
determinants that are known or suspected risk factors for ARM from the literature and those 
covariates that differed between cases and controls in our data. To prevent having too many 
covariates in the initial multivariable models, we first checked whether a factor changed the 
risk of ARM by at least 10% in bivariable analyses. In addition, child age at time of filling in 
the questionnaire was included as well as some background variables. However, those that 
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shared the causal pathway between the risk factor of interest and the outcome were 
excluded. All relevant variables were included in multivariable logistic regression models for 
each potential maternal and paternal risk factor in order to calculate adjusted ORs with 95% 
CIs. For reasons of precision, covariates were excluded from the multivariable model when 
exclusion did not change the risk estimate of the potential risk factor by more than 10%. 
Only risk factors with two or more exposed cases were used in the analyses. Because of a 
potentially heterogeneous etiology, we performed stratified analyses for ARM cases with 
and without the VACTERL association, the former being referred to as ARM-VACTERL.  Due 
to small numbers, the results for ARM-VACTERL cases could not be adjusted for 
confounding.  
 
Results 
Ninety-five case parents and 650 control parents returned the questionnaires, resulting in a 
participation rate of 72% and 65%, respectively. Ten ARM cases were excluded because of 
chromosomal anomalies (n=1), known syndromes (n=4), cloaca (n=2), and vesicointestinal 
fissures (n=3). This resulted in 85 ARM cases and 650 controls being included in the study. 
Most of the ARM cases had a perineal fistula (55%) (Table 1). Almost half of the cases had 
isolated ARM (total 45%: 40% in boys, 53% in girls) and another 30% (31% in boys, 29% in 
girls) had only one associated anomaly, which were most often urogenital tract malforma-
tions, followed by skeletal malformations. The higher the ARM was located, the more 
additional malformations were present. Fourteen cases (17%) were diagnosed with the 
ARM-VACTERL association, which most often included vertebral (79%) and renal anomalies 
(64%), followed by cardiovascular defects (43%) and esophageal atresia/tracheo-esophageal 
fistula (38%). Only one case showed an upper limb anomaly (7%). 
All 85 case mothers and 83 case fathers as well as 642 control mothers and 600 
control fathers completed the questionnaire. Most case and control parents originated from 
Europe or The Netherlands (95% and 97%, respectively).  
The median age of the children at time of filling in the questionnaire was 5.4 years for 
cases and 6.5 years for controls (Table 2). Maternal and paternal age at childbirth was not 
different between the groups, but fathers of an ARM child were lower educated than 
controls. More ARM children were first borns, were born preterm or had a low birth weight 
compared to control children. Children with ARM were also more often conceived after a 
prolonged TTP. More case parents reported a family history of congenital malformations in 
first or second degree relatives (13.3% vs. 3.5%, respectively), and especially more ARM in at 
least one family member compared to controls (OR, 40.3; 95% CI, 4.8, 342.8).  
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Table 1. Classification of Anorectal Malformations and Presence of Other Congenital Malformations. 
 Total group 
(n=85) 
Male 
(n=49) 
Female 
(n=36) 
 No.  % No.  % No.  % 
Classification of ARM       
   Perineal fistula 47 55.3 24 49.0 23 63.9 
   Rectourethral fistula: bulbar 4 4.7 4 8.2 - - 
   Rectourethral fistula: prostatic 7 8.2 7 14.3 - - 
   Vestibular fistula 12 14.1 - - 12 33.3 
   Imperforate anus without fistula 7 8.2 6 12.2 1 2.8 
   Rectal atresia 3 3.5 3 6.1 - - 
   Anal stenosis 5 5.9 5 10.2 - - 
Other congenital malformations       
   Urogenital tract malformations 34 40.0 21 42.9 13 36.1 
   Skeletal malformations 23 27.1 16 32.7 7 19.4 
   Gastro-intestinal tract malformations 11 12.9 8 16.3 3 8.3 
   Circulatory tract malformations 12 14.1 7 14.3 5 13.9 
   Limb malformations 5 5.9 4 8.2 1 2.8 
   Central nervous system malformationsa 3 3.6 3 6.3 0 0 
ARM-VACTERL 14 16.5 11 22.4 3 8.3 
ARM, anorectal malformations; VACTERL, vertebral defects, anal atresia, cardiac defects, tracheo-
esophageal fistula and/or esophageal atresia, renal anomalies, radial dysplasia, and limb defects.  
aData on central nervous system malformations was missing in 1 boy.  
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shared the causal pathway between the risk factor of interest and the outcome were 
excluded. All relevant variables were included in multivariable logistic regression models for
each potential maternal and paternal risk factor in order to calculate adjusted ORs with 95% 
CIs. For reasons of precision, covariates were excluded from the multivariable model when
exclusion did not change the risk estimate of the potential risk factor by more than 10%.
Only risk factors with two or more exposed cases were used in the analyses. Because of a
potentially heterogeneous etiology, we performed stratified analyses for ARM cases with
and without the VACTERL association, the former being referred to as ARM-VACTERL. Due
to small numbers, the results for ARM-VACTERL cases could not be adjusted for
confounding.  
Results
Ninety-five case parents and 650 control parents returned the questionnaires, resulting in a
participation rate of 72% and 65%, respectively. Ten ARM cases were excluded because of
chromosomal anomalies (n=1), known syndromes (n=4), cloaca (n=2), and vesicointestinal
fissures (n=3). This resulted in 85 ARM cases and 650 controls being included in the study.
Most of the ARM cases had a perineal fistula (55%) (Table 1). Almost half of the cases had
isolated ARM (total 45%: 40% in boys, 53% in girls) and another 30% (31% in boys, 29% in
girls) had only one associated anomaly, which were most often urogenital tract malforma-
tions, followed by skeletal malformations. The higher the ARM was located, the more
additional malformations were present. Fourteen cases (17%) were diagnosed with the
ARM-VACTERL association, which most often included vertebral (79%) and renal anomalies
(64%), followed by cardiovascular defects (43%) and esophageal atresia/tracheo-esophageal
fistula (38%). Only one case showed an upper limb anomaly (7%).
All 85 case mothers and 83 case fathers as well as 642 control mothers and 600
control fathers completed the questionnaire. Most case and control parents originated from
Europe or The Netherlands (95% and 97%, respectively).
The median age of the children at time of filling in the questionnaire was 5.4 years for
cases and 6.5 years for controls (Table 2). Maternal and paternal age at childbirth was not
different between the groups, but fathers of an ARM child were lower educated than
controls. More ARM children were first borns, were born preterm or had a low birth weight
compared to control children. Children with ARM were also more often conceived after a
prolonged TTP. More case parents reported a family history of congenital malformations in
first or second degree relatives (13.3% vs. 3.5%, respectively), and especially more ARM in at
least one family member compared to controls (OR, 40.3; 95% CI, 4.8, 342.8). 
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aData on central nervous system malformations was missing in 1 boy.  
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Table 2. Maternal, paternal and child characteristics of the case and control study population.   
 Cases (n=85)a Controls (n=650)a Pb 
Age child at time study, median (range) 5.4 (0.0-15.1) 6.5 (1.6-9.3)    0.067c 
Age at childbirth ≥ 35 years 
   Mother, no. (%) 
 
12 (14.1) 
 
102 (16.0) 
 
   0.653 
   Father, no. (%) 30 (36.1) 219 (36.7)    0.924 
Educational level, low 
   Mother, no. (%) 
 
52 (61.9) 
 
397 (62.0) 
 
   0.982 
   Father, no. (%) 60 (73.2) 362 (60.6)    0.028 
Parity: first live born, no. (%) 44 (52.4) 263 (40.5)    0.037 
Preterm delivery (< 37 weeks), no. (%) 12 (14.5)   59 (9.5)    0.156 
Birth weight ≤ 2500 grams, no. (%) 11 (13.8)   50 (8.1)    0.090 
TTP > 6 months, no. (%) 26 (32.9) 135 (21.4)    0.022 
Family history of birth defects, no. (%) 11 (13.3)   21 (3.5)    0.001 
Family history of ARM, no. (%)   6 (7.2)     1 (0.2) < 0.001 
ARM, anorectal malformations; P, p-value; TTP, time to pregnancy.  
aThe maximum number of missing values was 6 in cases and 30 in controls, except for family history of 
birth defects and ARM with 53 missings in controls. 
bChi-square test. 
cMann-Whitney U test. 
 
Maternal risk factors for ARM are presented in Table 3. More case mothers were overweight 
before pregnancy (BMI ≥  25kg/m2) (OR,  1.8; 95% CI,  1.1, 2.8). Three mothers of ARM cases 
reported fever in the first trimester of pregnancy (3.7%) versus only four of the 624 control 
mothers (0.6%), resulting in a five times increased risk of ARM (OR, 5.1; 95% CI, 0.9, 28.1). 
Excluding the six cases and one control that had a family history of ARM did not change 
these results, whereas excluding ARM-VACTERL cases strengthened the association with 
fever (OR, 6.3; 95% CI, 1.1, 35.1). Maternal chronic diseases were only weakly associated 
with ARM.  
The intake of folic acid supplements before and during pregnancy was 72% in case and 
control mothers, not resulting in an increased risk of ARM. The same was true for folic acid 
use just before pregnancy up until the first trimester (58% in both groups). In the ARM-
VACTERL group (n=14), the percentage of folic acid use in the total period was only 57%, 
resulting in a crude OR of 0.5 (95% CI, 0.2, 1.5). Multivitamins, however, were taken 9% 
more often by case mothers compared to controls, resulting in an increased risk of 1.6 (95% 
CI, 1.0, 2.7), which was slightly weakened by excluding the ARM-VACTERL cases (OR, 1.4; 
95% CI, 0.8, 2.4), in which the risk was highest (OR, 3.4; 95% CI, 1.1, 10.2). These results 
remained the same when only the intake before conception and in the first trimester of 
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pregnancy was taken into account. Alcohol intake, smoking of cigarettes, and the use of 
medication before or during pregnancy were not associated with ARM, or with ARM-
VACTERL, irrespective of the number of glasses of alcohol, number of cigarettes, the type of 
medication, and the period of use before and during pregnancy.  
Most job exposures in mothers, including exposure to X-rays, cytostatics, paints, 
disinfectants, cosmetics, and exhaust fumes did not reveal an increased risk of ARM. 
Exposure to industrial cleaning agents and solvents used in a variety of jobs ranging from 
professional cleaners to nurses, however, was more prevalent among case mothers, 
resulting in an increased risk of ARM (OR, 2.9; 95% CI, 0.9, 9.3). Moreover, two mothers in 
the ARM-VACTERL group (14.3%) were exposed to cytostatics compared to 10 (1.6%) 
controls (OR, 10.2; 95% CI, 2.0, 51.8).  
 
Table 3. Associations between maternal factors and anorectal malformation.   
 Cases  
(n=85)a 
No. (%) 
Controls 
(n=642)a 
No. (%) 
Crude OR  
(95% CI) 
Adjusted OR  
(95% CI) 
BMI before pregnancy ≥ 25kg/m2  32 (38.1) 160 (26.0) 1.8 (1.1-2.8) - 
Fever in 1st trimester of pregnancy 3 (3.7)  4 (0.6) 6.0 (1.3-27.5) 5.1 (0.9-28.1)b 
Chronic disease  12 (14.1) 59 (9.2) 1.6 (0.8-3.2) - 
Fertility problems mother 6 (7.1) 63 (9.8) 0.7 (0.3-1.7) - 
Conception with medical treatment 4 (4.8) 43 ( 6.8) 0.7 (0.2-2.0) - 
Before or during pregnancy use of:  
   Folic acid tablets 
 
61 (71.8) 
 
456 (71.6) 
 
1.0 (0.6-1.7) 
 
- 
   Multivitamins 24 (28.9) 129 (20.3) 1.6 (1.0-2.7) - 
   Alcohol 34 (40.0) 260 (40.9) 1.0 (0.6-1.5) - 
   Cigarettes 19 (22.4) 171 (26.8) 0.8 (0.5-1.3) - 
   Medication  46 (54.1) 365 (57.6) 0.9 (0.6-1.4) - 
Job exposure during pregnancy: 
   X-rays 
   Cytostatics 
   Industrial cleaning agents and 
   solvents 
 
2 (2.4) 
2 (2.4) 
  5 (6.0) 
 
20 (3.2) 
10 (1.6) 
12 (1.9) 
 
0.7 (0.2-3.2) 
1.5 (0.3-6.9) 
3.2 (1.1-9.4) 
 
0.6 (0.1-2.6)c 
- 
2.9 (0.9-9.3)b 
BMI, body mass index; CI, confidence interval; OR, odds ratio.  
‘-‘ means that the association was not confounded by any covariate. 
aThe maximum number of missing values was 4 in cases and 27 in controls. 
bAdjusted for family history of ARM and paternal smoking. 
cAdjusted for maternal multivitamin use. 
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Table 2. Maternal, paternal and child characteristics of the case and control study population.   
 Cases (n=85)a Controls (n=650)a Pb 
Age child at time study, median (range) 5.4 (0.0-15.1) 6.5 (1.6-9.3)    0.067c 
Age at childbirth ≥ 35 years 
   Mother, no. (%) 
 
12 (14.1) 
 
102 (16.0) 
 
   0.653 
   Father, no. (%) 30 (36.1) 219 (36.7)    0.924 
Educational level, low 
   Mother, no. (%) 
 
52 (61.9) 
 
397 (62.0) 
 
   0.982 
   Father, no. (%) 60 (73.2) 362 (60.6)    0.028 
Parity: first live born, no. (%) 44 (52.4) 263 (40.5)    0.037 
Preterm delivery (< 37 weeks), no. (%) 12 (14.5)   59 (9.5)    0.156 
Birth weight ≤ 2500 grams, no. (%) 11 (13.8)   50 (8.1)    0.090 
TTP > 6 months, no. (%) 26 (32.9) 135 (21.4)    0.022 
Family history of birth defects, no. (%) 11 (13.3)   21 (3.5)    0.001 
Family history of ARM, no. (%)   6 (7.2)     1 (0.2) < 0.001 
ARM, anorectal malformations; P, p-value; TTP, time to pregnancy.  
aThe maximum number of missing values was 6 in cases and 30 in controls, except for family history of 
birth defects and ARM with 53 missings in controls. 
bChi-square test. 
cMann-Whitney U test. 
 
Maternal risk factors for ARM are presented in Table 3. More case mothers were overweight 
before pregnancy (BMI ≥  25kg/m2) (OR,  1.8; 95% CI,  1.1, 2.8). Three mothers of ARM cases 
reported fever in the first trimester of pregnancy (3.7%) versus only four of the 624 control 
mothers (0.6%), resulting in a five times increased risk of ARM (OR, 5.1; 95% CI, 0.9, 28.1). 
Excluding the six cases and one control that had a family history of ARM did not change 
these results, whereas excluding ARM-VACTERL cases strengthened the association with 
fever (OR, 6.3; 95% CI, 1.1, 35.1). Maternal chronic diseases were only weakly associated 
with ARM.  
The intake of folic acid supplements before and during pregnancy was 72% in case and 
control mothers, not resulting in an increased risk of ARM. The same was true for folic acid 
use just before pregnancy up until the first trimester (58% in both groups). In the ARM-
VACTERL group (n=14), the percentage of folic acid use in the total period was only 57%, 
resulting in a crude OR of 0.5 (95% CI, 0.2, 1.5). Multivitamins, however, were taken 9% 
more often by case mothers compared to controls, resulting in an increased risk of 1.6 (95% 
CI, 1.0, 2.7), which was slightly weakened by excluding the ARM-VACTERL cases (OR, 1.4; 
95% CI, 0.8, 2.4), in which the risk was highest (OR, 3.4; 95% CI, 1.1, 10.2). These results 
remained the same when only the intake before conception and in the first trimester of 
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pregnancy was taken into account. Alcohol intake, smoking of cigarettes, and the use of 
medication before or during pregnancy were not associated with ARM, or with ARM-
VACTERL, irrespective of the number of glasses of alcohol, number of cigarettes, the type of 
medication, and the period of use before and during pregnancy.  
Most job exposures in mothers, including exposure to X-rays, cytostatics, paints, 
disinfectants, cosmetics, and exhaust fumes did not reveal an increased risk of ARM. 
Exposure to industrial cleaning agents and solvents used in a variety of jobs ranging from 
professional cleaners to nurses, however, was more prevalent among case mothers, 
resulting in an increased risk of ARM (OR, 2.9; 95% CI, 0.9, 9.3). Moreover, two mothers in 
the ARM-VACTERL group (14.3%) were exposed to cytostatics compared to 10 (1.6%) 
controls (OR, 10.2; 95% CI, 2.0, 51.8).  
 
Table 3. Associations between maternal factors and anorectal malformation.   
 Cases  
(n=85)a 
No. (%) 
Controls 
(n=642)a 
No. (%) 
Crude OR  
(95% CI) 
Adjusted OR  
(95% CI) 
BMI before pregnancy ≥ 25kg/m2  32 (38.1) 160 (26.0) 1.8 (1.1-2.8) - 
Fever in 1st trimester of pregnancy 3 (3.7)  4 (0.6) 6.0 (1.3-27.5) 5.1 (0.9-28.1)b 
Chronic disease  12 (14.1) 59 (9.2) 1.6 (0.8-3.2) - 
Fertility problems mother 6 (7.1) 63 (9.8) 0.7 (0.3-1.7) - 
Conception with medical treatment 4 (4.8) 43 ( 6.8) 0.7 (0.2-2.0) - 
Before or during pregnancy use of:  
   Folic acid tablets 
 
61 (71.8) 
 
456 (71.6) 
 
1.0 (0.6-1.7) 
 
- 
   Multivitamins 24 (28.9) 129 (20.3) 1.6 (1.0-2.7) - 
   Alcohol 34 (40.0) 260 (40.9) 1.0 (0.6-1.5) - 
   Cigarettes 19 (22.4) 171 (26.8) 0.8 (0.5-1.3) - 
   Medication  46 (54.1) 365 (57.6) 0.9 (0.6-1.4) - 
Job exposure during pregnancy: 
   X-rays 
   Cytostatics 
   Industrial cleaning agents and 
   solvents 
 
2 (2.4) 
2 (2.4) 
  5 (6.0) 
 
20 (3.2) 
10 (1.6) 
12 (1.9) 
 
0.7 (0.2-3.2) 
1.5 (0.3-6.9) 
3.2 (1.1-9.4) 
 
0.6 (0.1-2.6)c 
- 
2.9 (0.9-9.3)b 
BMI, body mass index; CI, confidence interval; OR, odds ratio.  
‘-‘ means that the association was not confounded by any covariate. 
aThe maximum number of missing values was 4 in cases and 27 in controls. 
bAdjusted for family history of ARM and paternal smoking. 
cAdjusted for maternal multivitamin use. 
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Exposure to occupational hazards was more frequently seen among fathers than in mothers 
and a few of these paternal exposures showed an association with ARM (Table 4). In the 
univariable analyses paints/varnish/adhesives/ink/thinners, welding fumes and exhaust 
fumes seemed to increase the risk of ARM in offspring. After controlling for confounders, 
however, only exhaust fumes remained associated with ARM (OR, 1.9; 95% CI, 1.0, 3.6). In 
separate analyses, excluding the six cases and one control that had a family history of ARM, 
the results for maternal and paternal occupational exposures were the same.  
Fathers smoking cigarettes in the three months before conception also seemed to be 
at risk of having a child with ARM (OR, 1.8; 95% CI, 1.1, 2.9). Numbers of cigarettes smoked 
was similar between the smoking case and control fathers. Paternal alcohol use did not 
influence the risk of ARM, and neither did the existence of a chronic disease, like asthma or 
rheumatic diseases. In contrast to mothers, fertility problems among fathers occurred more 
frequently in the case group (6.0%) compared to controls (2.8%) (OR, 2.2; 95% CI, 0.8, 6.1). 
These problems especially seemed to increase the risk of having a child with the ARM-
VACTERL association (crude OR, 5.7; 95% CI, 1.2, 27.5).  
 
Table 4. Associations between paternal factors and anorectal malformation. 
 Cases 
(n=83)a 
No. (%) 
Controls 
(n=600)a 
No. (%) 
Crude OR 
(95% CI) 
Adjusted OR  
(95% CI) 
 
BMI before pregnancy ≥ 25kg/m2  40 (50.0) 313 (54.4) 0.8 (0.5-1.3) - 
Chronic disease  7 (8.5) 41 (7.0) 1.2 (0.5-2.9) - 
Fertility problems father 5 (6.0) 17 (2.8) 2.2 (0.8-6.1) - 
Smoking 3 months before conception 41 (50.0) 210 (35.7) 1.8 (1.1-2.9) - 
Alcohol use 3 months before conception 70 (85.4) 479 (81.7) 1.3 (0.7-2.5) - 
Job exposure 3 months before conception: 
   Exhaust fumes  
   Industrial cleaning agents and solvents 
   Paint/ varnish/ adhesives/ ink/ thinner 
   Welding fumes       
 
14 (17.3) 
5 (6.8) 
7 (9.0) 
7 (8.8) 
 
59 (10.0) 
37 (6.4) 
31 (5.4) 
30 (5.1) 
 
1.9 (1.0-3.6) 
1.1 (0.4-2.8) 
1.7 (0.7-4.1) 
1.8 (0.8-4.2) 
 
- 
0.6 (0.2-1.7)b 
1.4 (0.6-3.7)c 
1.3 (0.5-3.3)d 
BMI, body mass index; CI, confidence interval; OR, odds ratio.  
‘-‘ means that the association was not confounded by any covariate. 
aThe maximum number of missing values was 10 in cases and 26 in controls.   
bAdjusted for family history of ARM, maternal BMI before pregnancy, paternal smoking and paternal job 
exposure to exhaust fumes. 
cAdjusted for family history of ARM. 
dAdjusted for family history of ARM and paternal job exposure to exhaust fumes. 
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Discussion 
This study investigating a wide spectrum of potential parental risk factors for ARM in 
children using structured questionnaires, revealed risk factors such as maternal fever, 
overweight, multivitamin use, paternal smoking, and occupational exposures, as well as a 
familial component. 
To interpret these results properly, the strengths and weaknesses of our study have to 
be discussed. We studied a representative group of ARM cases for this referral hospital as 
we compared them to all 264 ARM cases born in or referred to the same hospital between 
1974 and 1995.16 Both groups present similar gender and ARM type distributions with higher 
percentages of boys, presumably because of a more complex embryologic development in 
boys and more missed or delayed diagnoses in girls. The only difference between our study 
and the older group of cases is the number of isolated cases, 45% versus 33%, respectively, 
which can be explained by our exclusion of cloacas, known syndromes, and deceased cases. 
The latter may have resulted in survival bias, assuming different risk factors in ARM cases 
with multiple congenital anomalies. A group of 174 ARM cases in France, however, consisted 
of 50% isolated cases, with urogenital and skeletal malformations being the most prevalent 
additional anomalies, similar to our study.17 The control parents appear to be representative 
for the general population as well. The percentages of, for example, smoking, alcohol 
consumption, and folic acid supplementation are similar to those found in the general popu-
lation and in studies investigating pregnant women in the Netherlands.18-20 Another strong 
point of our study is the wide range of risk factors that was investigated in both mother and 
father allowing thorough adjustment for confounders, which is unique in studying ARM. 
All risk factors studied were self-reported, so random misclassification of exposure and 
recall bias cannot be excluded, especially since parents were asked to recall events that had 
occurred some time ago. Because the control parents were not aware of their control status, 
however, severe recall bias is not very likely, except for family history of birth defects and 
ARM. This may have caused overestimation of the ORs for these factors, whereas random 
misclassification could have resulted in underestimation of other risks. Differential 
misclassification due to recall times is not probable as small differences in recall time 
between cases and controls did not seem to be relevant in the multivariable models. The 
relatively small sample size of cases made it difficult to provide reliable findings for less 
frequently occurring risk factors and for the ARM-VACTERL group.  Although the gender 
distribution in our study differed between cases (58% boys) and controls (100% boys), we do 
not expect this to have biased our results, because no indications exist that the chances of 
being exposed to the investigated risk factors of ARM during pregnancy differ by gender of 
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Exposure to occupational hazards was more frequently seen among fathers than in mothers 
and a few of these paternal exposures showed an association with ARM (Table 4). In the 
univariable analyses paints/varnish/adhesives/ink/thinners, welding fumes and exhaust 
fumes seemed to increase the risk of ARM in offspring. After controlling for confounders, 
however, only exhaust fumes remained associated with ARM (OR, 1.9; 95% CI, 1.0, 3.6). In 
separate analyses, excluding the six cases and one control that had a family history of ARM, 
the results for maternal and paternal occupational exposures were the same.  
Fathers smoking cigarettes in the three months before conception also seemed to be 
at risk of having a child with ARM (OR, 1.8; 95% CI, 1.1, 2.9). Numbers of cigarettes smoked 
was similar between the smoking case and control fathers. Paternal alcohol use did not 
influence the risk of ARM, and neither did the existence of a chronic disease, like asthma or 
rheumatic diseases. In contrast to mothers, fertility problems among fathers occurred more 
frequently in the case group (6.0%) compared to controls (2.8%) (OR, 2.2; 95% CI, 0.8, 6.1). 
These problems especially seemed to increase the risk of having a child with the ARM-
VACTERL association (crude OR, 5.7; 95% CI, 1.2, 27.5).  
 
Table 4. Associations between paternal factors and anorectal malformation. 
 Cases 
(n=83)a 
No. (%) 
Controls 
(n=600)a 
No. (%) 
Crude OR 
(95% CI) 
Adjusted OR  
(95% CI) 
 
BMI before pregnancy ≥ 25kg/m2  40 (50.0) 313 (54.4) 0.8 (0.5-1.3) - 
Chronic disease  7 (8.5) 41 (7.0) 1.2 (0.5-2.9) - 
Fertility problems father 5 (6.0) 17 (2.8) 2.2 (0.8-6.1) - 
Smoking 3 months before conception 41 (50.0) 210 (35.7) 1.8 (1.1-2.9) - 
Alcohol use 3 months before conception 70 (85.4) 479 (81.7) 1.3 (0.7-2.5) - 
Job exposure 3 months before conception: 
   Exhaust fumes  
   Industrial cleaning agents and solvents 
   Paint/ varnish/ adhesives/ ink/ thinner 
   Welding fumes       
 
14 (17.3) 
5 (6.8) 
7 (9.0) 
7 (8.8) 
 
59 (10.0) 
37 (6.4) 
31 (5.4) 
30 (5.1) 
 
1.9 (1.0-3.6) 
1.1 (0.4-2.8) 
1.7 (0.7-4.1) 
1.8 (0.8-4.2) 
 
- 
0.6 (0.2-1.7)b 
1.4 (0.6-3.7)c 
1.3 (0.5-3.3)d 
BMI, body mass index; CI, confidence interval; OR, odds ratio.  
‘-‘ means that the association was not confounded by any covariate. 
aThe maximum number of missing values was 10 in cases and 26 in controls.   
bAdjusted for family history of ARM, maternal BMI before pregnancy, paternal smoking and paternal job 
exposure to exhaust fumes. 
cAdjusted for family history of ARM. 
dAdjusted for family history of ARM and paternal job exposure to exhaust fumes. 
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Discussion 
This study investigating a wide spectrum of potential parental risk factors for ARM in 
children using structured questionnaires, revealed risk factors such as maternal fever, 
overweight, multivitamin use, paternal smoking, and occupational exposures, as well as a 
familial component. 
To interpret these results properly, the strengths and weaknesses of our study have to 
be discussed. We studied a representative group of ARM cases for this referral hospital as 
we compared them to all 264 ARM cases born in or referred to the same hospital between 
1974 and 1995.16 Both groups present similar gender and ARM type distributions with higher 
percentages of boys, presumably because of a more complex embryologic development in 
boys and more missed or delayed diagnoses in girls. The only difference between our study 
and the older group of cases is the number of isolated cases, 45% versus 33%, respectively, 
which can be explained by our exclusion of cloacas, known syndromes, and deceased cases. 
The latter may have resulted in survival bias, assuming different risk factors in ARM cases 
with multiple congenital anomalies. A group of 174 ARM cases in France, however, consisted 
of 50% isolated cases, with urogenital and skeletal malformations being the most prevalent 
additional anomalies, similar to our study.17 The control parents appear to be representative 
for the general population as well. The percentages of, for example, smoking, alcohol 
consumption, and folic acid supplementation are similar to those found in the general popu-
lation and in studies investigating pregnant women in the Netherlands.18-20 Another strong 
point of our study is the wide range of risk factors that was investigated in both mother and 
father allowing thorough adjustment for confounders, which is unique in studying ARM. 
All risk factors studied were self-reported, so random misclassification of exposure and 
recall bias cannot be excluded, especially since parents were asked to recall events that had 
occurred some time ago. Because the control parents were not aware of their control status, 
however, severe recall bias is not very likely, except for family history of birth defects and 
ARM. This may have caused overestimation of the ORs for these factors, whereas random 
misclassification could have resulted in underestimation of other risks. Differential 
misclassification due to recall times is not probable as small differences in recall time 
between cases and controls did not seem to be relevant in the multivariable models. The 
relatively small sample size of cases made it difficult to provide reliable findings for less 
frequently occurring risk factors and for the ARM-VACTERL group.  Although the gender 
distribution in our study differed between cases (58% boys) and controls (100% boys), we do 
not expect this to have biased our results, because no indications exist that the chances of 
being exposed to the investigated risk factors of ARM during pregnancy differ by gender of 
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the expected child. Even the results for low birth weight did not change substantially in a 
subanalysis of only boys (data not shown). 
This is the first time that maternal fever is indicated as a potential risk factor for ARM. 
Another epidemiologic study investigating maternal influenza and congenital abnormalities 
in Hungary did not reveal an increased risk of ARM.21 Antifebrile treatment could have 
masked an existing association, however, because they only found associations in mothers 
who had not received antifebrile treatment. We cannot assess whether the increased risk 
observed in our study is indicative of a causal relation or was due to reporting bias. However, 
we expected a greater percentage of women with fever in the control group than in the 
general population, because infections, often associated with fever, tend to run in families of 
children with persistent ear infections.22 The few women who reported fever in the first 
trimester of pregnancy might have been those with serious fever or fever for a long episode, 
that could really have an effect on the development of the anorectal area. In animals, 
hyperthermia has been shown to cause cell death, membrane and vascular disruption, and 
placental infarction.23 Moreover, a relation has been observed between fever and neural 
tube defects and congenital renal anomalies in humans.24-26 
In contrast to a Chinese study,12 use of folic acid supplements was not associated with 
ARM. Surprisingly, multivitamin intake before and during the sensitive period of pregnancy 
appeared to increase the risk of having a child with ARM, especially for children with the 
ARM-VACTERL association. Eight out of the 24 case mothers reported to have taken other 
than specific pregnancy multivitamins, which contain higher amounts of vitamin A than 
advised during pregnancy. As information on dose and frequency of use is lacking, one could 
only speculate that the high vitamin A intake could have had detrimental effects on embryo-
genesis, such as shown in the study by Rothman and co-workers.27 An overdose of 
etretinate, a long acting vitamin A analogue, induced ARM in murine embryos by disrupting 
the retinoic-acid signaling pathway.28 
Mothers of children with ARM were more likely to be overweight (BMI ≥  25 kg/m2) 
than control mothers. This result is supported by a study in the US that showed an 
association between anorectal atresia and maternal obesity (BMI ≥  30 kg/m2).29 Paternal 
smoking in the three months prior to conception seemed to give a relatively small increased 
risk of having a child with ARM. So far, paternal smoking has only been found as a risk factor 
for other congenital malformations, such as cleft lip and/or cleft palate, hypospadias, and 
ventricular septal defect.19,30,31 The proposed effects of maternal smoking9 and drinking7 on 
ARM could not be confirmed in our study.  
Exposure to a few occupational hazards revealed an increased risk of ARM, such as 
maternal exposure to industrial cleaning agents and solvents and paternal exposure to 
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exhaust fumes. Some associations between paternal exposure to occupational hazards and 
ARM have been found earlier, such as for organic solvents and metals in vehicle 
manufacturers.8,11 Organic solvents have also been associated with birth defects in general.32 
The question remains, however, whether the rather inaccurate assessment of exposure to 
occupational agents of the parents reflects the real exposure.  
Our study indicates an association of ARM with prolonged TTP and probably with 
established paternal fertility problems, supporting the existing literature on the association 
between subfertility and ARM. Some studies demonstrated higher rates of ARM children 
born after assisted reproductive techniques33-35 and others showed a prolonged TTP in 
couples that had a child with the VACTERL association.36 We could not replicate these  
results, but we did find an association between ARM-VACTERL and established paternal 
fertility problems. Adding up all of the evidence, it is still not clear whether the fertility 
problem itself or the related fertility treatment plays a role in the etiology of ARM.  
In addition to potential environmental risk factors for ARM, we found an indirect 
indication for a genetic role in the embryologic development of the anorectal area. A 
reported history of ARM in first or second degree relatives was strongly associated with ARM 
in offspring. This association may be overrated because of selective inquiry about ARM in 
case families, but our results are supported by the study of Falcone Jr and coworkers,37 
which showed an increased heritability of certain types of ARM.  
 
Conclusion 
The results from our study suggest a role in the etiology of ARM for maternal fever in the 
first trimester of pregnancy, maternal overweight, use of multivitamins, paternal smoking, 
and job exposures to industrial cleaning agents in women and exhaust fumes in men. In 
addition, primiparity, fertility problems, and a family history of congenital malformations or 
ARM seem to increase the risk of ARM even more. However, these results need to be 
confirmed in other studies before firm conclusions can be drawn.  
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the expected child. Even the results for low birth weight did not change substantially in a 
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This is the first time that maternal fever is indicated as a potential risk factor for ARM. 
Another epidemiologic study investigating maternal influenza and congenital abnormalities 
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Abstract 
 
Background Fertility treatment seems to play a role in the etiology of congenital anorectal 
malformations, but it is unclear whether the underlying parental subfertility, ovulation 
induction, or the treatment itself is involved. Therefore, we investigated the odds of 
anorectal malformations among children of subfertile parents who conceived with or 
without treatment compared with fertile parents. 
 
Methods We performed a case-control study among 380 cases with anorectal 
malformations treated at three departments of Pediatric Surgery in The Netherlands and 
1,973 population-based controls, born between August 1988 and August 2012. Parental 
questionnaires were used to obtain information on fertility-related issues and potential 
confounders.  
 
Results In singletons, increased risks of anorectal malformations were observed for parents 
who underwent intracytoplasmic sperm injection (ICSI) or in vitro fertilization (IVF) 
treatment compared with fertile parents (odds ratio = 2.4 [95% confidence interval = 1.0-5.9] 
and odds ratio = 4.2 [1.9-8.9], respectively). For subfertile parents who conceived after IVF 
treatment, an elevated risk was also found when they were compared with subfertile 
parents who conceived without treatment (3.2 [1.4-7.2]). Among children of the latter 
category of parents, only the risk of anorectal malformations with other major congenital 
malformations was increased compared with fertile parents (2.0 [1.3-3.3]). No associations 
were found with intrauterine insemination or use of hormones for ovulation induction.  
 
Conclusions We found evidence of a role of ICSI and IVF treatments in the etiology of 
anorectal malformations. However, subfertility without treatment increased only the risk of 
anorectal malformations with additional congenital malformations. 
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Introduction 
Congenital anorectal malformations are major anomalies of the gastrointestinal system, with 
a prevalence of approximately 1 in 3000 births worldwide.1 Anorectal malformations are 
characterized by disrupted embryonic development of the anus and rectum in the 4th to 8th 
week after conception, often also involving other organs, such as the bladder or vagina. 
Although the physical and psychosocial impact is large for patients with anorectal 
malformations and their parents,2 knowledge about the potential risk factors is still limited.  
In the past decade, the risks of congenital malformations following assisted 
reproductive techniques (ART), including in vitro fertilization (IVF) and intracytoplasmic 
sperm injection (ICSI), received large amounts of scientific attention. Most studies showed 
an increased prevalence of congenital malformations after ART, but they investigated only 
heterogeneous patient groups consisting of broad categories of congenital malformations, 
such as all gastrointestinal malformations.3,4 Four studies, specifically focused on anorectal 
malformations, found ART to increase the risk of anorectal malformations more than 3 times 
compared with spontaneous conceptions,5-8 whereas two studies did not.9,10 Clearly 
increased risks of anorectal malformations were not found when all fertility treatments, also 
including intrauterine insemination (IUI) and ovulation induction, were analyzed 
together.10,11 However, two studies showed an association between anorectal 
malformations and ovulation induction without ICSI or IVF,10,12 whereas one study did not.13 
The role of parental subfertility was investigated in only one study, which suggested an 
association between anorectal malformations and paternal but not maternal subfertility.11 
Limitations of the previous studies, however, were low case numbers, moderately to 
poorly characterized cases, nonspecific or pooled exposure groups, lack of information on 
potential confounders, and/or different methods of data collection among cases and 
controls. Furthermore, none of these studies combined the effects of parental subfertility, 
prolonged time to pregnancy, and types of fertility treatment within one study. Therefore, 
we aimed to elucidate whether the excess risk of anorectal malformations is attributable to 
the underlying parental subfertility, the hormones used for ovulation induction, or the ART 
procedure itself. We performed a case-control study to investigate the role of parental 
subfertility and prolonged time to pregnancy without fertility treatment or with a range of 
fertility treatments in the etiology of nonsyndromic anorectal malformations. We also 
assessed these effects in subgroups of isolated anorectal malformations and anorectal 
malformations with one or more other major congenital malformations as etiologic 
heterogeneity was suggested previously.10,14 
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Methods 
Study Population 
AGORA (Aetiologic research into Genetic and Occupational/environmental Risk factors for 
Anomalies in children) is a large data- and biobank with clinical and questionnaire data and 
DNA samples from children with congenital malformations or childhood cancer, population-
based control children, and their parents (www.AGORAproject.nl). In total, 448 cases with 
anorectal malformations were derived from the AGORA databank. These cases were 
diagnosed shortly after birth and treated at the departments of Pediatric Surgery of the 
Radboud university medical center in Nijmegen, the Sophia Children’s Hospital – Erasmus 
Medical Centre in Rotterdam, or the University Medical Center Groningen in the 
Netherlands. They were born between August 1988 and August 2012 and recruited from 
2007 onward. Pediatric surgeons, clinical geneticists and researchers reviewed the medical 
records to obtain information on anorectal malformation phenotypes and additional 
congenital malformations.  
Phenotypes of anorectal malformations were classified according to the international 
Krickenbeck criteria15 and additional congenital malformations were divided into major and 
minor malformations according to the EUROCAT classification.16 Cases with syndromic forms 
of anorectal malformations, chromosomal abnormalities, or cloacal exstrophy were excluded 
from the study (n=41, 9%). The remaining cases were divided in isolated anorectal 
malformations with or without minor congenital malformations and anorectal 
malformations with one or more additional major congenital malformations. The latter 
subgroup also included  cases with the VACTERL association (Vertebral, Anal, Cardiac, 
Tracheo-Esophageal, Renal, and Limb defects), defined as cases with anorectal 
malformations and the presence of at least two other features of this association.17 Eighty of 
the cases with anorectal malformations in this study (21%) were also included in our 
previous study, in which a wide range of potential risk factors for anorectal malformations 
were evaluated, such as parental lifestyle factors, occupational exposures and pooled 
exposure groups of fertility-related issues.11  
Control children were also derived from the AGORA databank (n=2,196). They were 
born between January 1990 and March 2011 and randomly sampled and recruited in 2010-
2011 via 39 municipalities in geographical areas that covered the referral areas of the three 
hospitals where the cases were treated. Control children with major congenital 
malformations, chromosomal abnormalities or syndromes were excluded based on the 
questionnaire data (n=56, 3%). In addition, 7 cases and 2 controls were excluded because a 
sibling was already, leaving 400 cases and 2,138 controls.  
159 
Ethical approval for the study protocol of the AGORA data- and biobank was granted by the 
regional Committee on Research involving Human Subjects. All parents of cases and controls 
gave informed consent for the study. 
 
Data collection and definitions 
Cases and controls were all between 0 and 22 years of age. Their parents were invited to 
participate in AGORA. Both parents were asked to fill in a questionnaire with questions 
about demographic factors, family history of congenital malformations, and health and 
lifestyle before and during pregnancy. We used these questionnaires to obtain information 
about fertility issues and characteristics of cases and controls. Mothers were asked whether 
their pregnancies were planned, whether they or their partners had received any type of 
fertility treatment, and about the number of months between the start of trying to conceive 
and conception. Both mothers and fathers were asked whether they were ever diagnosed 
with subfertility by a physician. For this study, subfertile parents were defined as parents 
that had a time to pregnancy of more than 12 months, were diagnosed with either maternal 
or paternal subfertility, or both. We assumed that parents with an unplanned pregnancy 
were fertile. Parents were excluded from the analyses when information on time to 
pregnancy or parental subfertility was unknown (20 cases [5%] and 165 controls [8%]), 
leaving 380 cases and 1,973 controls for the final analyses. In addition, the following types of 
fertility treatment were evaluated: ICSI, IVF, intrauterine insemination (IUI; with or without 
donor), ovulation induction only, and surgical (e.g. removal of adhesions in fallopian tube) or 
other treatment. Parents were classified according to the above priority sequence if more 
than one treatment was reported. In the Netherlands, treatment for subfertility typically 
starts after 12 months of trying to conceive. 
Infant and parental characteristics included sex and year of birth of the child, 
maternal and paternal ethnicity (Dutch vs. other), maternal and paternal age at delivery, 
maternal and paternal education, anorectal malformations in first degree relatives of the 
child, multiple pregnancy (vs. singleton pregnancy), parity (nulliparity vs. multiparity), 
periconceptional folic acid use (any use of folic acid supplements or multivitamins containing 
folic acid in 4 weeks before through 10 weeks after conception), maternal pre-existing and 
gestational diabetes, and maternal prepregnancy body mass index (BMI). The latter was 
calculated using reported weight (in kg) and height (in m) before conception and categorized 
in 4 groups (<18.5, 18.5-24.9, 25.0-29.9, and ≥30.0 kg/m2). 
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Ethical approval for the study protocol of the AGORA data- and biobank was granted by the 
regional Committee on Research involving Human Subjects. All parents of cases and controls 
gave informed consent for the study. 
 
Data collection and definitions 
Cases and controls were all between 0 and 22 years of age. Their parents were invited to 
participate in AGORA. Both parents were asked to fill in a questionnaire with questions 
about demographic factors, family history of congenital malformations, and health and 
lifestyle before and during pregnancy. We used these questionnaires to obtain information 
about fertility issues and characteristics of cases and controls. Mothers were asked whether 
their pregnancies were planned, whether they or their partners had received any type of 
fertility treatment, and about the number of months between the start of trying to conceive 
and conception. Both mothers and fathers were asked whether they were ever diagnosed 
with subfertility by a physician. For this study, subfertile parents were defined as parents 
that had a time to pregnancy of more than 12 months, were diagnosed with either maternal 
or paternal subfertility, or both. We assumed that parents with an unplanned pregnancy 
were fertile. Parents were excluded from the analyses when information on time to 
pregnancy or parental subfertility was unknown (20 cases [5%] and 165 controls [8%]), 
leaving 380 cases and 1,973 controls for the final analyses. In addition, the following types of 
fertility treatment were evaluated: ICSI, IVF, intrauterine insemination (IUI; with or without 
donor), ovulation induction only, and surgical (e.g. removal of adhesions in fallopian tube) or 
other treatment. Parents were classified according to the above priority sequence if more 
than one treatment was reported. In the Netherlands, treatment for subfertility typically 
starts after 12 months of trying to conceive. 
Infant and parental characteristics included sex and year of birth of the child, 
maternal and paternal ethnicity (Dutch vs. other), maternal and paternal age at delivery, 
maternal and paternal education, anorectal malformations in first degree relatives of the 
child, multiple pregnancy (vs. singleton pregnancy), parity (nulliparity vs. multiparity), 
periconceptional folic acid use (any use of folic acid supplements or multivitamins containing 
folic acid in 4 weeks before through 10 weeks after conception), maternal pre-existing and 
gestational diabetes, and maternal prepregnancy body mass index (BMI). The latter was 
calculated using reported weight (in kg) and height (in m) before conception and categorized 
in 4 groups (<18.5, 18.5-24.9, 25.0-29.9, and ≥30.0 kg/m2). 
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Statistical analyses 
Statistical analyses were performed using SPSS 20.0 for Windows (IBM SPSS, Chicago, IL, 
USA). Logistic regression analyses were used to calculate crude and adjusted odds ratios 
(ORs) with 95% confidence intervals (CIs) for associations between anorectal malformations 
and parental fertility-related issues. The parents were divided into three groups: fertile 
parents who conceived spontaneously (reference), subfertile parents who conceived without 
treatment, and subfertile parents who conceived after any type of fertility treatment. We 
also distinguished among the types of fertility treatment and performed subgroup analyses 
that included singletons and nulliparous women only. The latter was done because multiple 
pregnancy seemed to be associated with both anorectal malformations and fertility 
treatment and because a previous study showed divergent results for the association 
between anorectal malformations and fertility treatment in singleton compared with 
multiple pregnancies.7 In addition, associations between anorectal malformations and 
classes of time to pregnancy (1-3, 4-6, 7-12, >12 months) were assessed in singletons 
conceived spontaneously as a measure of fecundity, to study whether increased risks of 
anorectal malformations occurred with increasing time to pregnancy. Potential confounders 
included year of birth of the child (continuous), maternal age at delivery, maternal 
education, pre-existing diabetes mellitus, and prepregnancy BMI, because these factors 
were previously identified in the literature as risk factors or found to be associated with 
anorectal malformations in this study. Potential confounding factors that changed the ORs in 
bivariable analyses were included in the multivariable models, from which they were 
excluded when the OR did not change more than 10% upon removal. Only maternal age at 
delivery and BMI, in two analyses, were found to be true confounders. We repeated the 
analyses for isolated anorectal malformations and anorectal malformations with one or 
more other major congenital malformations. Finally, we performed sensitivity analyses by 
including and excluding unplanned pregnancies and infants with affected first degree 
relatives. 
 
Results 
Response rates were 57% among cases and 34% among controls. After applying the 
exclusion criteria, maternal questionnaire data were available for 380 cases and 1,973 
controls and paternal questionnaire data for 350 cases and 1,762 controls. In total, 230 cases 
had isolated anorectal malformations (61%) and 150 cases had anorectal malformations with 
one or more additional major congenital malformations (39%). Among the latter, 40 cases 
fulfilled the criteria for VACTERL. Vertebral (14%), cardiac (11%), and renal malformations 
(10%) were the most commonly associated major congenital malformations. The majority of 
161 
cases were diagnosed with perineal fistulas (56%), followed by rectourethral fistulas (14%) in 
boys and vestibular fistulas (13%) in girls. We did not observe substantial differences 
between cases and controls in sex of the child, maternal ethnicity, multiple pregnancy, and 
nulliparity (Table 1). However, cases as well as their mothers were slightly younger and more 
often had a first degree relative with anorectal malformations compared with controls. In 
addition, low education, periconceptional folic acid use, pre-existing or gestational diabetes, 
and pre-pregnancy overweight or obesity were more common among case mothers than 
among control mothers. The distributions of paternal characteristics, including age at 
delivery, ethnicity, and education, were similar to those of the maternal characteristics. 
 
Table 1. Characteristics of cases with anorectal malformations and controls, The Netherlands, 1988-
2012. 
 Cases  
(n=380) 
No. (%)a 
Controls  
(n=1,973) 
No. (%)a 
Sex of child 
  Boy 
  Girl 
 
185 (48.7) 
195 (51.3) 
 
975 (49.4) 
998 (50.6) 
Year of birth of child 
  1988-1990 
  1991-1995 
  1996-2000 
  2001-2005 
  2006-2010 
  2011-2012 
 
10 (2.6) 
77 (20.3) 
91 (23.9) 
84 (22.1) 
103 (27.1) 
15 (3.9) 
 
58 (2.9) 
413 (20.9) 
494 (25.0) 
464 (23.5) 
540 (27.4) 
4 (0.2) 
Maternal age at delivery  (years) 
  <25 
  25-29 
  30-34 
  ≥35 
 
25 (6.6) 
133 (35.0) 
161 (42.4) 
61 (16.1) 
 
119 (6.1) 
613 (31.2) 
867 (44.2) 
364 (18.5) 
Maternal ethnicity 
  Dutch 
  Other 
 
336 (90.1) 
37 (9.9) 
 
1,812 (91.8) 
161 (8.2) 
Maternal educationb 
  Low 
  Middle 
  High 
 
97 (25.5) 
164 (43.2) 
119 (31.3) 
 
335 (17.0) 
908 (46.2) 
724 (36.8) 
Anorectal malformations in 1st degree relatives 5 (1.4) 0 (0.0) 
Multiple pregnancy 18 (4.8) 78 (4.0) 
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 Cases  
(n=380) 
No. (%)a 
Controls  
(n=1,973) 
No. (%)a 
Nulliparity 147 (38.9) 771 (39.2) 
Periconceptional folic acid use 233 (67.9) 1,126 (65.6) 
Diabetes mellitus 
   Pre-existing 
   Gestational 
 
5 (1.4) 
12 (3.3) 
 
10 (0.5) 
38 (2.0) 
Pre-pregnancy body mass indexc 
  Underweight (<18.5)  
  Normal (18.5-24.9) 
  Overweight (25.0-29.9) 
  Obese (≥30.0) 
 
19 (5.2) 
232 (63.9) 
74 (20.4) 
38 (10.5) 
 
65 (3.5) 
1,319 (71.2) 
351 (18.9) 
118 (6.4) 
aNumbers do not add up to total numbers due to missing values (<1% in all variables, except for ARM in 
1st degree relatives [11%, mainly due to missing paternal questionnaires], folic acid use [13%, mainly due 
to exclusion of mothers who used supplements outside the advised period], pre-existing diabetes mellitus 
[3%], gestational diabetes [2%] and body mass index [6%]. 
bLow: no, primary, lower vocational, or intermediate secondary education; middle: intermediate 
vocational or higher secondary education; high: higher vocational or academic education. 
cBody mass index in weight (kg)/height (m)2. 
 
Approximately 20% of all parents reported parental subfertility with or without fertility 
treatment, ranging from 18% in control parents to 21% in cases parents. The adjusted odds 
ratios for anorectal malformations among children of subfertile parents with and without 
fertility treatment for all births and for singleton births only are shown in Table 2. The risk of 
having a child with anorectal malformations seemed to be slightly increased for subfertile 
parents who conceived without treatment (OR = 1.3 [95% CI = 0.9–1.8]) compared with 
fertile parents. This increased risk was apparent in nulliparous women only (OR = 1.6 [0.9-
2.7]). Subfertile parents included parents with a TTP >12 months and parents who ever had a 
diagnosis of parental subfertility with a normal TTP (≤ 12 months), unplanned pregnancy, or 
unknown TTP. No association with anorectal malformations was observed among the latter 
group of parents (OR = 1.2 [0.7-2.1]). One-third of these parents reported that the reason for 
subfertility was unknown (33%), while the reported reasons included polycystic ovary 
syndrome (11%) and irregular menstrual cycles (9%) as the main groups. In subanalyses 
stratifying on mutually exclusive groups of maternal (13 cases and 60 controls), paternal (9 
cases and 27 controls) and couple subfertility without fertility treatment (1 case and 5 
controls), only the OR for subfertility of the father without treatment deviated from unity 
(OR = 1.8 [0.8-3.9]).  
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Approximately 8% of all infants were born after any type of fertility treatment. These births 
seemed to be associated with a slightly increased risk of anorectal malformations, as 
compared with births among fertile parents (OR = 1.3 [0.9–1.8]). Ovulation induction was 
the most common treatment among controls, whereas parents of cases most often 
underwent IVF treatment. Surgical or other fertility treatments were not reported by case 
parents. When we restricted the analyses to ICSI, IVF, IUI, and ovulation induction, a slightly 
higher OR was found for any fertility treatment (OR = 1.4 [1.0-2.1]). This increased risk was 
due only to the relatively strong associations between anorectal malformations and ICSI or 
IVF treatments (OR = 2.0 [0.9-4.5] and OR = 2.7 [1.4-5.4], respectively), however, since no 
associations were observed between anorectal malformations and treatments that did not 
involve gamete manipulation, including IUI and ovulation induction. Most risk estimates 
were stronger for singleton births only, especially the estimates for ICSI and IVF treatment 
compared with fertile parents (OR = 2.4 [1.0-5.9] and OR = 4.2 [1.9-8.9], respectively).  
For methodological reasons explained above, the further analyses were performed 
among singletons only. The adjusted odds ratios for isolated anorectal malformations and 
anorectal malformations with one or more additional major congenital malformations 
among children of subfertile parents with and without fertility treatment are presented in 
Table 3. No associations were observed between isolated anorectal malformations and 
parental subfertility without treatment or with any type of fertility treatment in singletons, 
except for IVF treatment compared with fertile parents (OR = 2.6 [1.0-7.3]). In contrast to 
isolated anorectal malformations, the risk of anorectal malformations with one or more 
additional malformations was increased for parental subfertility without fertility treatment 
(OR = 2.0 [1.3-3.3]), especially for subfertile parents with a TTP longer than 12 months (OR = 
2.3 [1.3-3.9]). For ICSI or IVF treatments, the risks of anorectal malformations with other 
congenital malformations were increased five- to eight-fold. The risk estimates for anorectal 
malformations with additional major congenital malformations were similar or slightly 
stronger when cases with the VACTERL association were excluded. Sensitivity analyses 
performed by restricting the above-mentioned analyses to planned pregnancies or to infants 
without first degree relatives with anorectal malformations only, did not yield different 
results. 
The risks of anorectal malformations and subgroups of anorectal malformations 
among children of subfertile parents who conceived with fertility treatment were also 
compared with subfertile parents who conceived without treatment to estimate the risk of 
treatment beyond the underlying subfertility. Overall, smaller risk estimates were observed 
when we used subfertile parents without treatment as the reference group (Table 4) 
compared with using fertile parents as reference group (Table 3). Interestingly, however, the 
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risk of anorectal malformations was still increased for subfertile parents who underwent IVF 
when they were compared with subfertile parents who conceived without treatment (OR = 
3.2 [1.4-7.2]), whereas a lower OR with a broader confidence interval was found after ICSI 
treatment (OR 1.8 [0.7-4.8]). Comparable risk estimates were observed for subgroups of 
anorectal malformations, including isolated anorectal malformations and anorectal 
malformations with other congenital malformations. 
To investigate whether fecundity plays a role in the occurrence of anorectal 
malformations, we assessed whether increased risks of anorectal malformations with 
increasing classes of time to pregnancy could be observed in singletons conceived 
spontaneously excluding unplanned pregnancies and pregnancies with unknown time to 
pregnancy (Table 5). For anorectal malformations as a group, a pattern of increasing risks of 
anorectal malformations with increasing time to pregnancy seemed to be present, but this 
may completely be due to the increased risk of anorectal malformations with additional 
congenital malformations after a time to pregnancy longer than 12 months, indicating 
parental subfertility. No pattern of increasing risks of isolated anorectal malformations with 
increasing time to pregnancy was observed. 
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risk of anorectal malformations was still increased for subfertile parents who underwent IVF 
when they were compared with subfertile parents who conceived without treatment (OR = 
3.2 [1.4-7.2]), whereas a lower OR with a broader confidence interval was found after ICSI 
treatment (OR 1.8 [0.7-4.8]). Comparable risk estimates were observed for subgroups of 
anorectal malformations, including isolated anorectal malformations and anorectal 
malformations with other congenital malformations. 
To investigate whether fecundity plays a role in the occurrence of anorectal 
malformations, we assessed whether increased risks of anorectal malformations with 
increasing classes of time to pregnancy could be observed in singletons conceived 
spontaneously excluding unplanned pregnancies and pregnancies with unknown time to 
pregnancy (Table 5). For anorectal malformations as a group, a pattern of increasing risks of 
anorectal malformations with increasing time to pregnancy seemed to be present, but this 
may completely be due to the increased risk of anorectal malformations with additional 
congenital malformations after a time to pregnancy longer than 12 months, indicating 
parental subfertility. No pattern of increasing risks of isolated anorectal malformations with 
increasing time to pregnancy was observed. 
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Discussion 
Previous studies found indications for a role of parental fertility-related issues in the etiology 
of anorectal malformations.5-8,10-12 This large case-control study provided additional evidence 
that these factors are associated with an increased risk of anorectal malformations in 
offspring, including both isolated anorectal malformations and anorectal malformations with 
one or more additional congenital malformations. ICSI and IVF treatments, in particular, 
seemed to play a role in the etiology of anorectal malformations, compared both to fertile 
parents and to subfertile parents who conceived without treatment. Although much smaller 
than the impact of ICSI and IVF treatment, subfertility itself seems to have an effect on the 
occurrence of anorectal malformations, but only for anorectal malformations with additional 
congenital malformations. 
 Our study population consisted of large numbers of well-characterized cases and 
population-based controls. The prevalence of associated congenital malformations in 39% of 
the cases in our study was slightly lower than in previous studies, but these included 
syndromic and chromosomal forms of anorectal malformations and/or terminations of 
pregnancies as well.18-20 The relatively large number of cases enabled subanalyses on 
isolated anorectal malformations and anorectal malformations with additional congenital 
malformations separately. Unfortunately, we could not perform separate analyses on more 
specific phenotypes of anorectal malformations, VACTERL, multiple births or first 
pregnancies only, as the numbers of case parents who underwent fertility treatment in these 
subgroups were too small for reliable analyses. Population-based controls were a 
representative group, as they were recruited via municipalities in comparable geographical 
areas as the cases and were of similar age. 
Another strength of our study was the combination of information on several 
fertility-related issues, including the diagnosis of parental subfertility, time to pregnancy, 
and type of fertility treatment, within one study. Furthermore, information on several 
potential maternal and paternal confounders was used in our analyses. These data were 
more comprehensive than in previous studies on anorectal malformations and assisted 
conception.6-8 Additional analyses on the underlying reasons for parental subfertility were 
not feasible, as this information was often unknown. 
Despite the relatively low response rate, we do not think that selection bias was a 
major issue, because the parents were probably unaware of the potential association 
between fertility issues and anorectal malformations because the questionnaires covered 
many pregnancy-related topics, such as pregnancy complications and lifestyle during preg-
nancy. Moreover, the rates of fertility treatment in the control group were representative 
for the Dutch general population,21 which probably excludes selection due to a higher or 
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Previous studies found indications for a role of parental fertility-related issues in the etiology 
of anorectal malformations.5-8,10-12 This large case-control study provided additional evidence 
that these factors are associated with an increased risk of anorectal malformations in 
offspring, including both isolated anorectal malformations and anorectal malformations with 
one or more additional congenital malformations. ICSI and IVF treatments, in particular, 
seemed to play a role in the etiology of anorectal malformations, compared both to fertile 
parents and to subfertile parents who conceived without treatment. Although much smaller 
than the impact of ICSI and IVF treatment, subfertility itself seems to have an effect on the 
occurrence of anorectal malformations, but only for anorectal malformations with additional 
congenital malformations. 
 Our study population consisted of large numbers of well-characterized cases and 
population-based controls. The prevalence of associated congenital malformations in 39% of 
the cases in our study was slightly lower than in previous studies, but these included 
syndromic and chromosomal forms of anorectal malformations and/or terminations of 
pregnancies as well.18-20 The relatively large number of cases enabled subanalyses on 
isolated anorectal malformations and anorectal malformations with additional congenital 
malformations separately. Unfortunately, we could not perform separate analyses on more 
specific phenotypes of anorectal malformations, VACTERL, multiple births or first 
pregnancies only, as the numbers of case parents who underwent fertility treatment in these 
subgroups were too small for reliable analyses. Population-based controls were a 
representative group, as they were recruited via municipalities in comparable geographical 
areas as the cases and were of similar age. 
Another strength of our study was the combination of information on several 
fertility-related issues, including the diagnosis of parental subfertility, time to pregnancy, 
and type of fertility treatment, within one study. Furthermore, information on several 
potential maternal and paternal confounders was used in our analyses. These data were 
more comprehensive than in previous studies on anorectal malformations and assisted 
conception.6-8 Additional analyses on the underlying reasons for parental subfertility were 
not feasible, as this information was often unknown. 
Despite the relatively low response rate, we do not think that selection bias was a 
major issue, because the parents were probably unaware of the potential association 
between fertility issues and anorectal malformations because the questionnaires covered 
many pregnancy-related topics, such as pregnancy complications and lifestyle during preg-
nancy. Moreover, the rates of fertility treatment in the control group were representative 
for the Dutch general population,21 which probably excludes selection due to a higher or 
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lower participation rate among control parents who underwent fertility treatment. A 
limitation of this study was the possibility of misclassification due to the self-reported nature 
of the data with the concomitant potential for recall problems, especially since the range of 
the time interval between childbirth and filling out the questionnaires was 0 to 22 years. 
However, this range was similar for cases and controls, and we do not expect parental 
subfertility and fertility treatment to be highly susceptible to recall errors, as these are major 
life events. In addition, the assumption that parents with an unplanned pregnancy were 
fertile may have resulted in non-differential misclassification, but this seemed negligible as 
sensitivity analyses showed that the results were similar when unplanned pregnancies were 
excluded. In many studies on congenital malformations, the effects of fertility treatment 
may be underestimated when only live-born cases and controls are included in the study, as 
subfertile parents who receive fertility treatment may be more likely to be offered prenatal 
screening, possibly resulting in a termination of pregnancy. However, anorectal malforma-
tions can hardly be diagnosed prenatally.22 Therefore, the potential for underestimation due 
to inclusion of live-borns only is limited in the analyses on isolated anorectal malformations. 
However, the results on anorectal malformations with other congenital malformations may 
be underestimated if pregnancies were terminated because of severe associated 
malformations. 
 We found increased risks of anorectal malformations for subfertile parents who 
received ICSI or IVF treatment compared with fertile parents who conceived spontaneously, 
with even larger effects in singletons only, which is consistent with previous studies.7,8 
Interestingly, ICSI and IVF treatments were still associated with increased occurrences of 
anorectal malformations when the analyses were restricted to subfertile parents with or 
without treatment, which has never been done before. This may point to an added effect of 
gamete manipulation, including culture medium and timing of fertilization, and/or of the 
hormones involved in ovulation induction as part of ICSI and IVF treatment, over and above 
possible adverse effects of the underlying parental subfertility. However, no association was 
found between anorectal malformations and the use of ovulation induction hormones 
without ICSI or IVF. This is in line with a large population-based study,13 but not with two 
register-based studies.10,12 Furthermore, the associations may still be confounded by the 
indication for ICSI or IVF treatment, as some of the subfertile parents who conceived after 
ICSI or IVF may be more severely subfertile than those who conceived without treatment. 
This indicates that, although subfertile parents who conceived without treatment were used 
as the reference group, the underlying parental subfertility and/or its causal factors could 
still play a role. This was confirmed by our finding that subfertility without treatment led to 
an increased risk of anorectal malformations with additional major congenital malforma-
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tions. Disturbed epigenetic processes as a consequence of ICSI or IVF and/or male 
subfertility may also be explanations for their involvement in the etiology of anorectal 
malformations,23,24 as was shown for the Beckwith-Wiedemann syndrome.25  
Previously, increased risks of anorectal malformations after ICSI or IVF were found in 
singletons, whereas no associations were found in multiple births.7 Due to small numbers, 
we could not calculate risk estimates for multiple births, but we did find higher odds ratios in 
singleton births only than in singleton and multiple births combined. We did not find indica-
tions for changes over time in the risk of anorectal malformations after fertility treatment as 
the risk estimates for IVF treatment were similar when the analyses were stratified into 
before and after 2000. We were unable to stratify the analyses for more time windows or for 
ICSI treatment due to small numbers. The association between anorectal malformations and 
IVF was observed among isolated anorectal malformations, but was much more pronounced 
for anorectal malformations with one or more additional congenital malformations, which 
was also shown by Zwink et al.8 Furthermore, subfertile parents who conceived without 
treatment were found to have an increased risk of anorectal malformations with additional 
major congenital malformations, but not isolated anorectal malformations. Cases with addi-
tional congenital malformations more often have severe forms of anorectal malformations, 
such as rectourethral fistulas or cloacas, which may imply stronger associations of parental 
subfertility and in vitro fertilization with severe forms of anorectal malformations. 
 Parental subfertility without treatment doubled the risk of anorectal malformations 
with additional congenital malformations. Subfertile parents were defined as those who had 
a TTP > 12 months and/or were ever diagnosed with maternal and/or paternal subfertility. In 
some parents in the latter group, however, fertility might have been restored prior to this 
pregnancy, which could have led to underestimation of the effects due to non-differential 
misclassification. Therefore, we performed separate analyses for these two groups and 
observed stronger associations between anorectal malformations and a TTP > 12 months, 
which we considered most reliable. In addition, we found only an association between 
anorectal malformations and parental subfertility without treatment in nulliparous women, 
which may point to a difference in the severity of parental subfertility between nulliparous 
and multiparous women and their partners in this study. This was not in line with a previous 
study on heterogeneous patient groups with congenital malformations that found similar 
results in nulliparous women as in the total group of women, including multiparous women 
as well.3 In our previous small study, we evaluated the role of parental subfertility in the 
etiology of anorectal malformations; we found paternal subfertility to potentially increase 
the risk of anorectal malformations, but not maternal subfertility.11 This is in line with the 
finding for subfertility of the father in the present study, in which only 21% of the cases were 
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Interestingly, ICSI and IVF treatments were still associated with increased occurrences of 
anorectal malformations when the analyses were restricted to subfertile parents with or 
without treatment, which has never been done before. This may point to an added effect of 
gamete manipulation, including culture medium and timing of fertilization, and/or of the 
hormones involved in ovulation induction as part of ICSI and IVF treatment, over and above 
possible adverse effects of the underlying parental subfertility. However, no association was 
found between anorectal malformations and the use of ovulation induction hormones 
without ICSI or IVF. This is in line with a large population-based study,13 but not with two 
register-based studies.10,12 Furthermore, the associations may still be confounded by the 
indication for ICSI or IVF treatment, as some of the subfertile parents who conceived after 
ICSI or IVF may be more severely subfertile than those who conceived without treatment. 
This indicates that, although subfertile parents who conceived without treatment were used 
as the reference group, the underlying parental subfertility and/or its causal factors could 
still play a role. This was confirmed by our finding that subfertility without treatment led to 
an increased risk of anorectal malformations with additional major congenital malforma-
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tions. Disturbed epigenetic processes as a consequence of ICSI or IVF and/or male 
subfertility may also be explanations for their involvement in the etiology of anorectal 
malformations,23,24 as was shown for the Beckwith-Wiedemann syndrome.25  
Previously, increased risks of anorectal malformations after ICSI or IVF were found in 
singletons, whereas no associations were found in multiple births.7 Due to small numbers, 
we could not calculate risk estimates for multiple births, but we did find higher odds ratios in 
singleton births only than in singleton and multiple births combined. We did not find indica-
tions for changes over time in the risk of anorectal malformations after fertility treatment as 
the risk estimates for IVF treatment were similar when the analyses were stratified into 
before and after 2000. We were unable to stratify the analyses for more time windows or for 
ICSI treatment due to small numbers. The association between anorectal malformations and 
IVF was observed among isolated anorectal malformations, but was much more pronounced 
for anorectal malformations with one or more additional congenital malformations, which 
was also shown by Zwink et al.8 Furthermore, subfertile parents who conceived without 
treatment were found to have an increased risk of anorectal malformations with additional 
major congenital malformations, but not isolated anorectal malformations. Cases with addi-
tional congenital malformations more often have severe forms of anorectal malformations, 
such as rectourethral fistulas or cloacas, which may imply stronger associations of parental 
subfertility and in vitro fertilization with severe forms of anorectal malformations. 
 Parental subfertility without treatment doubled the risk of anorectal malformations 
with additional congenital malformations. Subfertile parents were defined as those who had 
a TTP > 12 months and/or were ever diagnosed with maternal and/or paternal subfertility. In 
some parents in the latter group, however, fertility might have been restored prior to this 
pregnancy, which could have led to underestimation of the effects due to non-differential 
misclassification. Therefore, we performed separate analyses for these two groups and 
observed stronger associations between anorectal malformations and a TTP > 12 months, 
which we considered most reliable. In addition, we found only an association between 
anorectal malformations and parental subfertility without treatment in nulliparous women, 
which may point to a difference in the severity of parental subfertility between nulliparous 
and multiparous women and their partners in this study. This was not in line with a previous 
study on heterogeneous patient groups with congenital malformations that found similar 
results in nulliparous women as in the total group of women, including multiparous women 
as well.3 In our previous small study, we evaluated the role of parental subfertility in the 
etiology of anorectal malformations; we found paternal subfertility to potentially increase 
the risk of anorectal malformations, but not maternal subfertility.11 This is in line with the 
finding for subfertility of the father in the present study, in which only 21% of the cases were 
172 
derived from the previous study. In the latter, however, the subfertile groups included 
parents with and without fertility treatment and no analyses on subgroups of anorectal 
malformations were performed. In our time to pregnancy analyses, we found weak 
indications that fertile parents who conceive within 3 months have the smallest risk of 
having a child with anorectal malformations, since the odds ratios for almost all other classes 
of time to pregnancy were above unity.  
 In conclusion, we found evidence for a role of ICSI and IVF treatment in the etiology 
of anorectal malformations, even compared with subfertile parents who conceived without 
treatment. We also found indications for an independent role of subfertility in the etiology 
of anorectal malformations with other congenital malformations. Future studies are needed 
to unravel the underlying biological mechanisms through which the development of the 
anorectal channel may be disrupted by these factors. The findings of this study on anorectal 
malformations, in combination with the existing literature on ART and other congenital 
malformations, may also provide guidance to counseling of subfertile couples.   
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Abstract 
 
Background Both genetic and nongenetic factors are suggested to be involved in the 
etiology of congenital anorectal malformations (ARM). Maternal periconceptional use of 
folic acid supplements were inconsistently suggested to play a role in the prevention of 
ARM. Therefore, we investigated independent associations and interactions of maternal 
periconceptional folic acid supplement use and the infant and maternal MTHFR 
(methylenetetrahydrofolate reductase) C677T polymorphisms with the risk of ARM and 
subgroups of ARM.  
 
Methods A case-control study was conducted among 371 nonsyndromic ARM cases and 714 
population-based controls born between 1990 and 2012 using maternal questionnaires and 
DNA samples from mother and child. Cases were treated for ARM at departments of 
Pediatric Surgery of the Radboud university medical center, Sophia Children’s Hospital-
Erasmus Medical Centre Rotterdam, and the University Medical Center Groningen in The 
Netherlands and hospitals throughout Germany.  
 
Results No association with folic acid use was present (odds ratio = 1.1; 95% confidence 
interval: 0.8–1.4) for ARM as a group. Infant and maternal MTHFR C677T polymorphisms 
were weakly associated with isolated ARM in particular. Lack of folic acid supplement use in 
combination with infants or mothers carrying the MTHFR C677T polymorphism did not seem 
to increase the risk of ARM or subgroups of ARM. The relative excess risks due to interaction 
did not clearly indicate interaction on an additive scale either.  
 
Conclusion This first study investigating interactions between periconceptional folic acid 
supplement use and infant and maternal MTHFR C677T polymorphisms in the etiology of 
ARM did not provide evidence for a role of this gene-environment interaction.  
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Introduction 
Anorectal malformations (ARM) are common congenital malformations of the digestive 
system, but are still rare with a prevalence of 2 to 6 cases per 10,000 births worldwide.1 
ARM are characterized by disturbed embryonic development of the hindgut in weeks 4 to 8 
after conception and include a wide range of malformations of the rectum and anus, often 
also involving the urogenital tract. Despite improved surgical treatment, ARM patients 
encounter lifelong functional and psychosocial problems.2,3 The etiology for most forms of 
ARM remains to be elucidated, but is assumed to be an interplay between genetic and 
nongenetic factors. No major gene is identified yet, while only a few nongenetic risk factors 
have consistently been found to increase the risk of ARM, including assisted reproductive 
techniques,4-8 multiple pregnancy,7-11 maternal prepregnancy overweight or obesity,12-15 and 
pre-existing diabetes mellitus.15-20  
Maternal periconceptional use of folic acid supplements plays an important role in 
the prevention of neural tube defects.21 Other studies also showed decreased risks of some 
other congenital malformations, such as congenital heart defects and orofacial clefts, after 
maternal folic acid supplement use.22,23 Inconsistent results were, however, observed for 
ARM.14,20,24-26 A few studies did not find an association between ARM and folic acid use,14,26 
whereas others found slightly reduced risks.20,24,25 
The B-vitamin folate is a one-carbon donor and as such essential for biosynthesis of 
nucleotides and the remethylation of homocysteine to methionine, an important step that 
donates methylgroups to DNA, RNA, proteins, and lipids. Therefore, folate is important for 
rapid cell division and gene expression, essential for cellular growth and differentiation 
during embryogenesis. Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in 
the folate metabolism and catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate (active form of folate), which leads to the remethylation of 
homocysteine. The MTHFR C677T polymorphism reduces MTHFR enzyme activity, leading to 
decreased plasma levels of active folate and increased levels of homocysteine.27 Use of folic 
acid supplements during embryonic development may compensate for reduced folate levels 
due to genetic polymorphisms in the MTHFR gene. 
Associations between ARM and the MTHFR C677T polymorphism have never been 
studied, but may exist as they do for other congenital malformations.28,29 Previous studies on 
orofacial clefts and congenital heart malformations showed synergistic associations of the 
MTHFR C677T polymorphism and a lack of folic acid use,23,30 but gene-environment 
interactions have never been evaluated for ARM either. However, the inconsistent findings 
regarding an association between ARM and folic acid use may be explained by differences in 
genetic background. Therefore, we aimed to investigate independent associations and 
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interactions of the MTHFR C677T polymorphism and folic acid supplementation with the risk 
of ARM. As previous studies showed indications for etiologic heterogeneity among different 
subgroups of ARM,8,31 we also studied these associations and interactions in subgroups of 
ARM.  
 
Materials and methods 
Aetiologic research into Genetic and Occupational/environmental Risk factors for Anomalies 
in children (AGORA) is a large data- and biobank with clinical and questionnaire data and 
DNA samples from children with congenital malformations or childhood cancer, control 
children, and their parents coordinated by the Radboud university medical Center 
(Radboudumc) (www.AGORAproject.nl). In the current case-control study, cases were live 
born children treated for ARM at the Departments of Pediatric Surgery of the Radboudumc, 
Sophia Children’s Hospital-Erasmus MC Rotterdam (EMC), or the University Medical Center 
Groningen (UMCG) in The Netherlands. From 2007 onwards, the parents of ARM cases were 
asked to participate in AGORA at the child’s first admittance to the Radboudumc. The 
parents of older cases treated at the Radboudumc and cases treated at the EMC or UMCG 
were invited to participate by mail. We collected blood or saliva samples from cases born 
between January 1990 and April 2012, and from their parents, as well as parental 
questionnaire information concerning demographics, family history, and health and lifestyle 
before and during pregnancy. From cases born before 1990, blood or saliva samples were 
collected, but parental questionnaires were not. CURE-Net, a German Network for 
Congenital Uro-REctal malformations, provided DNA samples with year of birth and ethnicity 
of 150 additional German ARM cases and their mothers. They were recruited through the 
German self-help organization for ARM patients (SoMA e.V.) and pediatric surgical 
departments throughout Germany. These cases were included in the genetic analyses to 
increase power, but were excluded from the folic acid and interaction analyses. ARM cases 
with syndromic forms of ARM, chromosomal abnormalities, or cloacal exstrophy were 
excluded, but other major congenital malformations may be present among the cases. Our 
population-based controls were children born between January 1990 and December 2010, 
randomly sampled from 39 municipalities in the same geographical areas as the cases. 
Control children with major congenital malformations were excluded from the analyses. To 
ensure independent analyses, only one case or control per family was included. The parents 
of control children filled in the same questionnaires as the case parents and provided saliva 
samples from both mother and child. The regional Committee on Research involving Human 
Subjects approved the AGORA protocol and the Ethics Committee of the University of Bonn 
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and the University of Heidelberg approved the CURE-Net protocol. Written informed 
consent was obtained from all children and/or parents. 
Pediatric surgeons, clinical geneticists, and researchers reviewed the medical records 
of the ARM patients to obtain clinical information on ARM phenotype and additional 
congenital malformations. ARM phenotypes were classified according to the Krickenbeck 
criteria32 and other minor and major congenital malformations according to the EUROCAT 
classification.33 For the main analyses, we created two subgroups of ARM: isolated ARM 
cases (with or without minor other congenital malformations) and ARM cases with one or 
more additional major congenital malformations. The latter group also included ARM cases 
with the VACTERL association (Vertebral, Anal, Cardiac, Tracheo-Esophageal, Renal, and Limb 
defects). ARM-VACTERL cases were defined as ARM cases with at least two other congenital 
malformations included in the VACTERL association.34 
Blood was collected in EDTA containing tubes and saliva in Oragene containers (DNA 
Genotek Inc., Ottawa, Canada). DNA was extracted from blood or saliva using standard 
methods. Samples were genotyped for the MTHFR C677T polymorphism (rs1801133) using 
the 5’-nuclease Taqman single nucleotide polymorphism genotyping assay (C_1202883_20, 
Applied Biosystems, Foster City, CA). Polymerase chain reactions (PCRs) were carried out in 
96 or 384 wells plates in a 5 μl reaction volume containing 10 ng genomic DNA, 2 μl Taqman 
universal PCR master mix, 0.05 μl assay mix, and 1.95 μl milli-Q. The PCR consisted of an 
initial denaturation step at 95°C for 10 minutes, followed by 40 denaturation cycles at 92C 
for 15 seconds and annealing and extension at 60°C for 60 seconds. After PCR, allele-specific 
fluorescence was measured on ABI 7500 FAST and 7900 HT instruments (Applied 
Biosystems) for 96 or 384 wells plates, respectively. In each plate, four blanks were added 
and five wells were loaded with internal controls for quality control purposes. Genotyping 
was performed in a laboratory recognized and granted accreditation for quality control by 
the coordinating committee for improvement of quality control of laboratory research in 
health care. 
In the maternal questionnaires, mothers were asked about their use of folic acid or 
multivitamin supplements in the 3 months before conception and during pregnancy, 
including information about exact weeks before and/or during pregnancy and brand name of 
the multivitamin. Users were defined as mothers reporting use of folic acid supplements or 
multivitamins containing folic acid in the 4 weeks before conception and/or the first 10 
weeks after conception. Nonusers were mothers who reported no use during the entire 
period of 3 months before conception until the end of pregnancy. Mothers who did not 
know the period of use or began using more than 10 weeks after conception, were excluded 
from the analyses. Infant and maternal characteristics extracted from the questionnaires 
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interactions of the MTHFR C677T polymorphism and folic acid supplementation with the risk 
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and the University of Heidelberg approved the CURE-Net protocol. Written informed 
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was performed in a laboratory recognized and granted accreditation for quality control by 
the coordinating committee for improvement of quality control of laboratory research in 
health care. 
In the maternal questionnaires, mothers were asked about their use of folic acid or 
multivitamin supplements in the 3 months before conception and during pregnancy, 
including information about exact weeks before and/or during pregnancy and brand name of 
the multivitamin. Users were defined as mothers reporting use of folic acid supplements or 
multivitamins containing folic acid in the 4 weeks before conception and/or the first 10 
weeks after conception. Nonusers were mothers who reported no use during the entire 
period of 3 months before conception until the end of pregnancy. Mothers who did not 
know the period of use or began using more than 10 weeks after conception, were excluded 
from the analyses. Infant and maternal characteristics extracted from the questionnaires 
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included gender, year of birth, ethnicity of the child (European vs. non European), maternal 
age at delivery, maternal education (low: no/primary/lower vocational/intermediate 
secondary education; middle: intermediate vocational/higher secondary education; high: 
higher vocational/academic education), ARM in first degree relatives of the child, fertility 
treatment (also including ovulation induction), multiple pregnancy (singleton vs. multiple), 
parity (nulliparity vs. multiparity), pre-existing diabetes, and maternal prepregnancy body 
mass index. The latter was calculated using reported weight (kg) and height (m) before 
conception and categorized in 4 groups (<18.5, 18.5-24.9, 25.0-29.9, and ≥30.0 kg/m2).  
Statistical analyses were performed using SPSS 20.0 for Windows (IBM SPSS, Chicago, 
IL, USA). The MTHFR C677T genotype frequencies in controls were tested for deviation from 
Hardy Weinberg equilibrium (HWE). Univariable and multivariable logistic regression 
analyses were used to calculate crude and adjusted odds ratios (ORs) with 95% confidence 
intervals (CIs) for independent associations between ARM and periconceptional folic acid 
use and infant and maternal MTHFR C677T genotypes. The homozygous wild type (CC) was 
used as reference category. As MTHFR enzyme activity is already reduced by 35% in the 
heterozygous genotype (CT),27 the analyses were repeated by assuming a dominant effect 
(CT/TT vs. CC).  In addition, the role of interactions between periconceptional folic acid use 
and MTHFR C677T genotypes in the etiology of ARM was examined. We calculated adjusted 
ORs for ARM among the following groups for both infant and maternal genotypes and 
different models of inheritance: MTHFR 677CC with periconceptional folic acid use 
(reference), MTHFR 677CC without periconceptional folic acid use, MTHFR C677T 
polymorphism (CT, TT or CT/TT) with periconceptional folic acid use, MTHFR C677T 
polymorphism without periconceptional folic acid use (interaction). We also calculated 
relative risks due to interaction (RERIs) to assess interaction on an additive scale using the 
method and Excel spreadsheet (www.epinet.se) developed by Andersson et al.35 We 
considered ethnicity of the child, maternal age at delivery, maternal education, multiple 
pregnancy, fertility treatment, pre-existing diabetes, and prepregnancy body mass index as 
potential confounders in the analyses that included folic acid use, because these factors 
were previously reported as risk factors or found to be associated with ARM in this study. 
Only potential confounding factors that changed the OR of the determinant of interest in 
bivariable analyses were included in the full multivariable logistic regression models to 
prevent instable models due to too many covariates. Because risk estimates for infant 
MTHFR C677T genotypes may also be mediated by maternal genetic effects as these may 
partially determine uterine environment,36-38 we included infant and maternal MTHFR C677T 
genotypes in multivariable analyses of the MTHFR C677T polymorphism only and in the 
interaction analyses. For reasons of precision, we excluded factors from the full models 
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when the OR did not change more than 10% upon removal. The above-mentioned analyses 
were repeated for subgroups of ARM. 
 
Results 
Response rates were 57% among cases and 34% among controls. After applying the 
exclusion criteria and exclusion of one control-mother pair because of Mendelian errors, 371 
cases and 714 controls were eligible for the entire case-control study. The genetic analyses 
were performed using DNA samples of 643 cases and 714 controls, including German cases 
and Dutch cases without questionnaire information. Genotyping was completed successfully 
in more than 97% of the infant and maternal DNA samples. Of the total 643 cases, 373 had 
isolated ARM (58%) and 265 were ARM cases with other major congenital malformations 
(42%), including 83 ARM-VACTERL cases (Table 1). Perineal fistulas were the most common 
ARM phenotype, with the highest percentage in isolated ARM cases (58%). Vertebral (14%), 
cardiac (11%), and/or renal malformations (14%) were most commonly associated with 
ARM. No substantial differences were observed between cases and controls regarding 
gender, year of birth, nulliparity, and pre-existing diabetes (Table 2). Non-European descent, 
young maternal age, low maternal education, ARM in first degree relatives, fertility 
treatment, multiple pregnancy, and maternal obesity were more common among cases than 
controls.  
In total, 69% of all mothers reported use of folic acid or multivitamin supplements in 
the period of 4 weeks before through 10 weeks after conception. Of these mothers, 69% 
took supplements containing folic acid only, 9% took multivitamins, and 22% took both folic 
acid supplements and multivitamins. Use of folic acid was similar in cases and controls, 
resulting in an OR of 1.1 (95% CI: 0.8–1.4) after adjustment for maternal education. We did 
not find associations between folic acid use and the subgroups of isolated ARM and ARM 
with other major congenital malformations either.  
Table 3 shows the independent associations between ARM and subgroups of ARM 
and infant and maternal MTHFR C677T genotypes. Genotype frequencies of MTHFR C677T 
were in HWE among control mothers (P > 0.05), but not among control children (P = 0.03). 
The homozygous TT variant was present in approximately 10 to 12% of children and 
mothers, but this variant did not increase the risk of ARM (OR = 0.9; 95% CI: 0.6–1.3 and OR 
= 1.1; 95% CI: 0.7–1.5, respectively). However, both infant and maternal heterozygosity (CT) 
slightly increased the risk of ARM compared to the wild type (OR = 1.3; 95% CI: 1.0–1.7 and 
OR = 1.2; 95% CI: 0.9–1.5, respectively). Assuming dominant effects, the combined infant or 
maternal CT and TT genotypes were slightly more common among cases than among 
controls as well. These weak associations were observed for isolated ARM, but not for ARM 
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with other major congenital malformations. No differences in risk estimates were observed 
after mutual adjustment for infant and maternal MTHFR C667T genotypes. When the 
analyses were restricted to Dutch cases and controls only, the risk estimates were slightly 
lower.  
 
Table 1. Different phenotypes of anorectal malformations, The Netherlands and Germany, 1953-
2012. 
 Total ARM cases  
(n=643)a,b 
 
No. (%) 
Isolated ARM casesc  
(n=373) 
 
No. (%) 
ARM cases with 
other major defects 
(n=265) 
No. (%) 
Phenotypes of ARM 
Perineal fistula 293 (45.6) 215 (57.6) 78 (29.4) 
Vestibular fistula 103 (16.0) 53 (14.2) 50 (18.9) 
ARM without fistula 32 (5.0) 16 (4.3) 16 (6.0) 
Rectourethral fistula 
  Bulbar 
  Prostate 
  Unspecified 
 
50 (7.8) 
46 (7.2) 
30 (4.7) 
 
24 (6.4) 
17 (4.6) 
13 (3.5) 
 
26 (9.8) 
29 (10.9) 
16 (6.0) 
Rectovesical fistula 16 (2.5) 5 (1.3) 11 (4.2) 
Cloaca 30 (4.7) 7 (1.9) 23 (8.7) 
Anal stenosis 14 (2.2) 11 (2.9) 3 (1.1) 
Rare typesd 16 (2.5) 8 (2.1) 8 (3.0) 
Type unknown 13 (2.0) 4 (1.1) 5 (1.9) 
Additional major congenital malformations 
ARM-VACTERL 83 (12.9) - 83 (31.3) 
Vertebral malformations 87 (13.6) - 87 (32.8)  
Cardiac defects 73 (11.4) - 73 (27.5) 
Tracheo-Esophageal atresia 51 (8.0) - 51 (19.2) 
Renal malformations 88 (13.8) - 88 (33.2) 
Radial limb defects 35 (5.5) - 35 (13.2) 
aNumbers of isolated ARM cases and ARM cases with other major defects do not add up to total number 
of ARM cases due to missing information about additional major congenital malformations in 5 ARM 
cases. 
bARM cases include 493 cases from The Netherlands and 150 cases from Germany. 
cIsolated ARM cases may have additional minor congenital malformations. 
dIncluding rectovaginal fistula, rectal atresia, rectal stenosis, postanal sinus, dorsal cloaca-like defect with 
complex H-fistula. 
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Table 2. Characteristics of cases with anorectal malformations and controls, The Netherlands, 1990-
2012. 
 Cases (n=371) 
No. (%)a 
Controls (n=714)b 
No. (%)a 
Gender of child 
  Male 
  Female 
 
180 (48.5) 
191 (51.5) 
 
331 (46.4) 
383 (53.6) 
Year of birth of child 
  1990-1995 
  1996-2000 
  2001-2005 
  2006-2010 
  2010-2012  
 
81 (21.8) 
96 (25.9) 
84 (22.6) 
100 (27.0) 
10 (2.7) 
 
158 (22.1) 
197 (27.6) 
168 (23.5) 
191 (26.8) 
0 (0.0) 
Ethnicity of child 
  European 
  Non European 
 
337 (91.3) 
32 (8.7) 
 
676 (94.7) 
37 (5.2) 
Maternal age at delivery   
  <25 years 
  25-29 years 
  30-34 years 
  ≥35 years   
 
27 (7.3) 
123 (33.2) 
156 (42.0) 
65 (17.5) 
 
28 (3.9) 
217 (30.4) 
346 (48.5) 
123 (17.2) 
Maternal education 
  Low 
  Middle 
  High 
 
98 (26.4) 
156 (42.0) 
117 (31.5) 
 
112 (15.8) 
339 (47.7) 
260 (36.6) 
ARM in 1st degree relatives 5 (1.5) 0 (0.0) 
Fertility treatment 33 (9.0) 21 (3.0) 
Multiple pregnancy 18 (4.9) 21 (2.9) 
Nulliparity 144 (39.0) 282 (39.7) 
Pre-existing diabetes mellitus 3 (0.9) 2 (0.3) 
Pre-pregnancy body mass index 
  Underweight (<18.5 kg/m2)  
  Normal (18.5-24.9 kg/m2) 
  Overweight (25.0-29.9 kg/m2) 
  Obese (≥30.0 kg/m2) 
 
18 (5.1) 
228 (64.8) 
72 (20.5) 
34 (9.7) 
 
23 (3.4) 
487 (71.7) 
127 (18.7) 
42 (6.2) 
aNumbers do not add up to total numbers due to missing values (<1%  missings in all variables, except for 
ARM in 1st degree relatives with approximately 10% missings [mainly due to missing paternal 
questionnaires] and pre-pregnancy diabetes mellitus and body mass index with approximately 5% 
missings).  
bNo questionnaire data were available for one control child. 
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The effects of interactions of periconceptional folic acid supplement use and MTHFR C677T 
genotypes on the risk of ARM and subgroups of ARM are shown in Tables 4 and 5, 
respectively. Lack of periconceptional folic acid use in combination with an infant carrying 
the CT or TT genotype did not seem to increase the risk of ARM (OR = 1.3; 95% CI: 0.8–2.0 
and OR = 0.9; 95% CI: 0.4–2.1, respectively) compared to folic acid supplement users with 
infants carrying the wild type. Nevertheless, the RERIs of 0.5–0.6 provided weak indications 
for additivity in the joint associations, although statistical significance was not reached. 
Neither additivity nor increased risks of ARM were suggested when mothers did not use folic 
acid supplements and carried the CT or TT genotype (OR 1.0; 95% CI: 0.6–1.6, RERI 0.2; 95% 
CI: -0.4–0.7 and OR = 1.3; 95% CI: 0.5–2.9, RERI 0.6, 95% CI -0.6–1.7, respectively). Similar 
results were observed for isolated ARM, although with slightly stronger risk estimates and 
maternal RERIs. For ARM with other major congenital malformations, none of the risk 
estimates or RERIs were suggestive for a role of interaction between lack of folic acid 
supplement use and infants or mothers carrying the CT or TT genotype (ORs and RERIs 
ranging from 0.6 to 1.1 and -0.1 to 0.7, respectively). The results for all interaction analyses 
were similar after adjusted for infant and maternal MTHFR C677T genotypes.  
None of the risk estimates for isolated ARM differed when only isolated ARM with 
perineal fistulas were studied. No substantial differences were observed either when ARM-
VACTERL cases were excluded from the analyses on ARM with other congenital 
malformations. In addition, restriction of the analyses to children without first-degree 
relatives with ARM or to children from European descent only did not yield different results.  
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genotypes on the risk of ARM and subgroups of ARM are shown in Tables 4 and 5, 
respectively. Lack of periconceptional folic acid use in combination with an infant carrying 
the CT or TT genotype did not seem to increase the risk of ARM (OR = 1.3; 95% CI: 0.8–2.0 
and OR = 0.9; 95% CI: 0.4–2.1, respectively) compared to folic acid supplement users with 
infants carrying the wild type. Nevertheless, the RERIs of 0.5–0.6 provided weak indications 
for additivity in the joint associations, although statistical significance was not reached. 
Neither additivity nor increased risks of ARM were suggested when mothers did not use folic 
acid supplements and carried the CT or TT genotype (OR 1.0; 95% CI: 0.6–1.6, RERI 0.2; 95% 
CI: -0.4–0.7 and OR = 1.3; 95% CI: 0.5–2.9, RERI 0.6, 95% CI -0.6–1.7, respectively). Similar 
results were observed for isolated ARM, although with slightly stronger risk estimates and 
maternal RERIs. For ARM with other major congenital malformations, none of the risk 
estimates or RERIs were suggestive for a role of interaction between lack of folic acid 
supplement use and infants or mothers carrying the CT or TT genotype (ORs and RERIs 
ranging from 0.6 to 1.1 and -0.1 to 0.7, respectively). The results for all interaction analyses 
were similar after adjusted for infant and maternal MTHFR C677T genotypes.  
None of the risk estimates for isolated ARM differed when only isolated ARM with 
perineal fistulas were studied. No substantial differences were observed either when ARM-
VACTERL cases were excluded from the analyses on ARM with other congenital 
malformations. In addition, restriction of the analyses to children without first-degree 
relatives with ARM or to children from European descent only did not yield different results.  
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Discussion 
This is the first study investigating the role of gene-environment interactions between 
maternal periconceptional folic acid supplement use and infant and maternal MTHFR 
677CT/TT genotypes in the etiology of ARM. No major role was observed for this gene-
environment interaction. We did not find evidence for an independent association between 
ARM and periconceptional folic acid supplement use either and only found weak 
associations with the infant and maternal MTHFR C677T polymorphisms, for isolated ARM in 
particular. 
Major strengths of this study are the relatively large numbers of well-characterized 
ARM cases and population-based controls. The large case number enabled us to study 
subgroups of ARM separately, including isolated ARM, isolated ARM with perineal fistulas 
only, and ARM with one or more other major congenital malformations with and without 
ARM-VACTERL. However, the numbers were too small to study more detailed phenotypic 
subgroups of ARM. Approximately 42% of the cases had associated congenital 
malformations, which is in line with previous studies that reported rates of 40-70%, usually 
including syndromic or chromosomal forms of ARM as well.8,39 Our population-based 
controls were randomly sampled via municipalities in the same geographical areas as the 
cases and were of similar age. Although the response rate was relatively low, the control 
group seems to be representative as most maternal characteristics, such as multiple 
pregnancy and fertility treatment, were similar to the general Dutch pregnant population,40 
except for maternal education. Control mothers were slightly higher educated than case 
mothers, which may be due to a lower participation rate among low educated control 
mothers. Therefore, we adjusted the analyses that included folic acid use for maternal 
education. This may, however, have led to overadjustment due to a strong correlation 
between folic acid supplement use and maternal education.  
In this study, 69% of all mothers used folic acid supplements 4 weeks before 
conception and/or in the first 10 weeks after conception, which was similar to the findings in 
another recent Dutch study.41 We used a more inclusive definition of folic acid supplement 
use than consistent use only to include larger numbers of cases and controls while accepting 
some degree of random misclassification. As the majority of women in The Netherlands are 
aware of the correct period of folic acid supplement use, however, we expected the 
resulting bias towards the null to be small. This was confirmed in a subanalyses restricted to 
women who definitely used folic acid supplements consistently during the advised period, in 
which an OR of 1.2 (0.8-1.8) was found after adjustment for maternal education. 
An additional strength of this study was the possibility to investigate combinations of 
detailed questionnaire data on folic acid use with infant and maternal MTHFR genotype 
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This is the first study investigating the role of gene-environment interactions between 
maternal periconceptional folic acid supplement use and infant and maternal MTHFR 
677CT/TT genotypes in the etiology of ARM. No major role was observed for this gene-
environment interaction. We did not find evidence for an independent association between 
ARM and periconceptional folic acid supplement use either and only found weak 
associations with the infant and maternal MTHFR C677T polymorphisms, for isolated ARM in 
particular. 
Major strengths of this study are the relatively large numbers of well-characterized 
ARM cases and population-based controls. The large case number enabled us to study 
subgroups of ARM separately, including isolated ARM, isolated ARM with perineal fistulas 
only, and ARM with one or more other major congenital malformations with and without 
ARM-VACTERL. However, the numbers were too small to study more detailed phenotypic 
subgroups of ARM. Approximately 42% of the cases had associated congenital 
malformations, which is in line with previous studies that reported rates of 40-70%, usually 
including syndromic or chromosomal forms of ARM as well.8,39 Our population-based 
controls were randomly sampled via municipalities in the same geographical areas as the 
cases and were of similar age. Although the response rate was relatively low, the control 
group seems to be representative as most maternal characteristics, such as multiple 
pregnancy and fertility treatment, were similar to the general Dutch pregnant population,40 
except for maternal education. Control mothers were slightly higher educated than case 
mothers, which may be due to a lower participation rate among low educated control 
mothers. Therefore, we adjusted the analyses that included folic acid use for maternal 
education. This may, however, have led to overadjustment due to a strong correlation 
between folic acid supplement use and maternal education.  
In this study, 69% of all mothers used folic acid supplements 4 weeks before 
conception and/or in the first 10 weeks after conception, which was similar to the findings in 
another recent Dutch study.41 We used a more inclusive definition of folic acid supplement 
use than consistent use only to include larger numbers of cases and controls while accepting 
some degree of random misclassification. As the majority of women in The Netherlands are 
aware of the correct period of folic acid supplement use, however, we expected the 
resulting bias towards the null to be small. This was confirmed in a subanalyses restricted to 
women who definitely used folic acid supplements consistently during the advised period, in 
which an OR of 1.2 (0.8-1.8) was found after adjustment for maternal education. 
An additional strength of this study was the possibility to investigate combinations of 
detailed questionnaire data on folic acid use with infant and maternal MTHFR genotype 
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data. This is unique in etiologic research on ARM, as to our knowledge we were the first to 
study this gene-environment interaction. Detailed information was also collected on 
potential confounders that were used in the multivariable analyses. Except for maternal 
education, none of these proved to be true confounders in any of the associations and 
neither did infant or maternal MTHFR C667T genotypes. Selection bias due to the relatively 
low response rates does not seem to be an issue in the genetic analyses either as the 
distribution of MTHFR genotypes is probably unrelated to response. 
A limitation of this study was the potential for misclassification as information on 
folic acid supplement use was collected retrospectively using self-reported data. As 
pregnancy is a major life event and a great deal of attention is given to periconceptional folic 
acid use, however, we expect women to be able to adequately recall this information. In 
addition, the time interval between childbirth and filling out the questionnaires did not differ 
substantially between cases and controls. Deviation from HWE was not expected 
beforehand among the population-based control children. This phenomenon may rather be 
explained by genetic selection than by genotyping problems, as several researchers found 
selection in favor of the T allele in the last decade. They hypothesized that periconceptional 
folic acid use might have influenced genetic selection in favor of the MTHFR C677T 
polymorphism.42-44 Our finding of deviation from HWE among control children but not 
among control mothers strengthens this hypothesis as folic acid supplements were not used 
in the period that the control mothers were born. Genetic confounding can arise in case-
control designs due to population stratification, but this is minimal in ethnically 
homogeneous groups, such as the Dutch and German populations.45 
We did not find an association between ARM and folic acid supplement use, as in 
other European studies.14,26 In contrast, two non-European studies found slightly decreased 
risks.20,25 One of these latter studies was from China, where the prevalence of folate 
deficiency is high compared to other populations,46 which may explain the different results. 
We were the first to observe weak associations between ARM and infant and maternal 
MTHFR C677T polymorphisms and to investigate their interaction with periconceptional folic 
acid supplement use. The latter did not provide evidence that the MTHFR C677T 
polymorphism is involved in the etiology of ARM especially when no folic acid supplements 
are used in the critical time period of embryonic development of the anorectal channel. This 
result deviates from the findings in studies on other congenital malformations, such as 
neural tube defects, cleft lip and palate and congenital heart defects.23,30,47 Even if future 
studies with larger ARM patient series would show similar risk estimates with smaller 
confidence intervals, the role of this gene-environment interaction seems to be marginal. 
Folate acts in many biochemical processes, including DNA synthesis and methylation, but 
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this study suggests that it is not substantially involved in the development of the anorectal 
channel. The precise pathogenic mechanisms by which a lack of folic acid and reduced 
MTHFR enzyme activity act during embryogenesis are not fully understood. Several 
researchers hypothesized that a disturbed folate and/or homocysteine metabolism affects 
neural crest cell formation, leading to the above-mentioned neural-crest cell associated 
malformations.30,48,49 Both in vivo and in vitro experiments also suggested that altered levels 
of folate and/or homocysteine lead to abnormalities in neural crest cell outgrowth, 
differentiation and migration.48,50 This may explain why periconceptional folic acid use and 
the MTHFR C677T polymorphism do not play a major role in the etiology of ARM, which does 
not depend on neural crest cell formation.  
In conclusion, while the ultimate goal is to provide women who try to conceive with 
individualized lifestyle recommendations, we did not find evidence that periconceptional use 
of folic acid supplements reduces the risk of having a child with ARM, not even for women 
who carry the MTHFR C677T polymorphism. 
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Abstract 
 
Anorectal malformations (ARM) are rare congenital malformations, resulting from disturbed 
development of the hindgut. Evidence regarding the genetic etiology of ARM is still scarce. 
Therefore, we performed genotyping of 598 Caucasian ARM patients and 1,931 Caucasian 
population-based controls using the Illumina Human Exome BeadChip, which contains >240K 
rare coding variants. Single variant and gene-based analyses were performed. Statistically 
significant single variant results after Bonferroni correction (p < 1.13*10-6) were validated in 
patients using targeted resequencing with the molecular inversion probe (MIP) technique. 
Sanger sequencing was used to verify the results with a second validation method. An 
additional 175 Caucasian ARM patients and 3,201 controls as well as 307 Han Chinese 
patients and 466 controls were used to replicate the single variant results that were 
confirmed in the validation study. In total, 55 single variants reached statistical significance 
in the discovery study. Only three of these, residing in the CLCN1, LRBA, and ZNF423 genes, 
were validated, but the replication analyses in Caucasian and Han Chinese patients and 
controls did not confirm the results for these variants. In conclusion, we did not find 
evidence for associations between ARM and rare coding variants with large effect sizes 
captured by the exome chip. Future studies will need large sample sizes to identify common 
and rare variants with small to moderate effects, while stratifying on phenotypically 
homogeneous groups of ARM patients.  
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Introduction 
Congenital anorectal malformations (ARM) are major congenital malformations, resulting 
from disturbed development of the rectum and anus. Although ARM are one of the most 
frequently occurring malformations of the gastrointestinal tract, the prevalence of 2 to 6 in 
10,000 live births is relatively low (see URLs). ARM encompass a broad range of different 
phenotypes in both males and females, which are mostly classified according to the type of 
fistula to neighboring organs. In approximately 50% of the patients, ARM present with 
additional congenital malformations, such as vertebral, cardiac and/or renal 
malformations.1,2 Multiple surgical corrections are required during the first years of a 
patient’s life. Despite major improvements in the care and treatment of ARM patients in the 
past decade, a substantial number of patients face lifelong physical and psychosocial 
problems.3  
Our current understanding of the embryology and etiology of ARM is limited. A 
syndrome caused by a fully penetrant mutation in a single gene, such as Currarino or 
Townes-Brocks syndrome, is identified in approximately 10% of the patients.1 In the 
remaining patients, the involvement of both genetic and non-genetic factors in the 
occurrence of ARM seems likely. Previous studies consistently found non-genetic risk factors, 
such as fertility treatment,4-7 maternal overweight or obesity,8-10 and pre-existing diabetes,11-
13 to be associated with ARM. Familial aggregation of ARM was shown in some studies,10,14 
which may point to genetic factors. So far, genetic research into ARM has mainly focused on 
candidate genes that are involved in embryonic signaling pathways, such as sonic hedgehog 
(SHH), wingless-type integration site (WNT), and fibroblast growth factor (FGF) signaling.15 
However, human ARM studies did not provide substantial evidence to support a contribution 
of these genes.16-21 Hypothesis-generating approaches through genome-wide studies seem 
valuable to acquire new knowledge and hypotheses, as these have been successful in the 
identification of genetic variants for many multifactorial disorders, such as Hirschsprung’s 
disease.22  
Wong et al. performed the only genome-wide association study for ARM in a small 
sample of 175 patients. This study did not yield any associated common single nucleotide 
variants, nor did it suggest a role for common copy number variants (CNV) in the etiology of 
ARM.23 However, the authors did identify an excess of rare CNVs, observing many different 
rare CNVs in individual isolated ARM patients, but not in controls nor in healthy individuals 
from the Database of Genomic Variants.23 This suggests the importance of rare variation in 
the etiology of ARM. In the current study, we aimed to identify rare genetic variants for ARM 
by exome-wide genotyping of numerous known rare coding variants in the largest sample of 
well-characterized ARM patients in genetic ARM research so far. 
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Materials and Methods 
Discovery exome chip association study 
Study population 
AGORA (Aetiologic research into Genetic and Occupational/environmental Risk factors for 
Anomalies in children) is a large data- and biobank with DNA samples and clinical and 
questionnaire data from children with congenital malformations or childhood cancer, 
control children, and their parents. AGORA is a multicentre effort coordinated by the 
Radboud university medical center (Radboudumc) in Nijmegen, The Netherlands. For the 
current study, AGORA provided 429 blood or saliva samples from live born Caucasian 
patients who were treated for ARM at the departments of Surgery-Pediatric Surgery of the 
Amalia Children’s Hospital-Radboudumc, the Sophia Children’s Hospital-Erasmus MC 
Rotterdam (EMC), and the University Medical Center Groningen (UMCG) in The Netherlands. 
The German Network for Congenital Uro-REctal malformations (CURE-Net) provided 169 
additional DNA samples from ARM patients of Caucasian ancestry. These patients were 
recruited through the German self-help organization for ARM patients (SoMA e.V.) and 
pediatric surgical departments throughout Germany. DNA samples from ARM patients with 
chromosomal abnormalities or syndromes with a known genetic cause were not included in 
the study population. 
Pediatric surgeons, clinical geneticists, and researchers reviewed the medical records 
of the ARM patients extensively to obtain clinical information on ARM phenotypes and 
associated congenital malformations. We classified ARM phenotypes according to the 
Krickenbeck criteria24 and divided the congenital malformations in major and minor 
malformations according to the EUROCAT classification.25 The phenotypic characteristics of 
the ARM patients are shown in Supplemental Table 1. 
Controls were derived from the Nijmegen Biomedical Study (NBS), a population-
based survey conducted by the Department for Health Evidence and the Department of 
Laboratory Medicine of the Radboudumc (see URLs). In total, 22,451 age and sex stratified 
randomly selected adult inhabitants of the municipality of Nijmegen received an invitation to 
fill out a postal questionnaire on items such as lifestyle and medical history, and to donate 
two blood samples. The response to the questionnaire was 43% (n=9,350), and 69% 
(n=6,468) of the responders donated blood samples. For the current study, DNA samples of 
1,931 Caucasian controls were used. The Arnhem-Nijmegen Regional Committee on 
Research Involving Human Subjects approved the AGORA and NBS study protocols and the 
Ethics Committees of the University of Bonn and the University of Heidelberg approved the 
CURE-Net study protocol. Written informed consent was obtained from all participants and 
parental consent for children under 18 years of age.  
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Genotyping and quality control 
Using standard methods, DNA was extracted from blood collected in EDTA-containing tubes 
or saliva specimens collected in Oragene containers (DNA Genotek Inc., Ottawa, Canada). 
The DNA samples were genotyped using the Illumina Human Exome BeadChip (v1.1), which 
contains 242,901 markers throughout the exome. The majority of these markers (~220,000) 
are rare coding variants (nonsynonymous, splice site, stop gain, and stop loss variants) and a 
small proportion are non-coding variants. These markers were selected based on their 
occurrence in approximately 12,000 sequenced genomes and exomes from multiple 
populations of primarily European ancestry (see URLs). Approximately 20% of the markers 
have a minor allele frequency (MAF) >1% and 80% of the markers a MAF <1%. Genotyping 
and calling was performed at the Erasmus MC in Rotterdam, The Netherlands, as part of the 
ExomeChip Rainbow Project (RP10) of Biobanking and Biomolecular Research Infrastructure 
Netherlands (BBMRI-NL) (see URLs). Regular GenomeStudio (GS) clustering and calling was 
followed by re-calling of ‘no-calls’ only using zCall,26 for patient and control samples 
separately. zCall was especially designed as a tool for calling rare variants from array data.  
We applied quality control procedures to GS called data using PLINK v1.07 (see URLs). 
Samples and markers that did not meet quality control criteria were removed from the zCall 
genotype data, which were used for the analyses. In total, 2,467 of the 2,529 patient and 
control samples (97.5%) were successfully genotyped with call rates > 99% and could be 
included in the analyses. We excluded 11 samples (3 patients and 8 controls) based on sex 
discordance between genotype data and clinical information, 3 samples (1 patient and 2 
controls) with aberrant heterozygosity rates (> ±4 SD from the mean), 4 patients based on 
relatedness, and 2 patient duplicates. To identify population outliers, multidimensional 
scaling (MDS) analysis was carried out by calculating the pairwise identity-by-state from LD 
pruned markers, leading to 3 population outliers (3 patients) being excluded from further 
analyses. Regarding the markers, 241,385 of the 242,901 (99.4%) were successfully 
genotyped with a call rate > 95%. Markers with Hardy-Weinberg Equilibrium p-values < 
0.0001 in controls were excluded (n=208). As a result, 241,177 genotyped markers in 558 
patients and 1,886 controls remained for further analyses. 
 
Statistical analyses 
Statistical analyses were performed using PLINK v1.07, R statistical software v3.0.3, and SPSS 
v20.0. We used support files obtained from the Illumina website and the University of 
Michigan, as well as the UCSC genome browser (see URLs) and Alamut software version 2.3 
to assess variant types, amino acid changes, and genes. 
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Single variant analyses  
To reduce potential false-positives and have sufficient power to replicate a statistically 
significant variant in smaller replication samples, we restricted the single variant analyses to 
variants with a minor allele frequency (MAF) >0.4%, which corresponds to at least 20 minor 
alleles in the combined patient and control sample. Based on this criterion, 178,417 variants, 
including 134,298 monomorphic variants, were excluded, leaving 44,119 variants for the 
statistical analyses. We tested the associations between ARM and each variant using Fisher’s 
exact tests in both an allelic and additive genetic model, assuming Hardy Weinberg 
equilibrium. We used an exact method as the asymptotic score test is known to be too 
liberal and does not provide robust results when variant allele counts are low. As genotypic 
effects were not evaluated for Y chromosome and mitochondrial variants, 44,022 variants 
remained for these analyses. Potential of bias due to population stratification was assessed 
using the quantile-quantile plot (QQ plot) and by calculating the genomic control inflation 
factor, which was defined as the regression coefficient of the observed to expected –log p 
values from the Fisher’s exact test. Test statistics were adjusted for the genomic control 
inflation factor. We performed subgroup analyses on isolated ARM and ARM with additional 
congenital malformations separately for apparently statistically significant findings (55 
variants) in the total ARM group. A p-value below 1.13*10-6 was considered statistically 
significant in the single variant analyses, which corresponds to a Bonferroni correction for 
44,119 tests (number of variants tested).  
 
Gene-based analyses 
We performed gene-based analyses using the sequence kernel association (SKAT) test in R 
and the gene annotation file from the Illumina website (see URLs).27 SKAT has been shown to 
be a powerful method when both harmful and protective variants with different magnitudes 
of effect occur in one gene. We tested 13,864 genes with at least two variants that passed 
quality control and were polymorphic in either patients or controls. The analyses were 
performed using default settings.27 A p-value below 3.61*10-6 was declared statistically 
significant in the gene-based analyses, corresponding to a Bonferroni correction for 13,864 
tests (number of genes tested). The Globaltest R package method, which was developed by 
one of the co-authors (JG) and is nearly identical to the SKAT method,28 was used to visualize 
the individual contribution of each variant to the p-value of the identified genes. We also 
performed conditional analyses using SKAT to consider whether the gene-based test results 
were driven by the most statistically significant variant in a gene as determined in the single 
variant analyses by adjustment for the allele count of this variant.  
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Validation and replication studies 
Study populations 
To validate the results of the 55 variants that were found to be statistically significantly 
associated with ARM in the single variant analyses, the DNA samples from all patients that 
passed quality control in the discovery study were re-genotyped by targeted resequencing 
using the molecular inversion probe (MIP) technique.29,30 For 7 of the 558 samples, the 
amount of DNA was insufficient or the quality was too low for further genotyping, leaving 
551 patient DNA samples for validation. We validated the 55 variants in patient samples 
only, as most of these variants were rare or absent in controls. In a second validation step, 
10 of these variants were validated again using Sanger sequencing to verify the results of the 
targeted resequencing technique. For each variant, 5 patients were re-genotyped. 
A combined set of 175 additional Caucasian ARM patients from AGORA and CURE-
Net and 3 unrelated Caucasian population-based control series served as replication sample. 
The control series included participants of the Genome of The Netherlands Consortium 
(GoNL study) (n=498) (see URLs), the Dutch-Belgian Randomized Lung Cancer Screening Trial 
(NELSON study) (n=1,061),31 and the Utrecht Health Project (n=2,908).32 A second replication 
sample was derived from the University of Hong Kong, China, and consisted of DNA samples 
from 307 Han Chinese ARM patients and 466 Han Chinese healthy controls. The above-
mentioned patient classifications in the discovery sample were also applied to the Caucasian 
replication sample (see Supplemental Table 1), but detailed information on type of ARM and 
associated congenital malformations was not available for the Han Chinese ARM patients. 
The Ethics Committees in The Netherlands and Germany and at the University of Hong Kong, 
China, approved all study protocols and written informed consent was obtained from all 
participants.  
 
Genotyping and quality control 
The MIP technique was used to screen the 55 variants that were found in the discovery 
study in one single reaction by targeted resequencing of 112 bp surrounding the coding 
variant. MIPs are 70 nucleotide single stranded DNA molecules, including a 30 bp common 
linker sequence and a locus-specific extension and ligation arm of 40 bp that are 
complementary to the target DNA. At least two independent MIP probes were designed for 
each variant to reach good coverage of the genomic region in which the variant occurs. For 
one variant (exm779484 in OR1L4), only one working MIP could be developed. MIP capture 
and the subsequent polymerase chain reaction (PCR) were performed as described before,29 
with minor modifications. The MIP-captured next generation sequencing (NGS) libraries of 
551 ARM patients from the discovery study, 175 additional Caucasian ARM patients, 307 Han 
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China, approved all study protocols and written informed consent was obtained from all 
participants.  
 
Genotyping and quality control 
The MIP technique was used to screen the 55 variants that were found in the discovery 
study in one single reaction by targeted resequencing of 112 bp surrounding the coding 
variant. MIPs are 70 nucleotide single stranded DNA molecules, including a 30 bp common 
linker sequence and a locus-specific extension and ligation arm of 40 bp that are 
complementary to the target DNA. At least two independent MIP probes were designed for 
each variant to reach good coverage of the genomic region in which the variant occurs. For 
one variant (exm779484 in OR1L4), only one working MIP could be developed. MIP capture 
and the subsequent polymerase chain reaction (PCR) were performed as described before,29 
with minor modifications. The MIP-captured next generation sequencing (NGS) libraries of 
551 ARM patients from the discovery study, 175 additional Caucasian ARM patients, 307 Han 
206 
Chinese ARM patients, and 466 Han Chinese controls were sequenced on the Next-Seq500 
sequencer (Illumina, San Diego, CA, USA). After sequencing, next generation sequencing 
(NGS) reads were mapped and MIP arms were trimmed by BWA (version 0.7.7-r441). For all 
variant positions, the alignment pileups were extracted using a custom made Java program 
and Samtools (version 0.1.19-44428cd). Positions with less than 10x coverage were marked 
as missing genotypes due to insufficient coverage. If the reference allele constituted >80% of 
the base calls for a position, the position was considered to be homozygous reference, 
whereas the position was considered to be homozygous variant when the variant allele 
constituted >80% of the base calls. Values in between were considered as heterozygous for 
the variant allele. After manual checks of the sequences of samples with percentages of total 
reads in the ranges 10-30% and 70-90%, the scoring of genotypes did not alter. In total, 12 
samples (10 validation and 2 replication samples) had missing genotypes for all 55 variants, 
most likely due to low DNA input. As the MIPs covering the variant exm1131059 in KIF26A 
generated low sequence coverage in almost all samples, we excluded this variant from 
further analyses. Genotyping was completed successfully in 97.4% of the samples for the 
remaining 54 variants. Of these, 10 variants (exm1130982 in KIF26A, exm1610290 in 
CACNA1I, exm725230 in JRK, exm7090 in MEGF6, exm949028 in FUT4, exm78706 in 
COL11A1, exm1531889 in FOXS1, exm2254176 in SIRPA, exm1415838 in PEX11G, and 
exm428026 in LRBA) were selected for verification by Sanger sequencing with specifically 
designed primers. PCR was performed in a 12.5 μl reaction volume containing 5 μM of 
forward and reverse primer, 10 ng DNA and 6.25 μl Readymix (Sigma-Aldrich). The 
conditions were 95°C (5 min), a 2-step profile including 95°C (30 sec), 60°C (45 sec), and 72°C 
(40 sec) (two times), and 72°C for 10 min. PCR products were purified using exonuclease 
treatment. Samples were analyzed on a 3730 (XL) DNA sequencer (Applied Biosystems). The 
sequences obtained were compared with the reference sequence derived from the UCSC 
genome browser (Build hg38) using VECTOR NTI software 11.0.  
Genotype data based on NGS for the GoNL participants were derived from the online 
data source (see URLs). The samples from the participants of the NELSON study and the 
Utrecht Health Project were jointly genotyped in the same BBMRI-NL RP10 project as the 
patients and controls in our discovery study, using the same Illumina Human Exome 
BeadChip (v1.1) and GS and zCall for calling. Sample quality control was performed on 
GenomeStudio calls and low-quality samples were excluded from the zCall data. In total, 106 
samples from the NELSON study and 1,160 samples from the Utrecht Health Project were 
excluded as these had call rates <95% or heterozygosity rates > ±4 SD from the mean, were 
related to other samples, or were population outliers, leaving 955 samples from the NELSON 
study and 1,748 samples from the Utrecht Health Project for the analyses. The relatively high 
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numbers of excluded samples from the Utrecht Health Project was expected as many 
individuals were related or of non-Caucasian ancestry. The variants that were included in the 
replication study were successfully genotyped with call rates >99% in both cohorts, except 
for exm665970 in CLCN1. In addition, exm428026 in LRBA was not in HWE in either cohort. 
As the marker quality of these variants was doubtful, we excluded these from the replication 
analyses in both cohorts.  
 
Statistical analyses 
Genotypes and MAFs for the 54 variants in the 541 re-genotyped ARM patients were 
compared between the discovery study and the validation study. We calculated concordance 
per variant and for all variants combined. In addition, p values for associations between ARM 
and these 54 variants in the validation study were calculated in an allelic model using 
Fisher’s exact tests and the controls from the discovery study. Fisher’s exact p values were 
also calculated for the variants included in the replication study for both the Caucasian and 
the Han Chinese replication samples. The association analysis results of the validation and 
replication studies were combined in a meta-analysis using the inverse-variance method and 
assuming random effect models in Review Manager 5.3. 
 
URLs 
International Clearing House for Birth Defects Surveillance and Research. Annual report 
2012: with data for 2010, http://www.icbdsr.org/filebank/documents/ar2005/Report2012. 
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In total, 241,177 markers passed quality control, including 134,298 monomorphic variants 
(55.7%). A plot of the first two principal components was obtained by multidimensional 
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most likely due to low DNA input. As the MIPs covering the variant exm1131059 in KIF26A 
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conditions were 95°C (5 min), a 2-step profile including 95°C (30 sec), 60°C (45 sec), and 72°C 
(40 sec) (two times), and 72°C for 10 min. PCR products were purified using exonuclease 
treatment. Samples were analyzed on a 3730 (XL) DNA sequencer (Applied Biosystems). The 
sequences obtained were compared with the reference sequence derived from the UCSC 
genome browser (Build hg38) using VECTOR NTI software 11.0.  
Genotype data based on NGS for the GoNL participants were derived from the online 
data source (see URLs). The samples from the participants of the NELSON study and the 
Utrecht Health Project were jointly genotyped in the same BBMRI-NL RP10 project as the 
patients and controls in our discovery study, using the same Illumina Human Exome 
BeadChip (v1.1) and GS and zCall for calling. Sample quality control was performed on 
GenomeStudio calls and low-quality samples were excluded from the zCall data. In total, 106 
samples from the NELSON study and 1,160 samples from the Utrecht Health Project were 
excluded as these had call rates <95% or heterozygosity rates > ±4 SD from the mean, were 
related to other samples, or were population outliers, leaving 955 samples from the NELSON 
study and 1,748 samples from the Utrecht Health Project for the analyses. The relatively high 
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numbers of excluded samples from the Utrecht Health Project was expected as many 
individuals were related or of non-Caucasian ancestry. The variants that were included in the 
replication study were successfully genotyped with call rates >99% in both cohorts, except 
for exm665970 in CLCN1. In addition, exm428026 in LRBA was not in HWE in either cohort. 
As the marker quality of these variants was doubtful, we excluded these from the replication 
analyses in both cohorts.  
 
Statistical analyses 
Genotypes and MAFs for the 54 variants in the 541 re-genotyped ARM patients were 
compared between the discovery study and the validation study. We calculated concordance 
per variant and for all variants combined. In addition, p values for associations between ARM 
and these 54 variants in the validation study were calculated in an allelic model using 
Fisher’s exact tests and the controls from the discovery study. Fisher’s exact p values were 
also calculated for the variants included in the replication study for both the Caucasian and 
the Han Chinese replication samples. The association analysis results of the validation and 
replication studies were combined in a meta-analysis using the inverse-variance method and 
assuming random effect models in Review Manager 5.3. 
 
URLs 
International Clearing House for Birth Defects Surveillance and Research. Annual report 
2012: with data for 2010, http://www.icbdsr.org/filebank/documents/ar2005/Report2012. 
pdf; AGORA data- and biobank, www.agoraproject.nl; Exome chip design, http://genome. 
sph.umich.edu/wiki/Exome_Chip_Design; Nijmegen Biomedical Study, http://www. 
nijmegenbiomedischestudie.nl/; BBMRI-NL RP10 project, http://www.bbmri.nl/en-gb/ 
activities/rainbow-projects; PLINK v1.07, http://pngu.mgh.harvard.edu/~purcell/plink/; 
Support and documentation files Human Exome Chip, http://support.illumina.com/array/ 
array_kits/infinium_humanexome_beadchip_kit/downloads.ilmn, ftp://share.sph.umich.edu 
/HumanExomearray/ProposedContent/coding Content; UCSC genome browser, http:// 
genome.ucsc.edu/; GoNL study, http://www.nlgenome.nl/; NHLBI Exome Sequencing 
Project; Exome Variant Server, http://evs.gs.washington.edu/EVS/. 
 
Results 
Discovery exome chip association study 
Single variant analyses 
In total, 241,177 markers passed quality control, including 134,298 monomorphic variants 
(55.7%). A plot of the first two principal components was obtained by multidimensional 
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scaling analysis for all 558 patients and 1,886 controls (Supplemental Figure 1). No 
population substructures or differences in clustering between patients and controls or 
between the two different ARM studies AGORA and CURE-NET were observed. None of the 
first ten MDS components were associated with patient-control status. However, we found 
indications for inflation of the observed −log10(p-values), based on the QQ plot 
(Supplemental Figure 2) and the genomic control inflation factor of 1.066 after removal of 
the most statistically significant variants identified (allelic level). Each variant with MAF > 
0.4% was tested individually (44,119 variants), and 55 variants were found to be statistically 
significantly associated with ARM after adjustment for the genomic control inflation factor. 
The results for these variants are shown in Supplemental Tables 2 (all ARM patients) and 3 
(subgroups of ARM patients). The majority of variants identified were rare or even absent in 
controls. Similar p values were observed when an additive genetic model was assumed after 
adjustment for the corresponding genomic control inflation factor of 1.072 (data not 
shown).  
 
Gene-based analyses 
The gene-based analyses using SKAT yielded 86 statistically significant genes, which are 
shown in Supplemental Table 4. These results did, however, not lead to new insights as both 
visualization of the contribution of each variant to the gene-based test signal and conditional 
analyses on allele count showed that in each gene, one variant contributed to the signal in 
particular (see Supplemental Table 4). These variants also showed full or borderline 
statistically significant associations in the single variant analyses. Therefore, we only 
followed up those variants that were found in the single variant analyses. The figures 
displaying the contribution of each variant to the gene-based test signal are available on 
request. 
 
Validation and replication studies 
Validation study 
Patients with homozygous reference calls in the discovery study using the exome chip were 
almost always called similarly in the validation study using targeted resequencing with the 
MIP technique. This resulted in an overall concordance rate of 99.9%. However, patients 
with heterozygous or homozygous variant calls in the discovery study were mostly called 
with homozygous reference calls in the validation study. Control samples were not validated, 
but in light of this information, we excluded 3 variants with higher MAFs among controls 
than among patients in the discovery study from further analyses (exm230609 in SPOPL, 
exm179650 in EMILIN1, and exm779484 in OR1L4). For 44 of the remaining 51 variants, 
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none or only 1 or 2 of the heterozygote or homozygote variant patients in the discovery 
study had similar genotypes in the validation study, resulting in concordance rates close to 
0%. So these 44 variants were not found to be associated with ARM in the first validation 
study (Supplemental Table 5). To verify the results of the targeted resequencing technique, 9 
randomly chosen variants out of these 44 variants were validated again using Sanger 
sequencing. For each variant, five patients with discordant findings (heterozygous variant 
call in the discovery study using the exome chip, but homozygous reference call in the 
validation study using targeted resequencing) were re-genotyped. All calls found in the 
validation study using targeted resequencing were confirmed, whereas none of the 
heterozygous variant calls in the discovery study were confirmed using Sanger sequencing as 
a second validation technique. The remaining 7 variants were included in the replication 
study and their characteristics are presented in Table 1. Three of these variants (exm665970 
in CLCN1, exm428026 in LRBA, and exm1239020 in ZNF423) showed good validation with 
100% concordance for heterozygous calls; their association with ARM was confirmed in the 
validation study (Table 2). One of these variants (exm428026 in LRBA) was also included in 
the second validation step. The results were confirmed in all 5 patients with heterozygous 
calls submitted to Sanger sequencing. For the other 4 variants (exm2253769 in NUDT19, 
exm1293600 in MYH13, exm853474 in CALHM1, and exm1017978 in AVIL), concordance 
rates of the heterozygous calls were low (8-30%) and the p values in the validation study 
were high (Table 2). However, we further evaluated all 7 variants in the replication study, 
assuming that the MAFs in controls might also be lower than found in the discovery study. 
Subgroup analyses for these 7 variants based on the presence of associated congenital 
malformations yielded small differences in the results, pointing towards stronger 
associations with ARM with other birth defects for exm665970 and with isolated ARM for 
exm428026 and exm1239020 (Table 3).  
 
Replication study 
None of the 7 variants included in the replication study was found to be associated with 
ARM in either of the two replication samples or in the combined analysis (Table 4). Of the 
three variants that were found to be associated with ARM after validation, exm428026 in 
LRBA showed a much lower MAF in the patients of the Caucasian replication study than in 
those of the validation study (Tables 2 and 4). More or less similar MAFs in the patients of 
the validation study and the Caucasian replication study were observed for the variants in 
CLCN1 and ZNF423. However, the MAFs of these two variants were much lower in the 
controls of the discovery study than in the Caucasian control populations of the replication 
study, which were comparable to the NHLBI Exome Sequencing Project with frequency 
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scaling analysis for all 558 patients and 1,886 controls (Supplemental Figure 1). No 
population substructures or differences in clustering between patients and controls or 
between the two different ARM studies AGORA and CURE-NET were observed. None of the 
first ten MDS components were associated with patient-control status. However, we found 
indications for inflation of the observed −log10(p-values), based on the QQ plot 
(Supplemental Figure 2) and the genomic control inflation factor of 1.066 after removal of 
the most statistically significant variants identified (allelic level). Each variant with MAF > 
0.4% was tested individually (44,119 variants), and 55 variants were found to be statistically 
significantly associated with ARM after adjustment for the genomic control inflation factor. 
The results for these variants are shown in Supplemental Tables 2 (all ARM patients) and 3 
(subgroups of ARM patients). The majority of variants identified were rare or even absent in 
controls. Similar p values were observed when an additive genetic model was assumed after 
adjustment for the corresponding genomic control inflation factor of 1.072 (data not 
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study (Supplemental Table 5). To verify the results of the targeted resequencing technique, 9 
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sequencing. For each variant, five patients with discordant findings (heterozygous variant 
call in the discovery study using the exome chip, but homozygous reference call in the 
validation study using targeted resequencing) were re-genotyped. All calls found in the 
validation study using targeted resequencing were confirmed, whereas none of the 
heterozygous variant calls in the discovery study were confirmed using Sanger sequencing as 
a second validation technique. The remaining 7 variants were included in the replication 
study and their characteristics are presented in Table 1. Three of these variants (exm665970 
in CLCN1, exm428026 in LRBA, and exm1239020 in ZNF423) showed good validation with 
100% concordance for heterozygous calls; their association with ARM was confirmed in the 
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Replication study 
None of the 7 variants included in the replication study was found to be associated with 
ARM in either of the two replication samples or in the combined analysis (Table 4). Of the 
three variants that were found to be associated with ARM after validation, exm428026 in 
LRBA showed a much lower MAF in the patients of the Caucasian replication study than in 
those of the validation study (Tables 2 and 4). More or less similar MAFs in the patients of 
the validation study and the Caucasian replication study were observed for the variants in 
CLCN1 and ZNF423. However, the MAFs of these two variants were much lower in the 
controls of the discovery study than in the Caucasian control populations of the replication 
study, which were comparable to the NHLBI Exome Sequencing Project with frequency 
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information of European Americans (MAF is 2.5% for exm665970 in CLCN1 and 2.1% for 
exm1239020 in ZNF423 (see URLs)). The 7 variants included in the replication study were 
mostly monomorphic in both the Han Chinese patients and controls. Subgroup analyses for 
isolated ARM and ARM with other congenital malformations were impossible due to small 
patient numbers in the Caucasian replication sample and lacking detailed phenotypic 
information for the Han Chinese patients. The meta-analyses showed indications for 
increased odds ratios (ORs) for several variants, but the wide confidence intervals preclude 
any conclusions. 
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information of European Americans (MAF is 2.5% for exm665970 in CLCN1 and 2.1% for 
exm1239020 in ZNF423 (see URLs)). The 7 variants included in the replication study were 
mostly monomorphic in both the Han Chinese patients and controls. Subgroup analyses for 
isolated ARM and ARM with other congenital malformations were impossible due to small 
patient numbers in the Caucasian replication sample and lacking detailed phenotypic 
information for the Han Chinese patients. The meta-analyses showed indications for 
increased odds ratios (ORs) for several variants, but the wide confidence intervals preclude 
any conclusions. 
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Discussion 
This first exome chip association study on the role of rare coding variants in the etiology of 
congenital anorectal malformations did not provide evidence for associations between ARM 
and rare variants captured by the Illumina Human Exome BeadChip. Three variants were 
found to be statistically significant in both the discovery study and the validation study, but 
replication analyses in new series of patients and controls did not confirm these results. 
 As the prevalence of ARM is low, the inclusion of a relatively large number of 773 
Caucasian and 307 Han Chinese ARM patients in this study is unique in the genetic field of 
ARM. However, the power of this study was insufficient to detect associations with variants 
with small to moderate effects. We had 80% power to detect single variants with moderate 
to large effects (ORs of 3.7-8.4 or above) with MAFs of 0.4-2.0% in the discovery sample. The 
power to replicate variants with these effect sizes in our relatively small Caucasian 
replication sample was much smaller. Another limitation was the low power for subgroup 
analyses in the discovery study for specific phenotypic characteristics (e.g. type of fistula) 
and the inability to perform subgroup analyses in the replication studies based on presence 
of associated congenital malformations. These analyses seem relevant, as ARM patients 
comprise a phenotypically heterogeneous group of patients for which heterogeneity in 
underlying etiologies seems likely.6 In addition, the scope of this study was limited to the 
content of the Illumina Human Exome BeadChip, which was based on the coding and splice 
site variation observed in approximately 12,000 sequenced individuals of mainly European 
descent. Only ~80% of the initially selected content could be converted into this exome chip. 
Hence, a large proportion of human exome variation was not covered. Future exome or 
whole genome sequencing studies are needed to unravel the involvement of exome 
variation that was not covered by the current chip. 
 The validation study using two different validation methods targeting the highly 
associated variants in our discovery study appeared to make a substantial contribution to 
our investigation. The results of the targeted resequencing technique showed that many 
heterozygous calls in the exome chip data and their associations with ARM were not 
confirmed. A second validation step using Sanger sequencing confirmed the results of the 
targeted resequencing technique and provides evidence for the validity of these results and 
for the absence of most associations identified in the discovery study. Almost all 
heterozygous calls detected in ARM patients by targeted resequencing were also found to be 
heterozygous calls in the zCall exome chip patient data. Goldstein et al. introduced the zCall 
algorithm and showed that application of zCall after a default caller (Illumina’s GenCall 
algorithm and GenomeStudio software) improves rare variant calling (i.e. increases 
sensitivity), but also increases errors in which homozygous reference variants are called as 
217 
heterozygous variants.26 Hence, our observations in the validation study are in line with the 
conclusions of Goldstein et al. Moreover, patients and controls in our discovery study were 
genotyped and called separately, which may have resulted in differential misclassification of 
genotypes and most likely overestimation of positive allele frequency differences between 
patients and controls. Future case-control studies using exome chip techniques should be 
aware of this phenomenon, which may be detected by checks for batch effects.33 Based on 
the results of Goldstein et al., however, it does not seem likely that we missed potentially 
strong positive associations with rare variants.  
Three variants in the CLCN1, LRBA, and ZNF423 genes were confirmed in the 
validation study. One of these genes, LRBA, is located in a region on 4q31.3-q32.3, which 
was suggested as a susceptibility locus for Hirschsprung’s disease using genome-wide linkage 
analysis in a multigenerational family.34 Hirschsprung’s disease is a congenital malformation 
of the large intestine, which rarely coexists with ARM. The other two genes have not been 
associated with ARM in the literature either. None of the three variants was replicated in a 
small Caucasian patient population, although the MAFs for two of the three variants were 
comparable to those in the discovery sample. We observed lower MAFs, however, in the 
Caucasian controls of the discovery study than in controls of the Caucasian replication study 
and the NHLBI Exome Sequencing Project with frequency information of Caucasians. This 
may be due to chance or to genotyping errors in controls of the discovery study. In addition, 
we could not replicate our findings in a Han Chinese replication sample. Caution is needed in 
the interpretation of these replication results, as the results for one single rare variant in a 
gene identified in a Caucasian population may not always be generalizable to non-Caucasian 
populations.   
 Exome chips have been applied successfully to identify rare variant associations for a 
number of multifactorial traits, such as blood lipids,35 insulin secretion,36 and a rare 
autoimmune systemic vasculitis (Takayasu arteritis).37 We failed to identify rare variants for 
ARM in the current study. A GWAS among a small group of ARM patients did not find 
common variants to be associated with ARM either.23 This indicates that major effects of 
rare or common single nucleotide variants as captured by exome- and genome-wide arrays 
do not seem to play a role in the development of ARM. ARM appears to comprise a 
genetically heterogeneous set of malformations, as was also suggested by Wong et al.38 A 
potential hypothesis regarding the etiology is that ARM may only be caused by single-gene 
defects in a, probably small, proportion of patients. Since ARM comprise a wide spectrum of 
phenotypes, several different monogenic forms of ARM may exist. This hypothesis was also 
suggested for congenital abnormalities of the kidney and urinary tract (CAKUT).39 Equally, 
ARM may be a truly multifactorial disorder with involvement of many genetic as well as non-
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genetic risk factors with relatively small effects simultaneously in the majority of patients. 
Support for this scenario derives from findings of several non-genetic factors being 
associated with ARM.15  
In conclusion, the present study among more than 1,000 ARM patients did not yield 
evidence for associations between ARM and rare coding variants with large effect sizes as 
captured by an exome chip. Future studies with even larger sample sizes are needed to 
identify potential common and/or rare genetic variants with small to moderate effects on 
the occurrence of ARM. For these studies, international collaborations are essential. Genetic 
studies in phenotypically homogeneous subgroups of ARM patients may further contribute 
to the elucidation of underlying genetic causes. 
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Supplemental Table 1. Phenotypes of anorectal malformation, additional congenital malformations, 
and gender among patients in the discovery study and the Caucasian replication study. 
 ARM patients 
Discovery studya  
(n=558) 
No. (%) 
ARM patients 
Caucasian replication 
study (n=175) 
No. (%) 
Phenotypes of ARM   
Perineal fistula 242 (43.4) 60 (34.3) 
Vestibular fistula 89 (15.9) 23 (13.1) 
ARM without fistula 29 (5.2) 11 (6.3) 
Rectourethral fistula 
   Bulbar 
   Prostate 
   Unspecified 
 
43 (7.7) 
35 (6.3) 
33 (5.9) 
 
2 (1.1) 
3 (1.7) 
28 (16.0) 
Rectovesical fistula 17 (3.0) 4 (2.3) 
Cloaca 29 (5.2) 5 (2.9) 
Anal stenosis 12 (2.2) 2 (1.1) 
Rare typesb 13 (2.3) 12 (6.9) 
Type unknown 16 (2.9) 25 (14.3) 
Additional major congenital malformations   
Vertebral malformations 86 (15.5) 19 (11.3) 
Cardiac malformations 81 (14.6) 27 (16.1) 
Tracheo-Esophageal atresia 63 (11.4) 18 (10.7) 
Renal malformations 94 (17.0) 31 (18.5) 
Radial limb defects 32 (5.8) 1 (5.4) 
Subgroups of anorectal malformations   
Isolated ARM 301 (53.9) 93 (53.1) 
ARM with other congenital malformations 253 (45.3) 75 (42.9) 
Unknown 4 (0.7) 7 (4.0) 
Gender   
Male 294 (52.7) 89 (50.9) 
Female 264 (47.3) 86 (49.1) 
ARM: anorectal malformations. 
aAll patients in the discovery study were Caucasians. 
bIncluding rectovaginal fistula, rectal atresia, rectal stenosis, dorsal cloaca-like defect with complex H-
fistula. 
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Supplemental Table 4. All statistically significant associations between anorectal malformations and 
genes in the discovery study. 
Gene Number of variants on 
exome chip 
Pa Adjusted Pb 
RP1L1 53 1.82 x 10-160 0.338 
FAM155A 6 5.32 x 10-102 0.343 
MSLN 21 5.05 x 10-95 0.466 
FOXS1 4 2.48 x 10-78 0.473 
PHLPP1 8 2.83 x 10-74 0.083 
KIF26A 21 3.05 x 10-65 0.014c 
LRRC61 3 7.94 x 10-54 0.679 
MAPT-AS1, SPPL2C 22 2.68 x 10-50 0.982 
EXOC3L4 13 2.89 x 10-38 0.056 
COL1A1 9 1.41 x 10-36 0.731 
HECW2 5 7.29 x 10-35 0.607 
NCL 4 7.66 x 10-30 0.166 
IRAK1 4 2.88 x 10-29 1.000 
FUT4 3 4.94 x 10-28 0.231 
PEX11G 6 6.30 x 10-28 0.519 
SIRPA 3 2.03 x 10-27 0.444 
MEGF6 31 1.10 x 10-26 0.368 
KIAA1967 9 4.06 x 10-26 0.337 
ELN 13 9.82 x 10-24 4.04 x 10-5 
SLC12A7 16 1.41 x 10-23 0.588 
LIPC 9 3.13 x 10-23 0.723 
OSBP 2 4.29 x 10-21 0.593 
PYCR1 4 7.33 x 10-21 0.266 
NUDT19 7 1.07 x 10-20 0.310 
TRPM2 30 6.76 x 10-20 0.039 
UTRN 37 4.81 x 10-19 0.206 
TALDO1 5 3.99 x 10-18 0.310 
PODXL 11 8.68 x 10-18 0.044 
FTCD 12 1.04 x 10-17 0.389 
COL11A1 21 4.35 x 10-17 0.477 
CENPC1 5 2.18 x 10-16 0.570 
KLF14 3 1.25 x 10-15 0.377 
KTN1 7 1.90 x 10-15 0.858 
CSMD2, HMGB4 4 2.03 x 10-15 0.295 
SUSD5 13 2.25 x 10-15 0.445 
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Supplemental Table 4. All statistically significant associations between anorectal malformations and 
genes in the discovery study. 
Gene Number of variants on 
exome chip 
Pa Adjusted Pb 
RP1L1 53 1.82 x 10-160 0.338 
FAM155A 6 5.32 x 10-102 0.343 
MSLN 21 5.05 x 10-95 0.466 
FOXS1 4 2.48 x 10-78 0.473 
PHLPP1 8 2.83 x 10-74 0.083 
KIF26A 21 3.05 x 10-65 0.014c 
LRRC61 3 7.94 x 10-54 0.679 
MAPT-AS1, SPPL2C 22 2.68 x 10-50 0.982 
EXOC3L4 13 2.89 x 10-38 0.056 
COL1A1 9 1.41 x 10-36 0.731 
HECW2 5 7.29 x 10-35 0.607 
NCL 4 7.66 x 10-30 0.166 
IRAK1 4 2.88 x 10-29 1.000 
FUT4 3 4.94 x 10-28 0.231 
PEX11G 6 6.30 x 10-28 0.519 
SIRPA 3 2.03 x 10-27 0.444 
MEGF6 31 1.10 x 10-26 0.368 
KIAA1967 9 4.06 x 10-26 0.337 
ELN 13 9.82 x 10-24 4.04 x 10-5 
SLC12A7 16 1.41 x 10-23 0.588 
LIPC 9 3.13 x 10-23 0.723 
OSBP 2 4.29 x 10-21 0.593 
PYCR1 4 7.33 x 10-21 0.266 
NUDT19 7 1.07 x 10-20 0.310 
TRPM2 30 6.76 x 10-20 0.039 
UTRN 37 4.81 x 10-19 0.206 
TALDO1 5 3.99 x 10-18 0.310 
PODXL 11 8.68 x 10-18 0.044 
FTCD 12 1.04 x 10-17 0.389 
COL11A1 21 4.35 x 10-17 0.477 
CENPC1 5 2.18 x 10-16 0.570 
KLF14 3 1.25 x 10-15 0.377 
KTN1 7 1.90 x 10-15 0.858 
CSMD2, HMGB4 4 2.03 x 10-15 0.295 
SUSD5 13 2.25 x 10-15 0.445 
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Gene Number of variants on 
exome chip 
Pa Adjusted Pb 
TAF4 3 2.25 x 10-14 0.637 
GLP2R 7 3.76 x 10-14 0.158 
PITX2 2 6.54 x 10-14 0.592 
PTPRN2 19 6.58 x 10-14 0.684 
PPM1J 9 1.50 x 10-13 0.119 
MYH13 13 3.87 x 10-13 0.686 
MED16 13 4.85 x 10-13 0.696 
HDAC5 7 8.09 x 10-13 0.003 
CLCN1 11 9.07 x 10-13 0.778 
PDZRN4 16 1.47 x 10-12 0.150 
QRFP 5 3.61 x 10-12 0.157 
C6orf120 2 4.43 x 10-12 0.347 
NLRP8 24 5.37 x 10-12 0.425 
PKP3 13 5.94 x 10-12 0.949 
FGFR4 8 6.51 x 10-12 0.231 
CALHM1 6 7.17 x 10-12 0.235 
PAX7 3 9.68 x 10-11 0.724 
C5orf25 3 1.46 x 10-10 0.590 
LEFTY2 2 1.70 x 10-10 0.590 
JRK 12 3.50 x 10-10 0.458 
ABHD10 5 3.86 x 10-10 0.770 
ABCA7 32 6.36 x 10-10 0.024 
RTEL1, RTEL1-
TNFRSF6B 
24 1.64 x 10-9 0.213 
MUC6 28 2.04 x 10-9 0.916 
CACNA1I 9 4.67 x 10-9 0.133 
WAC 5 2.66 x 10-8 0.884 
PTRF 6 3.67 x 10-8 0.309 
MRPL44 3 4.46 x 10-8 0.360 
WDR41 9 5.13 x 10-8 0.686 
PRSS57 5 6.33 x 10-8 0.488 
WDR74 3 7.99 x 10-8 0.588 
ZNF423 13 8.22 x 10-8 0.739 
AVIL 11 8.65 x 10-8 0.430 
CAND2 27 1.32 x 10-7 0.005 
NPTX1 2 1.62 x 10-7 0.107 
VWDE 34 1.81 x 10-7 0.190 
231 
Gene Number of variants on 
exome chip 
Pa Adjusted Pb 
PVR 10 2.01 x 10-7 0.011 
BMP6 5 2.21 x 10-7 0.293 
VPS4A 3 2.77 x 10-7 0.695 
TRMT1 5 3.23 x 10-7 0.492 
FASN 27 3.25 x 10-7 0.017 
TBCC 8 3.67 x 10-7 0.241 
TMEM201 6 4.01 x 10-7 0.021 
MGAT3 5 4.14 x 10-7 0.409 
MSI2 4 4.40 x 10-7 0.351 
CRHR2 7 6.67 x 10-7 0.381 
OSBPL6 6 1.02 x 10-6 0.117 
MAN1C1 5 1.70 x 10-6 0.482 
ZNF507 5 2.28 x 10-6 0.644 
GAS6 12 3.20 x 10-6 0.206 
PAX1 4 3.24 x 10-6 0.689 
aP value based on SKAT analyses. 
bP value after adjustment for the allele count of the most statistically significant variant in the single 
variant analyses. 
cP value adjusted for the two variants in the KIF26A gene (exm1130982 and exm1131059) that were 
found to be statistically significant in the single variant analyses. 
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Supplemental Figure 1. The first two principal components obtained by multidimensional scaling 
analysis for controls (black), anorectal malformation patients AGORA (red), anorectal malformation 
patients CURE-Net (green). 
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Supplemental Figure 1. The first two principal components obtained by multidimensional scaling 
analysis for controls (black), anorectal malformation patients AGORA (red), anorectal malformation 
patients CURE-Net (green). 
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Supplemental Figure 2. Quantile-quantile (QQ) plot for the unadjusted single variant analyses on 
anorectal malformations in the discovery study (allelic effects) before (blue) and after (black) 
removing identified variants. The red line represents the null hypothesis of no association. Genomic 
control inflation factor was: λ = 1.066. 
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Supplemental Figure 2. Quantile-quantile (QQ) plot for the unadjusted single variant analyses on 
anorectal malformations in the discovery study (allelic effects) before (blue) and after (black) 
removing identified variants. The red line represents the null hypothesis of no association. Genomic 
control inflation factor was: λ = 1.066. 
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This thesis presents the results of our research project with the main aim to obtain more 
knowledge on the involvement of genetic and non-genetic risk factors in the etiology of 
congenital anorectal malformations (ARM). Etiologic research into ARM received relatively 
little scientific attention in the past decades, particularly genetic research on ARM. We 
performed several case-control studies on potential non-genetic risk factors using parental 
questionnaire and registry-based data. The main findings from these studies are summarized 
in Table 1. In addition, we were the first to study the assumed role of a gene-environment 
interaction in the development of ARM, and we performed an exome chip association study 
on rare variants in the by far largest sample of ARM cases described in genetic studies on 
this congenital malformation so far. However, no evidence was found for associations 
between ARM and rare genetic variants with large effect sizes captured by the Illumina 
Human Exome BeadChip in this study. Before we will further discuss our findings in light of 
the objectives and the existing literature, some methodological issues will be addressed. 
Thereafter, we will provide directions for future research and consider the clinical 
implications. 
 
Table 1. Main findings from studies on non-genetic risk factors for anorectal malformations. 
Potential risk factor Association with anorectal malformations? 
Our studies Other studies Global conclusion 
Fertility-related factors    
   Parental subfertility without treatment + NI (+) 
   ICSI or IVF treatment + + + 
   Hormonal treatment +/- +/- +/- 
   Other reproductive treatments (-) NI (-) 
Pregnancy-related factors    
   Nulliparity +/- +/- +/- 
   Multiple pregnancy + + + 
   Maternal overweight or obesity + + + 
   Maternal epilepsy + NI (+) 
   Fever during first trimester + NI (+) 
   Preeclampsia + (+) (+) 
Lifestyle factors    
   Maternal folic acid supplement use - +/- (-) 
   Paternal smoking +/- (-) +/- 
   Parental job exposures + (+) (+) 
+ positive association; (+) possible association; - no association; (-) probably no association; +/- inconsis-
tent findings; NI not investigated 
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Methodological issues 
Study design 
All studies on potential risk factors described in this thesis were based on case-control 
designs with retrospectively collected data. Compared to randomized controlled trials, the 
paradigm of epidemiologic study designs, this observational design provides lesser amounts 
of evidence for causal inferences based on the study results. However, it is a very commonly 
used design that has proven to be efficient to assess associations between exposures and 
outcome, particularly when the outcome under study is rare, as is the case for ARM. Several 
potential biases may be associated with observational studies, mainly related to the 
recruitment of the study participants and the methods of data collection. These issues are 
addressed below. 
 
Study populations 
The recruitment of cases and/or controls is an important step both in studying prevalence 
rates and in designing case-control studies. The ARM cases studied within the realm of this 
thesis were mainly derived from AGORA and/or CURE-Net in The Netherlands and Germany, 
respectively. A major strength of these data sources was that cases were well-characterized 
as they were reviewed by experienced clinical geneticists, pediatric surgeons, and ARM 
researchers. The detailed case characterization enabled us to calculate prevalence rates of 
different ARM phenotypes and associated congenital malformations. These prevalence rates 
partly depend on the inclusion and exclusion criteria for the cases, as was reflected in the 
studies described in this thesis. We included live born cases without chromosomal 
abnormalities or known genetic syndromes in most studies (Chapters 3, 7, 8, 9 and 10), 
whereas live born and stillborn cases and induced abortions without chromosomal 
abnormalities or known genetic syndromes were included in the European Surveillance of 
Congenital Anomalies (EUROCAT) study (Chapter 6), and live born cases including those with 
chromosomal abnormalities or known genetic syndromes in the ARM-NET study (Chapter 4). 
Consequently, the prevalence of associated congenital malformations ranged between 39% 
and 55% in the first-mentioned studies, whereas it was 64% in the EUROCAT study and 72% 
in the ARM-NET study. Therefore, we need to be aware of potential differences in 
prevalence rates, due to variation in the inclusion and exclusion criteria for the cases. The 
consequences of the inclusion of live born cases only need to be considered in studies on 
potential risk factors for ARM as well. Isolated ARM is seldom fatal as more than 99% of the 
isolated ARM cases were found to be live born.1 In addition, terminations of pregnancy 
among fetuses with isolated ARM are scarce as ARM can hardly be diagnosed prenatally.2 
Therefore, the potential for selection due to the inclusion of live born participants only is 
245 
limited in analyses on isolated ARM. In contrast, stillbirth and induced abortion rates are 
higher for ARM with multiple congenital malformations, because of severe associated birth 
defects. Therefore, the results for ARM with other defects may be underestimated when 
stillbirth and/or induced abortion rates are higher among cases exposed to the determinant 
under study compared to non-exposed cases. In our studies, this may be the case for couples 
who underwent ICSI or IVF treatment or for mothers with pre-existing diabetes mellitus as 
they may have been offered prenatal screening more easily than other couples. 
Three types of controls were used in our studies on non-genetic risk factors, including 
malformed controls with chromosomal or known genetic syndromes (‘genetic controls’) 
(Chapter 6), hospital-based controls with otitis media with effusion (Chapters 3 and 7) and 
population-based controls (Chapters 8, 9 and 10). ‘Genetic’ or hospital-based controls are 
often used to reduce selective non-response and the potential for recall bias in studies on 
non-genetic risk factors. Recall bias occurs when the parents of cases and controls 
remember or report certain exposures differently, which may lead to differential 
misclassification in population-based studies. On the other hand, selection could be 
introduced in hospital-based studies when certain exposures are positively or negatively 
associated with the disorder of the controls, leading to underestimation or overestimation of 
the risk estimates, respectively. This problem was avoided in our studies using the 
population-based control group established especially for these ARM studies and for future 
studies within the AGORA data- and biobank. A limitation of this control group is, however, 
that the parents on average seem to be somewhat higher educated than the general Dutch 
population, probably due to lower response rates among low-educated parents. Therefore, 
maternal education was included as potential confounder in the multivariable regression 
analyses. The potential for recall bias cannot fully be excluded, although many potential risk 
factors studied do not seem to be prone to recall bias (e.g. fertility treatment and chronic 
diseases) and recall bias appears to be overrated in this area of research.3 So next to 
practical reasons, the choice for the most suitable control group in non-genetic studies may 
depend on the potential risk factor under study. We consider malformed or hospital-based 
controls appropriate only if the risk factor is prone to recall bias and is not associated with 
the control disorder, whereas population-based controls are preferred in all other situations, 
if chosen accurately. Ideally, the control population represents the geographical area and 
age distribution of the source population of the cases to minimize bias due to geographical 
or generational effects. We consider this to be achieved for all three control populations 
used in our studies. 
The selection of cases and controls in similar geographical areas is also essential to 
limit bias due to population stratification in genetic association studies. This form of 
11
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used in our studies. 
The selection of cases and controls in similar geographical areas is also essential to 
limit bias due to population stratification in genetic association studies. This form of 
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selection bias arises when differences in the allele frequencies of the genetic variants 
between cases and controls are due to systematic ancestry differences rather than real 
associations between the genetic variants and the disorder under study. We attempted to 
reduce this kind of bias by selecting or performing subanalyses on cases and controls of 
European ancestry only in our genetic associations studies (Chapters 9 and 10). In addition, 
we performed multidimensional scaling analyses in order to exclude population outliers in 
the exome chip association study (Chapter 10). Therefore, this kind of bias seems to be 
limited in our studies. 
 
Data collection 
Information on potential non-genetic risk factors for ARM was obtained using self-
administered parental questionnaires (Chapters 3, 7, 8 and 9) and register-based data 
(Chapter 6). Of these two methods, we consider retrospective data collection by means of 
parental questionnaires the superior approach because of the efficient way of collecting a 
large amount of data. More importantly, we were able to collect detailed information on 
important issues and information on timing of exposure to a wide range of potential risk 
factors, whereas only a limited amount of relevant information is usually available in 
register-based studies,4 such as EUROCAT. A disadvantage of questionnaire data may be the 
potential for differential misclassification due to recall bias, as discussed in the previous 
paragraph. We expect non-differential misclassification due to recall problems in parents of 
both cases and controls, however, to be more likely and to have led to underestimation of 
the results. Recall errors seem to be less of a problem in our study using register-based data, 
because information on exposure was mainly recorded from already existing hospital 
sources. Although more timely and detailed data can be collected and recall problems are 
negligible in prospective cohort studies, this design is not suited for studies on ARM as it 
would be far too expensive and time-consuming to collect data for a sufficient number of 
cases.  
Data on genetic variants were obtained through genotyping of case and control DNA 
samples (Chapters 9 and 10). Genotyping with the Illumina Human Exome BeadChip and 
calling (using zCall software) of the rare variants in the discovery phase of our exome chip 
association study were challenging procedures because of the innovative nature of this chip. 
Several rare variants were found to be associated with ARM. The case samples were re-
genotyped for the variants identified in a validation study using targeted resequencing with 
the molecular inversion probe (MIP) technique. This validation study appeared to be an 
important step in our study, as many heterozygous calls for the associated variants in the 
exome chip data were not confirmed in the validation study, and neither were the 
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associations between ARM and these variants. The separate genotyping and calling of case 
and control samples in the discovery study possibly caused differential misclassification of 
genotypes. This may have resulted in overestimation of positive allele frequency differences 
between cases and controls. We elaborated further on this issue in Chapter 10. 
 
Our findings in light of the objectives and the existing literature 
 
1. To increase knowledge on definitions and prevalence of ARM phenotypes and 
associated congenital malformations 
 
In the past decades, different international classification systems for ARM were proposed to 
define ARM phenotypes. We consider the comprehensive Krickenbeck classification to be 
the most useful system, just like the majority of pediatric surgeons and other medical 
professionals (Chapter 4).5 The WHO International Classification of Diseases (ICD) and the 
Human Phenotype Ontology (HPO), however, do not follow the Krickenbeck criteria and 
their classifications for ARM are far from comprehensive. As several studies, such as the 
EUROCAT study (Chapter 6), are based on ICD codes, comparisons between studies 
concerning ARM phenotypes are difficult or even impossible. In addition, a harmonized 
diagnostic classification system for the VACTERL (Vertebral, Anal, Cardiac, Tracheo-
Esophageal, Renal and Limb defects) association is still lacking but warranted, as we stressed 
in Chapter 5. Genetic and/or epidemiological evidence for certain risk factors in specific 
VACTERL phenotypes will probably help to define inclusion criteria for clinical features 
involved in VACTERL. Recent studies found indications for genetic aberrations in VACTERL 
cases,6-9 but a major contributing factor is not identified yet. 
The prevalences of ARM phenotypes and associated congenital malformations were 
assessed in several studies in this thesis, which add information to the existing literature.10-12 
Perineal fistula is the most commonly occurring ARM phenotype. Overall, the percentage of 
perineal fistula is higher in isolated ARM than in ARM with other congenital malformations. 
On the other hand, the more complex phenotypes, such as rectourethral fistula or cloaca, 
are more common among ARM with other defects compared to isolated ARM. The same 
pattern was observed among ARM cases treated in the Radboudumc between 1974 and 
1995, although these cases were not completely classified according to the Krickenbeck 
criteria.10 Comparisons with some other studies are impossible as less detailed classification 
systems were used.11-13 In addition, the occurrence of associated congenital malformations 
in ARM cases also differed substantially among our studies, mainly due to differences in the 
inclusion and exclusion of cases as described above. Associated malformations were mostly 
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congenital malformations that are described in the VACTERL association. The ARM-NET 
consortium represents a valuable resource of ARM cases as multiple centers in several 
European countries are involved (Chapter 4). However, 72% of the cases within the ARM-
NET register having other congenital malformations seems relatively high. A possible 
explanation would be that cases with only minor additional malformations were also 
classified as ARM with other congenital malformations, whereas these cases were classified 
as isolated ARM in most other studies. On the other hand, this relatively high proportion of 
ARM cases with other congenital malformations may be a consequence of referral of more 
complex cases to some of the participating centers within ARM-NET.  
 
2. To study a wide range of potential non-genetic risk factors for ARM 
 
The role of several potential non-genetic risk factors in the etiology of ARM was summarized 
in our systematic review (Chapter 2) and investigated in a number of studies described in 
this thesis (see Table 1). Strong indications for fertility-related factors increasing the risk of 
ARM were found in our studies (Chapters 6, 7 and 8) and in the existing literature.14-17 
Although ICSI/IVF treatment in particular was found to be associated with ARM, this was not 
the case in the EUROCAT study (Chapter 6). However, we consider the evidence for a 
positive association between ICSI/IVF treatment and ARM to be stronger than the evidence 
for a lack of association, because four out of five other studies on ARM identified relatively 
strong associations with ICSI/IVF treatment as well.14-18 The reasons for the negative finding 
in the EUROCAT study may be: 1) the use of ‘genetic controls’, which may have resulted in 
underestimated risk estimates, as associations have previously been found between ICSI/IVF 
treatment and chromosomal abnormalities,19 and 2) the low power to identify this 
underestimated risk as the numbers of case and control parents who underwent ICSI or IVF 
treatment were low in the EUROCAT database. Interestingly, we observed that the 
association between ARM and ICSI or IVF treatment remained when subfertile parents who 
conceived without treatment were used as the reference group (Chapter 8). This suggests 
that ICSI or IVF treatment plays a role above the possible effect of the underlying parental 
subfertility. However, confounding by indication cannot be excluded as subfertile parents 
who conceived after ICSI or IVF may be more severely subfertile than those who conceived 
without treatment. Therefore, we expect both parental subfertility and ICSI or IVF treatment 
to be involved in the etiology of ARM. This was confirmed by the finding that parental 
subfertility without treatment was associated with ARM with additional congenital 
malformations. Underlying disturbed epigenetic mechanisms may explain the involvement 
of parental subfertility, mainly male subfertility, and ICSI/IVF treatment in the etiology of 
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ARM. Epigenetic modifications refer to changes in DNA that occur through other 
modifications than variation in the DNA sequence. Children conceived through ICSI/IVF 
treatment were found to have altered DNA methylation levels in imprinted genes and an 
increased risk of imprinting disorders compared to children conceived spontaneously.20 
Novel findings were the relatively strong associations between ARM and maternal 
fever during the first trimester of pregnancy (Chapters 3, 6, and 7) and maternal epilepsy 
during pregnancy (Chapter 6), which need further clarification. Preeclampsia was found to 
be associated with ARM with other congenital malformations in particular. Although 
preeclampsia arises after the relevant time window for hindgut development, it may be a 
consequence of dysfunction of the placenta in early pregnancy, a condition in which the 
nutrient and hormone supply to the embryo may be insufficient. The associations with low 
birth weight, preterm delivery, and multiple pregnancy, as well as a possible association with 
nulliparity, also suggest a potential role for placental dysfunction in early pregnancy. We 
found the association with multiple pregnancy for ARM with other congenital 
malformations, but not for isolated ARM (Chapter 6). Furthermore, mean weight of the 
placenta was found to be significantly lower for ARM with other congenital malformations 
compared to controls, but not for isolated ARM compared to controls.12 These studies 
support the hypothesis that placental dysfunction is involved in the etiology of ARM with 
other congenital malformations.  
Several studies, including ours, showed increased risks of having a child with ARM for 
mothers with overweight or obesity and for mothers with pre-existing diabetes mellitus.21-26 
We studied pre-existing diabetes mellitus in the EUROCAT study only (Chapter 6), and did 
not identify an association in relatively small numbers of case mothers with pre-existing 
diabetes. However, the characteristics of the study population in Chapters 8 en 9 showed 
higher rates of pre-existing diabetes among case mothers than among control mothers. 
Hyperglycemia or poor glycemic control in diabetic mothers as well as in overweight or 
obese mothers may explain the increased risks of ARM.   
This thesis provided less evidence for a role of parental lifestyle factors in the etiology 
of ARM. Although maternal folic acid supplement use turned out to be effective in the 
prevention of neural tube defects, a major role in the prevention of ARM can be excluded 
based on the results in Chapter 9 and other studies.24,27-29 These studies did not observe 
associations with folic acid supplement use either, or found marginal effects only. 
Furthermore, inconsistent results or non-specific findings were observed for ARM and 
paternal smoking or various parental occupational exposures.  
Overall, the effects of non-genetic risk factors were more pronounced in ARM cases 
with other major congenital malformations than in isolated ARM cases. Possibly, these risk 
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factors are not unique for ARM, but result in other congenital malformations as well. In 
addition, ARM cases with other congenital malformations frequently suffer from more 
complex ARM phenotypes, such as rectourethral fistulas or persistent cloaca, as discussed 
above. Therefore, another explanation for associations being observed in ARM cases with 
other malformations in particular may be that non-genetic factors have stronger effects in 
more complex forms of ARM than in mild forms of ARM. 
 
3. To identify a potential gene-environment interaction and rare genetic variants that 
contribute to the development of ARM 
 
We were the first to study the role of a single nucleotide polymorphism (SNP) in the MTHFR 
gene (MTHFR C677T) and its interaction with maternal folic acid supplement use in the 
etiology of ARM. The MTHFR C677T polymorphism leads to decreased enzyme activity and 
consequently to reduced folate levels, while folate is essential for cell division and gene 
expression during embryogenesis. Elevated risks of neural tube defects, orofacial clefts, and 
congenital heart defects among mothers with the polymorphism and a lack of folic acid 
supplement use were reported before,30-32 but an important role in the etiology of ARM 
does not exist for this polymorphism and its gene-environment interaction with folic acid 
supplements. We elaborated on potential reasons for this finding in Chapter 9. 
 Our systematic review (Chapter 2) showed that knowledge about the involvement of 
genetic factors in the etiology of ARM is scarce. Previous genetic studies on ARM were 
mainly focused on candidate genes involved in embryonic signaling pathways, but did not 
yield any substantial evidence. No common genetic variants were identified in the first and 
only small genome-wide association study,33 and neither were common copy number 
variants (CNVs). The study did, however, identify a role for many different rare CNVs in 
individual isolated ARM cases, which were not found in controls. To identify rare genetic 
variants, we used a hypothesis-free approach studying 242,901 exome-wide rare variants 
with the Illumina Human Exome BeadChip. Fifty-five rare coding variants were found to be 
associated with ARM in the discovery study. Three of these variants were validated in the 
same ARM cases using the MIP validation study. However, replication analyses in new 
Caucasian and Han Chinese replication samples of cases and controls did not confirm these 
variants as being associated with ARM. Therefore, major single rare or common variants 
captured by genome- and exome-wide arrays do not seem to play a role in the development 
of ARM on the population level. However, genetic variants occurring in small numbers of 
cases and variants with moderate or small effects could still play a role, as our power was 
probably insufficient to identify these. The genetic etiology of ARM seems to be 
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heterogeneous, as was also suggested previously.33 In Chapter 10, we considered the 
contribution of both monogenic and multifactorial forms of ARM. As ARM comprise a wide 
spectrum of phenotypes, several etiologic mechanisms and pathways may be involved. 
Finally, both our genetic and non-genetic studies showed the importance of 
international collaborations to increase the power to detect potential contributors to the 
etiology of ARM, to be able to differentiate between ARM phenotypes in the analyses, and 
to replicate results in other patient cohorts. This was also emphasized in Chapter 3.  
 
Conclusions 
In conclusion, this thesis shows strong indications for associations between ARM and non-
genetic factors, such as ICSI or IVF treatment, maternal fever during the first trimester of 
pregnancy, and maternal overweight or obesity. The underlying parental subfertility or 
maternal infection, however, could also play a role. In contrast, maternal folic acid 
supplement use or its interaction with the MTHFR C677T polymorphism does not have a 
major role in the etiology of ARM, while the potential role of placental insufficiency needs 
further elucidation. Rare variants with large effect sizes captured by the Illumina Human 
Exome BeadChip do not seem to be involved in the occurrence of ARM. As ARM are most 
likely a genetically heterogeneous set of malformations, monogenic as well as multifactorial 
forms need to be investigated in future studies. 
 
Opportunities for future research 
The findings in this thesis provide several directions for future research to increase our 
knowledge on the underlying biological mechanisms in the development of ARM. Major 
efforts have been done to collect questionnaire and clinical data and DNA samples of large 
numbers of ARM cases and population-based controls and their parents within AGORA and 
ARM-NET. This represents a valuable resource for new research opportunities for ARM. 
 
Non-genetic studies 
To investigate our hypothesis that disturbed epigenetic processes may be an explanation for 
the associations of ARM with parental subfertility and ICSI or IVF treatment, studies on DNA 
methylation patterns may be valuable. We suggest to assess whether DNA methylation 
levels are disturbed (hyper- versus hypomethylation) in some genes using a candidate-gene 
approach or a genome-wide methylation assay on DNA samples of cases and controls who 
were conceived either with or without ICSI/IVF treatment, also taking into account the 
fertility status of the parents.  
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The effects of maternal fever and maternal epilepsy during the first part of pregnancy 
need to be disentangled from potential effects of maternal infection and/or drug use (e.g. 
antibiotic, anti-inflammatory or antiepileptic drugs) on the development of ARM. 
Clarification may come from future studies that, for example, differentiate the risks for 
mothers with fever or epilepsy between those who did and did not use medication. As the 
prevalences of these exposures are relatively low, large sample sizes are essential in case-
control studies with collection of detailed information on these risk factors and other 
potential teratogenic drugs, for which knowledge on their role in the etiology of ARM is 
limited. Information on medical drug use during pregnancy was collected using the maternal 
AGORA questionnaire, but a previous study showed that, depending on the type of medical 
drug, maternal recall of prescriptive drug use was moderate to poor using this retrospective 
questionnaire.34 Probably, more valid results can be obtained by linking AGORA data to 
Dutch pharmacy registers, a study that will be undertaken in the future.  
The association between ARM and preeclampsia also needs confirmation in future 
studies, which should also include chronic hypertension, as Bánhidy et al.35 found an 
association between ARM and preeclampsia superimposed on chronic hypertension in a 
relatively small study sample. Future studies may also clarify the possible role for placental 
dysfunction in early pregnancy in the etiology of ARM with other congenital malformations, 
as they have for hypospadias.36,37 As only indirect indications exist so far, an initial step may 
be to evaluate potential placental pathologies, such as abnormal size, weight or thickness of 
the placenta, infarction, and/or calcifications,38 in a group of placentas of ARM cases with 
other congenital malformations and healthy controls. In addition, low levels of Human 
Chorionic Gonadotropin (HCG) measured in the first 9-10 weeks of pregnancy may 
emphasize the role of placental dysfunction early in pregnancy.39-41 
Furthermore, the role of parental life style and occupational factors could be 
evaluated in more detail. The distribution of Food Frequency Questionnaires (FFQs) among 
mothers of cases and controls is planned for the near future, to evaluate possible 
associations between ARM and maternal intake of nutrients and vitamins during the first 
part of pregnancy. Two previous studies showed the value of etiologic research using FFQs. 
In these studies, a higher dietary glycemic index was found among ARM case mothers 
compared to control mothers without diabetes mellitus, which supports the role of maternal 
hyperglycemia in the etiology of ARM.42,43 As basic information on the occupation of both 
parents has already been collected in AGORA, one or more Job Exposure Matrices (JEMs) 
could be applied to study the role of parental occupational exposure in the etiology of ARM. 
For example, the JEM that was developed by our research group some years ago44 may be 
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used to assess the effects of occupational exposures to endocrine disruptors on the 
development of ARM. 
The majority of the studies mentioned above may be performed using the already 
collected data on ARM cases and population-based controls within AGORA, which will be 
extended with additional data from Dutch pharmacy registers and FFQs. In addition, new 
ARM cases will be recruited through continuous data collection within AGORA and ARM-NET 
and from other university medical centers in The Netherlands to increase the power of these 
future studies. 
 
Genetic studies 
Both monogenic and multifactorial forms of ARM need to be considered in future genetic 
studies. Exome and whole genome sequencing seem promising techniques to study small 
homogeneous groups of cases to identify genetic variants that may cause ARM in some of 
these patients. These groups should comprise selected cases, such as familial ARM cases, 
males with perineal fistula behind a bucket-handle, or females with a cloaca or an isolated 
vestibular fistula. To evaluate whether de novo mutations are involved in the occurrence of 
ARM, these techniques may be applied to case-parent triads. In addition, targeted 
resequencing using the MIP technique that we used in the study described in Chapter 10 for 
validation and replication of single variants seems very promising for sequencing of multiple 
candidate genes. This is currently being done for both ARM and VACTERL in one experiment 
within the Radboud university medical center. This experiment may yield causal variants in 
candidate genes that may explain the occurrence of ARM in a small part of the patients.  
For ARM cases in whom no single gene seems to play a causal role, many common 
and rare variants with moderate or small effects in combination with non-genetic factors 
may contribute to the occurrence of ARM. Additional genome-wide screening procedures 
will be needed to investigate the contribution of these potential genetic risk factors. The 
only genome-wide association study (GWAS) on ARM did not yield any common SNPs that 
were associated with ARM.33 As this study was performed among 175 cases only and used a 
relatively low-density array containing approximately 500,000 SNPs, it seems promising to 
perform another GWAS in our larger patient series using a newer array containing at least 
1,000,000 SNPs. Furthermore, the genotyping data of the Illumina Human Exome BeadChip 
(Chapter 10) may also be used to perform future analyses, such as pathway association 
analyses and repeated analyses using larger sample sizes with additional data of new ARM 
cases. Before that, however, it is essential to repeat the calling procedure for all cases and 
controls combined to reduce the potential for batch effects.45 New technologies, such as 
exome or whole genome sequencing, will create even more data, but these methods are not 
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yet feasible in large cohorts of cases and controls due to the high costs and the need for 
large processing capacity.  
Expression studies and functional studies will be needed to further evaluate genetic 
variants that may be discovered in the studies suggested above. Additional evidence for the 
involvement of these genes in the development of ARM may be derived from expression 
studies in human anorectal tissue or hindgut tissue of animal embryos with ARM. Functional 
studies in animal models may also add knowledge about the function of specific genes and 
about the involvement of potential pathways. A few animal models for ARM have been 
reported, such as retinoic acid induced ARM in mice,46 ethylenethiourea induced ARM in 
rats,47 and Danforth's short tail mice.48  
 
Clinical implications 
The most commonly asked questions of parents with a child with ARM are: ‘What is the 
diagnosis?’, ‘What is the best treatment and clinical care for my child?’, ‘What is the 
recurrence risk in future pregnancies?’, ‘What is the cause?’ and ‘What can I or anybody do 
to prevent having a child with ARM?’. Therefore, the ultimate objectives of research on ARM 
are to improve diagnostics, clinical care, outcome, and quality of life, to better guide parents 
of a child with ARM or couples with a child wish regarding their future pregnancies, and to 
develop preventive measures for ARM.  
In the coming years, registration of ARM patients in the ARM-NET registry will 
continue and several new centers within Europe will join ARM-NET or already joined 
recently. One of the major aims of the ARM-NET consortium is to provide better clinical care 
and outcome assessment, as several aspects of treatment and management of ARM patients 
are still debated among pediatric surgeons and health care professionals. This ARM-NET 
registry is a valuable basis for discussions on harmonized diagnostic classifications and the 
best treatment options for specific phenotypes, which may lead to improvement of the 
management of patients with ARM. 
To improve guidance of parents who have a child with ARM regarding future 
pregnancies, it is essential to provide knowledge about the recurrence risk of ARM. For 
parents who have a child with a syndromic form of ARM, such as the autosomal dominant 
Townes-Brocks syndrome, the recurrence risk can be up to 50%. For parents who have a 
child with ARM without a chromosomal abnormality or known genetic syndrome, the 
recurrence risk is much lower and estimated to be 1-2%. Results from future genetic studies 
may provide more precise estimations for individual patients and their parents.  
Couples who conceived after ICSI/IVF treatment, diabetic mothers, and mothers with 
overweight or obesity were consistently found to have an increased risk of having a child 
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with ARM. These ‘higher risk groups’ should be guided and informed about the potential 
risks before conception, although absolute risks are low and future studies are still needed 
to unravel the underlying mechanisms. The risk estimates that were found in this thesis were 
presented as odds ratios, which can be interpreted as relative risks since ARM is a rare 
anomaly. Assuming an odds ratio of 2.5 for the above-mentioned risk factors, the absolute 
risk of having a child with ARM for these couples changes from 0.03% (1 in 3000) to 0.08% (1 
in 1200). Previous studies, however, showed that the above-mentioned risk factors are not 
unique for ARM, but increase the risk of other congenital malformations as well.15,22,23,49 This 
also needs to be considered when guiding couples regarding future pregnancies.  
The implication of these risk factors at the population level depends on the 
prevalence of a given risk factor. The population attributable fraction (PAF) presents the 
proportion of cases in a population that are affected due to the risk factor under study and 
can be calculated as follows: PAF = p*(OR − 1) / (p*(OR–1) +1). Assuming ORs of 2.5 and a 
prevalence of 2% for ICSI or IVF treatment versus 6% for maternal obesity, the PAFs are 3% 
and 8%, respectively. The latter suggests that 8% of the ARM cases could be prevented if 
maternal obesity would be ruled out completely.  
Effective preventive measures, such as folic acid supplementation to prevent neural 
tube defects, do not seem to be available for the prevention of ARM yet, but the increased 
knowledge about the etiology of ARM provided within this thesis may be a first step to 
better guide couples with a child wish and the parents of patients with ARM. 
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Summary 
 
Congenital anorectal malformations (ARM) are defects in the development of the anus and 
the rectum, which occur in approximately 1 per 3,000 live births worldwide. One or more 
additional major congenital malformations are present in 40 to 70% of the ARM patients, 
mostly malformations of the VACTERL (Vertebral, Anal, Cardiac, Tracheo-Esophageal, Renal, 
and Limb defects) association. Multiple surgical procedures are usually required in the first 
years of a patient’s life to restore bowel function. Nevertheless, this disorder often accounts 
for substantial lifelong psychosocial and physical problems, such as constipation, fecal 
soiling, and sexual problems. Because of these problems, primary prevention of ARM is 
needed, but this requires extensive knowledge about the etiology of ARM. Therefore, the 
main objective of this thesis is to obtain more insight into the contribution of genetic and 
non-genetic risk factors to the occurrence of ARM. 
 
Part 1: Introduction, prevalence, and definitions 
After a brief general introduction in Chapter 1, we present an extensive systematic review of 
the existing literature about the genetic and non-genetic etiology of ARM in Chapter 2. 
Assisted reproductive techniques, multiple pregnancy, preterm delivery, low birth weight, 
maternal overweight or obesity, and pre-existing diabetes were consistently found to be 
associated with ARM. Furthermore, we showed that human research into the genetic 
etiology of ARM is remarkably scarce and that most studies were based on a candidate-gene 
approach. Although animal studies demonstrated the contribution of genes or targets in 
embryonic signaling pathways, such as the sonic hedgehog, wingless-type integration site, 
fibroblast growth factor, and bone morphogenetic protein signaling pathways, human 
studies did not provide substantial evidence for the involvement of genes in these pathways 
in the etiology of ARM. The first small genome-wide association study (GWAS) on ARM did 
not yield any single nucleotide polymorphisms (SNPs) or common copy number variants 
(CNVs), but did identify many different rare CNVs in individual isolated ARM cases, which 
were not found in controls. We concluded that large cohorts of ARM patients from 
international collaborations are needed to conduct future genetic studies with hypothesis-
generating approaches, such as GWAS to elucidate the role of common variants and exome 
or whole genome sequencing to study rare variants.  
To this end, the ARM-NET consortium described in Chapter 3 was established, with 
involvement of clinical geneticists, epidemiologists, pediatric surgeons, and members of 
patient organizations within Europe. Chapter 4 presents the first results on the prevalence of 
ARM phenotypes, additional congenital malformations, and surgical procedures within the 
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ARM-NET consortium among 203 ARM patients. Perineal fistula was the most prevalent 
ARM phenotype and 72% of the ARM cases had at least one additional major congenital 
malformation. In Chapter 5, we stressed the importance of a harmonized diagnostic 
classification system for the VACTERL association, which often includes ARM, to improve 
treatment and follow-up of VACTERL patients.  
 
Part 2: Non-genetic factors 
Chapter 6 describes the results of a register-based case-control study on pregnancy-related 
risk factors of ARM using data from 17 registries of the European Surveillance of Congenital 
Anomalies (EUROCAT). In this relatively large study, maternal epilepsy, fertility treatment, 
multiple pregnancy, primiparity, preeclampsia, and maternal fever during pregnancy were 
identified as potential risk factors for ARM, primarily for ARM with additional major 
congenital malformations. It remained unclear, however, whether epilepsy, fertility treat-
ment, and fever themselves play a role in the etiology of ARM or the pharmacological 
treatment or underlying disorders, such as parental subfertility and maternal infection. The 
associations between ARM and multiple pregnancy, primiparity, and preeclampsia may 
reflect situations of placental dysfunction in early pregnancy, which may result in insufficient 
supply of nutrients and hormones to the fetus.  
In Chapter 7, a wide range of potential maternal and paternal risk factors for ARM 
was evaluated using case-control data from the AGORA (Aetiologic research into Genetic and 
Occupational/environmental Risk factors for Anomalies in children) data- and biobank. This 
small study revealed indications that the risk of ARM was increased with a family history of 
ARM, maternal fever during the first trimester of pregnancy, maternal overweight, maternal 
multivitamin use, paternal smoking, and parental occupational exposures. No associations 
were observed between ARM and most lifestyle factors, such as folic acid supplement use, 
maternal smoking, and maternal and paternal alcohol use. 
The role of parental subfertility and a range of fertility treatments in the etiology of 
ARM was studied in more detail in a larger AGORA study population in Chapter 8. We did not 
find associations between ARM and hormonal treatment for ovulation induction or 
intrauterine insemination. However, for parents who conceived after intracytoplasmic sperm 
injection (ICSI) or in vitro fertilization (IVF) treatment, an increased risk of having a child with 
ARM was identified compared to fertile parents. The risk of ARM was also elevated when 
parents who underwent ICSI or IVF were compared to subfertile parents who conceived 
without treatment. Parental subfertility without treatment was only associated with ARM 
with additional congenital malformations. As these associations may be confounded by 
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indication, we concluded that both ICSI or IVF treatment and the underlying parental 
subfertility play a role in the etiology of ARM.  
 
Part 3: Genetic factors and gene-environment interaction 
Independent associations and interactions of maternal periconceptional folic acid 
supplement use and infant and maternal MTHFR (methylenetetrahydrofolate reductase) 
C677T polymorphisms with the risk of ARM were investigated in Chapter 9. Infant and 
maternal MTHFR C677T polymorphisms were only weakly associated with ARM, while no 
association was observed between ARM and maternal folic acid supplement use. No 
evidence was provided for a role of the gene-environment interaction in the etiology of ARM 
either.  
Chapter 10 describes our exome chip association study on rare coding variants using 
the Illumina Human Exome BeadChip in the largest sample of ARM cases studied so far, with 
the aim to identify new rare genetic variants that contribute to the occurrence of ARM. In 
total, 55 variants were statistically significant in the discovery study. Only three of these 
variants in the CLCN1, LRBA, and ZNF423 genes were validated using targeted resequencing 
with the molecular inversion probe (MIP) technique. However, replication analyses of these 
variants in Caucasian and Han Chinese replication samples did not confirm these results. 
Therefore, we did not find evidence for strong associations between ARM and rare genetic 
variants captured by this exome chip.   
 
Part 4: General discussion 
In the general discussion in Chapter 11, we considered several methodological issues that 
were associated with the case-control studies described in this thesis. These issues were 
mainly related to the study design, the recruitment and inclusion of the study participants, 
and the methods of data collection. We discussed, for example, the advantages and 
disadvantages of the three types of controls that were used in the different studies and the 
potential impact of recall problems when using parental questionnaire data in a case-control 
design. The findings from our studies were also summarized in light of the main objectives of 
the thesis and the existing literature. Furthermore, directions for future research were 
provided, such as studies on DNA methylation patterns in cases and controls who were born 
as a result of ICSI or IVF treatment, studies on potential teratogenic medical drugs, and 
studies on nutrition and parental occupational exposures. In addition, exome or whole 
genome sequencing and genome-wide screening procedures, such as a large GWAS, are 
needed to identify the contribution of as yet unknown genes or pathways. The ultimate goal 
of etiologic research on ARM is primary prevention and improved genetic counseling, but 
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effective preventive measures do not seem to be available for the prevention of ARM yet. 
However, the increased knowledge on the etiology of ARM provided in this thesis represents 
a first step to better guide couples with a child wish and the parents of patients with ARM.
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Samenvatting 
 
Aangeboren anorectale malformaties (ARM) zijn defecten in de ontwikkeling van de anus en 
de endeldarm, die wereldwijd in ongeveer 1 per 3.000 levendgeborenen voorkomen. Naast 
een anorectale malformatie heeft 40 tot 70% van de patiënten ook één of meerdere andere 
aangeboren aandoeningen, vaak behorend tot de VACTERL (Vertebrale, Anale, Cardiale, 
Trachea-oEsofageale, Renale en Ledemaat aandoeningen) associatie. Meestal zijn meerdere 
chirurgische ingrepen in de eerste levensjaren van de patiënt noodzakelijk om de 
darmfunctie te herstellen. Desondanks leidt deze aandoening vaak tot blijvende psycho-
sociale en fysieke problemen, zoals obstipatie, fecale incontinentie en seksuele problemen. 
Vanwege deze problemen is primaire preventie van ARM nodig, maar dit vereist uitgebreide 
kennis over de etiologie van ARM. Daarom is het belangrijkste doel van dit proefschrift om 
meer inzicht te krijgen in de rol van genetische en niet-genetische risicofactoren voor het 
ontstaan van ARM. 
 
Deel 1: Inleiding, prevalentie en definities 
Na een korte algemene inleiding in hoofdstuk 1, beschrijven we in hoofdstuk 2 een 
uitgebreide systematische review van de bestaande literatuur over de genetische en niet-
genetische etiologie van ARM. Daarin werden consistent associaties gevonden tussen ARM 
en vruchtbaarheidsbehandelingen, meerlingzwangerschappen, vroeggeboorte, laag geboor-
tegewicht, overgewicht of obesitas van de moeder en reeds vóór de zwangerschap 
bestaande diabetes. Bovendien bleek dat humaan onderzoek naar de genetische etiologie 
van ARM opmerkelijk schaars is en dat de meeste genetische studies gebaseerd waren op 
een kandidaatgen benadering. Hoewel dierstudies aantoonden dat genen en eiwitten in 
embryonale signaleringsroutes, zoals de Sonic Hedgehog (SHH), wingless-type integration 
(WNT), fibroblast growth factor (FGF) en bone morphogenetic protein (BMP) signalerings-
routes, een rol spelen in de etiologie van ARM, leverden humane studies geen substantieel 
bewijs voor de betrokkenheid van genen in deze signaleringsroutes bij het ontstaan van 
ARM. In de eerste kleine genoomwijde associatie studie (GWAS) naar ARM werden geen 
polymorfismen of veelvoorkomende zogenaamde kopie nummer variaties (CNVs) gevonden. 
Wel werden veel verschillende zeldzame CNVs geïdentificeerd in individuele geïsoleerde 
ARM-patiënten, die niet werden gevonden in controles. We concludeerden dat grote 
cohorten met ARM-patiënten nodig zijn om toekomstige genetische studies met een 
hypothese-genererende aanpak uit te voeren, zoals een GWAS om de rol van polymorfismen 
op te helderen en exoom- of genoom-sequencing om zeldzame varianten te bestuderen. 
Hiervoor zijn internationale samenwerkingsverbanden essentieel. 
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Hiervoor zijn internationale samenwerkingsverbanden essentieel. 
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In dat kader werd het ARM-NET consortium opgericht, dat beschreven is in hoofdstuk 3. In 
dit consortium zijn klinisch genetici, epidemiologen, kinderchirurgen en leden van patiënten-
organisaties uit Europa betrokken. Hoofdstuk 4 laat de eerste resultaten zien met betrekking 
tot de prevalentie van ARM fenotypes, additionele aangeboren aandoeningen en chirur-
gische ingrepen in 203 ARM-patiënten binnen het ARM-NET consortium. Een perineale fistel 
was het meest voorkomende ARM fenotype en 72% van de patiënten had naast ARM één of 
meerdere andere aangeboren aandoeningen. In hoofdstuk 5, hebben we het belang 
benadrukt van een geharmoniseerd diagnostisch classificatiesysteem voor de VACTERL 
associatie om de behandeling en de follow-up van VACTERL-patiënten te kunnen verbeteren. 
 
Deel 2: Niet-genetische factoren 
Hoofdstuk 6 beschrijft de resultaten van een patiënt-controle onderzoek naar 
zwangerschap-gerelateerde risicofactoren voor ARM. In deze studie hebben we gebruik 
gemaakt van gegevens uit 17 Europese registraties van EUROCAT (een Europees 
samenwerkingsverband van registraties van aangeboren aandoeningen). In deze relatief 
grote studie werden epilepsie bij de moeder, vruchtbaarheidsbehandelingen, meerling-
zwangerschappen, de eerste zwangerschap, pre-eclampsie en koorts tijdens de zwanger-
schap geïdentificeerd als potentiële risicofactoren voor ARM. Deze werden voornamelijk 
gevonden voor ARM-patiënten met andere aangeboren aandoeningen. Het blijft echter 
onduidelijk of de epilepsie, vruchtbaarheidsbehandeling of koorts zelf een rol speelt in de 
etiologie van ARM of de farmacologische behandeling of onderliggende oorzaken, zoals 
verminderde vruchtbaarheid van de ouders en een infectie bij de moeder. De associaties 
tussen ARM en meerlingzwangerschappen, de eerste zwangerschap en pre-eclampsie 
duiden mogelijk op placenta-disfunctie in een vroege fase van de zwangerschap. Placenta-
disfunctie kan leiden tot onvoldoende toevoer van voedingsstoffen en hormonen naar de 
foetus. 
In hoofdstuk 7 evalueerden we een breed scala aan potentiële maternale en 
paternale risicofactoren voor ARM met behulp van patiënt-controle gegevens uit de AGORA 
(Aetiologisch onderzoek naar Genetische en  Omgevings Risicofactoren voor Aandoeningen 
bij kinderen) data- en biobank. In deze kleine studie werden aanwijzingen gevonden voor 
een verhoogd risico op ARM bij het voorkomen van ARM in de familie, koorts tijdens het 
eerste trimester van de zwangerschap, maternaal overgewicht, gebruik van multivitaminen 
door de moeder, roken door de vader en beroepsmatige blootstellingen bij de moeder en/of 
vader. Er werden geen associaties gezien tussen ARM en een aantal leefstijlfactoren tijdens 
de zwangerschap, zoals het gebruik van foliumzuur, roken door de moeder en 
alcoholgebruik door moeder en/of vader. 
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De rol van verminderde vruchtbaarheid van de ouders en verschillende vruchtbaar-
heidsbehandelingen in het ontstaan van ARM werd in een grotere AGORA studiepopulatie 
en in meer detail bestudeerd in hoofdstuk 8. Hormonale behandeling voor ovulatie-inductie 
en intra-uteriene inseminatie waren niet geassocieerd met ARM. Het risico op een kind met 
ARM was echter wel verhoogd voor ouders die na een intracytoplasmatische sperma-injectie 
(ICSI) of in vitro fertilisatie (IVF) behandeling zwanger werden, vergeleken met vruchtbare 
ouders. Dit risico was nog steeds verhoogd wanneer de ouders die ICSI of IVF ondergingen, 
werden vergeleken met verminderd vruchtbare ouders die zonder behandeling zwanger 
waren geworden. Verminderde vruchtbaarheid zonder behandeling was alleen geassocieerd 
met ARM als ook andere aangeboren aandoeningen bij het kind aanwezig waren. Omdat 
confounding door medische indicatie een rol kan spelen in deze associaties, hebben we 
geconcludeerd dat zowel ICSI- of IVF-behandeling als de onderliggende verminderde 
vruchtbaarheid een rol spelen bij het ontstaan van ARM. 
 
Deel 3: Genetische factoren en gen-omgeving interactie 
Onafhankelijke associaties en interacties tussen periconceptioneel gebruik van foliumzuur-
supplementen en MTHFR (methyleentetrahydrofolaat reductase) C677T polymorfismen bij 
moeder en kind werden onderzocht in hoofdstuk 9. MTHFR C677T polymorfismen bij 
moeder en kind waren slechts zwak geassocieerd met ARM, terwijl er geen verband werd 
gezien tussen ARM en het gebruik van foliumzuursupplementen door de moeder. Ook werd 
er geen bewijs gevonden voor een rol van deze gen-omgeving interactie in de etiologie van 
ARM. 
Hoofdstuk 10 beschrijft onze exome chip associatiestudie naar zeldzame, coderende 
genetische varianten met de Illumina Human Exome BeadChip in de grootste ARM-populatie 
die tot nu toe bestudeerd is. Het doel was om nieuwe, zeldzame genetische varianten te 
identiferen die bijdragen aan het ontstaan van ARM. In totaal waren er 55 varianten 
statistisch significant geassocieerd met ARM in de initiële studie. Slechts drie van deze 
varianten, in de CLCN1, LRBA en ZNF423 genen, konden we valideren met behulp van de 
moleculaire inversie probe (MIP) techniek. Deze resultaten werden echter niet gerepliceerd 
in nieuwe DNA samples van Kaukasische en Han-Chinese ARM-patiënten. Dus we hebben 
geen bewijs gevonden voor sterke associaties tussen ARM en zeldzame, genetische 
varianten die we met deze exome chip konden bestuderen. 
 
Deel 4: Algemene discussie 
In de algemene discussie in hoofdstuk 11 gaan we in op een aantal methodologische 
aandachtspunten gerelateerd aan de patiënt-controle onderzoeken beschreven in dit 
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proefschrift. Deze aandachtspunten hebben betrekking op het onderzoeksontwerp, de 
onderzoekspopulaties en de methoden van dataverzameling. We bespreken bijvoorbeeld de 
voor- en nadelen van de drie soorten controlepopulaties in de verschillende studies en de 
mogelijke impact van herinneringsproblemen bij het gebruik van gegevens uit vragenlijsten 
in het patiënt-controle onderzoek. Tevens worden de bevindingen van onze studies 
samengevat in het licht van de belangrijkste doelstellingen van dit proefschrift en de 
bestaande literatuur. Ook worden suggesties gedaan voor richtingen van toekomstig 
onderzoek, zoals studies naar mogelijke verschillen in DNA-methylatie tussen patiënten en 
controles die zijn geboren na een ICSI- of IVF-behandeling, onderzoek naar mogelijke 
teratogene medicijnen en studies naar voeding en beroepsmatige blootstelling van de 
ouders. Bovendien zijn exoom- of genoom-sequencing en genoomwijde studies, zoals een 
grote GWAS, nodig om de bijdrage van nog onbekende genen te identificeren. Het 
uiteindelijke doel van etiologische onderzoek naar ARM is primaire preventie en verbeterde 
genetische counseling. Tot op heden lijken effectieve, preventieve maatregelen nog niet 
beschikbaar. De toegenomen kennis over de etiologie van ARM, beschreven in dit 
proefschrift, is echter een eerste stap naar een betere begeleiding van stellen met een 
kinderwens en van ouders van patiënten met ARM. 
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Dankwoord 
 
In de afgelopen jaren heb ik ontzettend veel geleerd en nieuwe ervaringen opgedaan op het 
gebied van onderzoek en op persoonlijk vlak. Ik wil graag een groot aantal mensen bedanken 
die hieraan hebben bijgedragen. Ik vond het een mooie tijd en ik zal met warme gevoelens 
aan deze periode terug blijven denken! De plek waar ik de basis vond voor de rest van mijn 
loopbaan en de plek waar ik de liefde van mijn leven leerde kennen.  
 
Allereerst veel dank aan mijn promotor en co-promotoren: 
Beste Han, wat fijn dat jij in 2011 het promotorschap over wilde nemen, toen Nine 
naar Utrecht vertrok. Bedankt voor het vertrouwen dat je me gaf, voor de kans die ik kreeg 
om het genetische hoofdstuk van mijn proefschrift goed af te ronden en dat je er op de 
juiste momenten was om mee te denken en te beslissen over belangrijke zaken.    
Beste Nel en Iris, waar moet ik beginnen met jullie te bedanken?! Jullie zijn geweldig 
als co-promotoren, maar ook als personen. Van jullie inhoudelijke kennis, uitgebreide 
feedback, enthousiasme, ervaring en van onze besprekingen heb ik veel geleerd en dit alles 
heeft mij ook enorm gemotiveerd. Ik voelde me vertrouwd bij jullie en heb de interesse in 
mij ontzettend gewaardeerd. Nel, aan het einde van mijn studie stelde je voor een 
subsidieaanvraag te schrijven voor een promotieproject. En dat had succes! Dat je dit 
vertrouwen in mij had, heeft veel voor me betekend. Iris, jij was er altijd, om me te 
adviseren of om mee te denken over kleine en grote vragen. Maar ook je gezelligheid was er 
altijd, tijdens (reizen naar) cursussen, meetings, congressen of gewoon even tussen het werk 
door. Nel en Iris, bedankt voor alles, ik ga jullie en onze fijne samenwerking missen, maar 
neem alle ervaring mee in mijn verdere loopbaan. 
Beste Ivo, ik heb jouw betrokkenheid als clinicus in dit project enorm gewaardeerd. 
Het was erg waardevol om via jou de link met de kliniek te hebben en te zien waar we het 
onderzoek voor doen. Ik heb veel bewondering voor hetgeen je voor de patiënten en hun 
ouders betekent. Bedankt voor het overbrengen van jouw klinische kennis, voor je 
betrokkenheid bij de dataverzameling en dat je altijd uitgebreid de tijd nam voor het 
onderzoek en mijn proefschrift in het bijzonder.  
Beste Nine, bedankt voor jouw vertrouwen in het schrijven van de subsidieaanvraag 
en voor alle begeleiding bij de start van mijn promotieproject. 
 
Beste leden van de manuscriptcommissie, hartelijk dank voor jullie bereidheid om zitting te 
nemen in de manuscriptcommissie en voor het beoordelen van dit proefschrift. 
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Beste (oud-)collega’s van HEV, ook de inmiddels uitgevlogen mede-promovendi, het was fijn 
om op een afdeling met zo’n prettige sfeer werkzaam te zijn! Bedankt voor de gezelligheid, 
de collegialiteit, de hulp bij het inpakken van héél veel vragenlijsten, de interesse in mijn 
onderzoek, de lekkere pauzes en de leuke uitjes.  
 Ursula, Annelies en Wim, bedankt voor jullie hulp binnen AGORA bij de 
dataverzameling en -verwerking en het invoeren van de vragenlijsten. 
Jelle, Sita, Bart en Tessel, bedankt voor de samenwerking en alle hulp, feedback en 
input bij (de analyses van) het ExomeChip project.  
Stagiaires en student-assistenten, Romy, Caro, Michelle, Loes en Fieke, bedankt voor 
jullie hulp bij de dataverzameling, het invoeren van de vragenlijsten en de (genetische) 
analyses. Romy, erg leuk dat jij als promovendus nu verder gaat op dit onderwerp, veel 
succes! 
En natuurlijk mijn kamergenootjes. In de eerste jaren waren dat Loes en Marleen, 
allebei in de afrondende fase van jullie promotie, dus ik kon de kunst van het promoveren bij 
jullie afkijken. Maar ook daarna kon ik bij jullie terecht voor praktische tips of inhoudelijke 
vragen over reproductie-epidemiologie of genetica. Dank jullie wel daarvoor! Daarna 
kwamen Tessel, Wieteke en Daniëlle. Lieve 3.10’ers, wat fijn om met jullie alles te kunnen 
delen. Bedankt dat jullie er waren, voor alle fijne gesprekken bij leuke en minder leuke 
momenten, voor alle goede zorgen (liters thee en soms een blikje cóóla!) en ook voor alle 
gezelligheid buiten 3.10!  
 
Alle (ex-)AGORA-betrokkenen, bedankt voor de goede besprekingen en alle hulp, input en 
inzet. In het bijzonder wil ik alle kinderchirurgen, Mariëtte van der Vorle en Marlaine 
Hammen en het secretariaat van de afdeling Kinderchirurgie bedanken voor de hulp en inzet 
in de dataverzameling voor dit promotieonderzoek. Ook de collega’s, vriendinnen en zusjes 
die geholpen hebben tijdens de succesvolle prikzaterdagen, bedankt! 
 
Ook wil ik een aantal mensen van de afdeling Genetica in het bijzonder noemen. Beste Carlo, 
beide bezig met een promotieonderzoek naar anorectale malformaties. Bedankt voor het 
delen van je genetische kennis, het meedenken bij artikelen en de fijne besprekingen! Alle 
mensen van het lab voor multifactoriële ziekten, heel erg bedankt dat jullie me wegwijs 
maakten op het lab, voor het isoleren van de samples en voor al jullie hulp bij het maken van 
de REMP-platen, de lab-analyses, enz. Ook de dames die zorgden voor het registreren en 
opslaan van alle samples, bedankt! Alex, met jouw hulp hebben we de resultaten van het 
ExomeChip project kunnen valideren met de MIP techniek. Dat bleek een erg belangrijke 
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stap. Dank je wel! En Christian, Maartje, Marloes en Petra, bedankt voor alle 
bioinformatische en lab-analyses die jullie hiervoor uitgevoerd hebben.  
 
Dit onderzoek hebben we alleen uit kunnen voeren dankzij een heel aantal waardevolle 
samenwerkingen.  
 De afdelingen Kinderchirurgie en Genetica van het Erasmus MC, in het bijzonder 
René Wijnen, Pim Sloots, Robert Hofstra, Alice Brooks, Annelies de Klein en Erwin Brosens, 
bedankt voor de samenwerking bij de dataverzameling, het organiseren van de prikzaterdag 
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 De afdeling Kinderchirurgie van het UMC Groningen, in het bijzonder Paul Broens, 
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 Hermien de Walle en Marian Bakker, bedankt voor de fijne samenwerking bij het 
analyseren en het schrijven van het artikel over de EUROCAT data. Dit was een erg leuke 
afwisseling tijdens de dataverzameling voor mijn AGORA onderzoek! 
 I would also like to thank our international colleagues. First of all, the members of the 
ARM-Net consortium, our collaboration in research on anorectal malformations was very 
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and I enjoyed getting to know each other during breaks and dinners. A special thanks to 
Heiko Reutter, Ekkehart Jenetzky, Markus Draaken and Nadine Zwink for our collaboration in 
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Mercè Garcia-Barcélo, I would like to thank you for our nice collaboration in the 
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hieraan hebben bijgedragen wil ik hiervoor hartelijk danken.  
 
Een grote dank gaat uit naar alle kinderen, hun ouders en volwassenen die deelgenomen 
hebben aan AGORA. Zonder jullie hadden we dit onderzoek niet uit kunnen voeren. Heel erg 
bedankt! 
 
Oud-leden van de RIHS PhD Council, het was een erg leuke afwisseling om naast mijn 
promotie samen met jullie activiteiten te organiseren voor mede-promovendi.  
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 Hermien de Walle en Marian Bakker, bedankt voor de fijne samenwerking bij het 
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valuable for me. I learned a lot from your knowledge during our meetings and conferences 
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Heiko Reutter, Ekkehart Jenetzky, Markus Draaken and Nadine Zwink for our collaboration in 
several chapters of this thesis.  
Mercè Garcia-Barcélo, I would like to thank you for our nice collaboration in the 
genetic study on anorectal malformations.  
 
Het was voor mijn onderzoek en is voor toekomstig onderzoek ontzettend waardevol dat we 
ook gegevens hebben kunnen verzamelen van zo’n grote controlegroep. Alle gemeenten die 
hieraan hebben bijgedragen wil ik hiervoor hartelijk danken.  
 
Een grote dank gaat uit naar alle kinderen, hun ouders en volwassenen die deelgenomen 
hebben aan AGORA. Zonder jullie hadden we dit onderzoek niet uit kunnen voeren. Heel erg 
bedankt! 
 
Oud-leden van de RIHS PhD Council, het was een erg leuke afwisseling om naast mijn 
promotie samen met jullie activiteiten te organiseren voor mede-promovendi.  
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Collega’s van het Trimbos-instituut, bedankt voor jullie interesse in de afronding van mijn 
promotieonderzoek en voor de kans om als epidemioloog mijn loopbaan te vervolgen 
binnen dit mooie instituut! 
 
Lieve familie, vrienden en vriendinnen, wat is het fijn om jullie om me heen te hebben. 
Lieve Jozette, Rachel, Kim, Emmy en Etienne, ik ben de laatste in de rij die gaat 
promoveren. Allemaal dr., dat vind ik eigenlijk best wel bijzonder! Ik heb veel bewondering 
voor de manier waarop jullie met je carrière bezig zijn en vind het heerlijk om daarnaast met 
jullie en Jasper, Thijs, Mark, Martin en Cindy leuke dingen te ondernemen, te lachen en 
goede gesprekken te voeren! 
Lieve NELL-meiden, ofwel Nicole, Esther en Lieke, samen kunnen we alle keuzes, 
dilemma’s en mooie momenten van een 30-jarige bespreken. Wat fijn om elkaar daar in te 
herkennen en dit te delen! Bedankt lieve vriendinnen! 
Lieve 8erhoekers, wat ben ik blij dat ik jullie door Gerwen heb leren kennen. Iedere 
verjaardag, etentje of kermis is een feest!  
Lieve vriendinnen uit Afferden, Cindy en Carolien, heel bijzonder en helemaal vertrouwd, 
al vriendinnen vanaf ‘maan, roos, vis’. Carolien, wij hebben altijd veel dezelfde interesses 
gehad en ik geniet van alle leuke momenten met jou! Renske, jou leerde ik later kennen op 
de fiets naar school, dank je wel voor alle gezelligheid! Cindy, met jou en Rob is het altijd 
gezellig en fijn. In jou heb ik een vriendin voor het leven... wat een vertrouwd gevoel dat jij 
als paranimf naast me staat tijdens de verdediging! 
 
De Limburgse gezelligheid is goed terug te vinden in de families Wijers en Reijnders! Fijn om 
zo’n leuke familie te hebben! Lieve Céline en Miek, bedankt voor de speciale band die ik van 
kleins af aan met jullie heb. Monique, wat is de voorkant van dit boekje ontzettend mooi 
geworden, dank je wel!  
 
Lieve schoonfamilie, met jullie kreeg ik er nog een grote, gezellige en warme familie (met 
nog eens 3 zusjes!) bij. Een mooie mix van persoonlijkheden met ieder hun eigen ambities, 
leuk om deel van uit te maken!  
 
Lieve pap, mam, Fieke, Lisa en Floor, ik ben erg gelukkig dat ik ben opgegroeid in zo’n warm 
gezin, waar onvoorwaardelijke liefde en steun vanzelfsprekend zijn. Van gezellige zaterdag-
avonden met chips en cola, hulp bij spreekbeurten over de Berlijnse muur en de krant en 
creatieve activiteiten tijdens alle seizoenen tot de gezelligste uitjes samen en de vele 
telefoontjes voor advies. Het heeft me gemaakt tot wie ik ben. 
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Lieve zusjes en Olaf, wat fijn om zo’n hechte band met jullie te hebben en er altijd 
voor elkaar te zijn. Het was voor mij dan ook direct duidelijk dat ik één van jullie wilde 
vragen om naast me te staan tijdens de verdediging. Lisa, ik ben heel blij met jou als 
paranimf!  
Lieve pap en mam, wat is het fijn om te merken dat jullie trots op me zijn en dat m’n 
zusjes en ik altijd op de eerste plaats staan. Ik had geen beter voorbeeld kunnen krijgen... 
het zou geweldig zijn als Gerwen en ik Veere net zo veel mee kunnen geven in haar leven als 
jullie mij meegegeven hebben. Jullie zijn fantastische ouders!  
 
Lieve Gerwen, aan het begin van mijn promotie, sloot jij je promotie af. Wat een gezellige 
avonden waren dat in de Aesculaaf! En nu, na die mooie lente in 2010, ben je mijn geweldige 
man en de vader van onze lieve Veere. Ik kan al mijn twijfels, al mijn onzekerheden en alle 
leuke en bijzondere momenten met je delen. Jij bent altijd daar met een creatief idee, de 
oplossing, de geruststelling of om iets gezellig samen te vieren, thuis of (on)gepland in de 
kroeg of een leuk restaurant! Jij bent de liefste en ik vind het geweldig om het leven met jou 
te delen en te vieren! Ik hou van je! 
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